FGFR2

UniProt ID: P21802
Organism: Homo sapiens
Review Status: COMPLETE
📝 Provide Detailed Feedback

Gene Description

FGFR2 (Fibroblast Growth Factor Receptor 2) encodes a receptor tyrosine kinase that mediates FGF signaling in development, tissue repair, and homeostasis. CRITICAL ISOFORM BIOLOGY: Alternative splicing of exon IIIb vs IIIc in the third Ig-like domain creates isoforms with MUTUALLY EXCLUSIVE ligand specificities: (1) FGFR2IIIb (P21802-3, KGFR) is expressed in EPITHELIAL cells and binds FGF1, FGF3, FGF7 (KGF), and FGF10. FGF7 and FGF10 bind ONLY to IIIb. (2) FGFR2IIIc (P21802-1, BEK) is expressed in MESENCHYMAL cells and binds FGF1, FGF2, FGF4, FGF6, and FGF9. FGF2 binds preferentially to IIIc. This isoform switching enables PARACRINE signaling between epithelium and mesenchyme: mesenchyme produces FGF7/10 to signal to epithelial IIIb, while epithelium produces FGF2/4 to signal to mesenchymal IIIc. Critical for limb development, lung branching morphogenesis, and wound healing. Additional isoforms: Secreted/soluble forms (P21802-14, P21802-19) may act as decoy receptors. Numerous other splice variants exist with various domain combinations. Cancer relevance: IIIb-to-IIIc isoform switching accompanies epithelial-mesenchymal transition (EMT) and correlates with metastatic potential in some cancers.

Existing Annotations Review

GO Term Evidence Action Reason
GO:0005007 fibroblast growth factor receptor activity
IBA
GO_REF:0000033
ACCEPT
Summary: FGFR2 is unambiguously a fibroblast growth factor receptor. UniProt confirms it is a "Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors." This applies to all transmembrane isoforms (both IIIb/KGFR and IIIc/BEK), though with different ligand specificities. Deep research confirms FGFR2 as a receptor tyrosine kinase whose primary function is transducing FGF signals via autophosphorylation and downstream pathway activation.
Reason: Core molecular function of FGFR2. Extensive experimental evidence from multiple studies (PMID:8663044, PMID:16597617, PMID:15629145) demonstrates FGF receptor activity. The IBA annotation appropriately captures the conserved function.
Supporting Evidence:
UniProtKB:P21802
Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors
file:human/FGFR2/FGFR2-deep-research-falcon.md
FGFR2 is a member of the FGFR receptor tyrosine kinase family that transduces extracellular fibroblast growth factor (FGF) signals into intracellular phosphorylation-dependent signaling programs that control proliferation, survival, differentiation, and migration.
GO:0005886 plasma membrane
IBA
GO_REF:0000033
ACCEPT
Summary: Plasma membrane localization is confirmed for all transmembrane FGFR2 isoforms (IIIb and IIIc). However, secreted isoforms (P21802-14, P21802-19) are not plasma membrane-localized. The annotation is appropriate at the gene level since most functional isoforms are transmembrane.
Reason: UniProt confirms "Cell membrane; Single-pass type I membrane protein" for main isoforms. Extensive localization data supports plasma membrane localization for functional receptor isoforms.
Supporting Evidence:
UniProtKB:P21802
SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane protein
GO:0008284 positive regulation of cell population proliferation
IBA
GO_REF:0000033
ACCEPT
Summary: FGFR2 signaling promotes cell proliferation in keratinocytes and immature osteoblasts. UniProt notes it "Promotes cell proliferation in keratinocytes and immature osteoblasts." This is a well-established downstream effect of FGF signaling through both IIIb and IIIc isoforms.
Reason: Core biological process for FGFR2. Multiple studies demonstrate proliferative effects (PMID:8663044, PMID:15629145, PMID:16597617). This applies to both major splice variants with different ligands driving the same outcome.
Supporting Evidence:
UniProtKB:P21802
Promotes cell proliferation in keratinocytes and immature osteoblasts
GO:0008543 fibroblast growth factor receptor signaling pathway
IBA
GO_REF:0000033
ACCEPT
Summary: FGFR2 is a core component of FGF receptor signaling. Ligand binding leads to receptor dimerization, autophosphorylation, and activation of downstream cascades including PLCG1, MAPK, and PI3K/AKT pathways.
Reason: Fundamental role of FGFR2. UniProt extensively documents signaling mechanism including phosphorylation of PLCG1, FRS2, and activation of RAS-MAPK and AKT pathways. Both IIIb and IIIc isoforms signal through these pathways.
Supporting Evidence:
UniProtKB:P21802
Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway
GO:0001525 angiogenesis
IBA
GO_REF:0000033
KEEP AS NON CORE
Summary: FGF signaling through FGFRs is known to promote angiogenesis, particularly FGF2 signaling through FGFR2IIIc (mesenchymal isoform). However, this may be more prominent for FGFR1 in endothelial cells. The annotation is reasonable but likely represents a non-core function.
Reason: Angiogenesis is documented for FGF/FGFR signaling generally, but FGFR2's primary roles are in epithelial-mesenchymal signaling for organ development rather than vascular biology. This is a secondary rather than core function.
GO:0043410 positive regulation of MAPK cascade
IBA
GO_REF:0000033
ACCEPT
Summary: MAPK cascade activation is a core downstream signaling event for FGFR2. UniProt confirms that FRS2 phosphorylation leads to recruitment of GRB2/SOS1 and activation of RAS-MAPK signaling.
Reason: Core signaling output of FGFR2. Well-documented in UniProt and multiple publications (PMID:15629145, PMID:17623664). Both IIIb and IIIc isoforms activate MAPK upon ligand binding.
Supporting Evidence:
UniProtKB:P21802
mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway
GO:0043235 receptor complex
IBA
GO_REF:0000033
ACCEPT
Summary: FGFR2 forms homodimers upon ligand binding and also forms complexes with heparan sulfate proteoglycan co-receptors. UniProt confirms "Homodimer after ligand binding."
Reason: FGFR2 functions as part of a receptor complex including FGF ligands, heparan sulfate, and in some cases KLB (for FGF19/21). Dimerization is required for receptor activation.
Supporting Evidence:
UniProtKB:P21802
Monomer. Homodimer after ligand binding.
GO:0017134 fibroblast growth factor binding
IBA
GO_REF:0000033
ACCEPT
Summary: FGFR2 binds multiple FGFs with isoform-specific preferences. IIIc (P21802-1) has high affinity for FGF1, FGF2; IIIb (P21802-3) has high affinity for FGF1, FGF7. CRITICAL ISOFORM NOTE - FGF7 binds ONLY to IIIb (epithelial); FGF2 binds preferentially to IIIc (mesenchymal).
Reason: Core molecular function. Extensive structural and biochemical data (PMID:8663044, PMID:10830168, PMID:12591959) document FGF binding. The annotation at gene level is appropriate though ligand specificity differs by isoform.
Supporting Evidence:
UniProtKB:P21802
Isoform 1 has high affinity for FGF1 and FGF2, but low affinity for FGF7. Isoform 3 has high affinity for FGF1 and FGF7
GO:0000166 nucleotide binding
IEA
GO_REF:0000043
ACCEPT
Summary: FGFR2 is a tyrosine kinase that binds ATP for its catalytic activity. Nucleotide binding is accurate but overly general - ATP binding is more specific.
Reason: True but general. FGFR2 has a kinase domain that binds ATP. The more specific term "ATP binding" is also annotated and preferred.
GO:0004672 protein kinase activity
IEA
GO_REF:0000002
ACCEPT
Summary: FGFR2 is a protein kinase. The annotation is correct but "protein tyrosine kinase activity" is more specific and preferred.
Reason: Correct parent term. FGFR2 has documented kinase activity (EC 2.7.10.1). More specific child term annotations also exist.
GO:0004713 protein tyrosine kinase activity
IEA
GO_REF:0000120
ACCEPT
Summary: FGFR2 is a receptor tyrosine kinase that autophosphorylates and phosphorylates substrates including PLCG1, FRS2, and PAK4 on tyrosine residues.
Reason: Core molecular function. UniProt confirms EC 2.7.10.1 classification and documents phosphorylation of multiple substrates. Applies to all kinase- containing isoforms.
Supporting Evidence:
UniProtKB:P21802
Phosphorylates PLCG1, FRS2 and PAK4
GO:0004714 transmembrane receptor protein tyrosine kinase activity
IEA
GO_REF:0000003
ACCEPT
Summary: FGFR2 is a single-pass type I transmembrane receptor tyrosine kinase. This is the most specific and appropriate molecular function term for membrane- bound isoforms.
Reason: Most specific appropriate MF term for transmembrane FGFR2 isoforms. Note that secreted isoforms (P21802-14, P21802-19) lack transmembrane domain and kinase activity.
GO:0005007 fibroblast growth factor receptor activity
IEA
GO_REF:0000120
ACCEPT
Summary: Duplicate of IBA annotation. FGFR2 is unambiguously an FGF receptor.
Reason: Core function - duplicates IBA annotation with different evidence. Correct.
GO:0005524 ATP binding
IEA
GO_REF:0000120
ACCEPT
Summary: FGFR2 kinase domain binds ATP. Crystal structures confirm ATP binding (PDB entries with ATP analogs).
Reason: Core function for kinase activity. Structural data confirms ATP binding site.
GO:0005576 extracellular region
IEA
GO_REF:0000044
ACCEPT
Summary: The secreted/soluble isoforms (P21802-14 soluble KGFR, P21802-19 soluble KGFR) are found in the extracellular region. For transmembrane isoforms, the N-terminal region including Ig-like domains is extracellular.
Reason: Appropriate for secreted isoforms. UniProt confirms isoforms 8 (K-sam-IV, Soluble KGFR) and 13 (Soluble KGFR) are secreted forms that would localize to the extracellular region.
GO:0005794 Golgi apparatus
IEA
GO_REF:0000044
ACCEPT
Summary: FGFR2 is N-glycosylated and transits through the Golgi. UniProt notes "N-glycan chains undergo further maturation to an Endo H-resistant form in the Golgi apparatus."
Reason: FGFR2 passes through Golgi during maturation. Also documented as "Golgi apparatus" in subcellular location. Represents trafficking intermediate.
Supporting Evidence:
UniProtKB:P21802
SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane protein. Golgi apparatus.
GO:0005886 plasma membrane
IEA
GO_REF:0000044
ACCEPT
Summary: Duplicate of IBA annotation. Plasma membrane localization for transmembrane isoforms is well established.
Reason: Correct - duplicates IBA with different evidence.
GO:0006915 apoptotic process
IEA
GO_REF:0000043
KEEP AS NON CORE
Summary: FGFR2 has complex effects on apoptosis - it can promote apoptosis in differentiated osteoblasts but inhibit it in keratinocytes and immature osteoblasts. The UniProt keyword may be too general.
Reason: UniProt notes FGFR2 "promotes apoptosis in differentiated osteoblasts" but this is context-dependent and not a primary function. The annotation is valid but represents a secondary/context-specific role.
Supporting Evidence:
UniProtKB:P21802
Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts
GO:0008201 heparin binding
IEA
GO_REF:0000043
ACCEPT
Summary: FGFR2 binds heparan sulfate glycosaminoglycans which serve as coreceptors. Heparin (a highly sulfated heparan sulfate) is used experimentally.
Reason: Documented function. UniProt confirms "Affinity for fibroblast growth factors (FGFs) is increased by heparan sulfate glycosaminoglycans that function as coreceptors." Crystal structures show heparin binding (PMID:11069186).
Supporting Evidence:
UniProtKB:P21802
Affinity for fibroblast growth factors (FGFs) is increased by heparan sulfate glycosaminoglycans that function as coreceptors
GO:0008284 positive regulation of cell population proliferation
IEA
GO_REF:0000120
ACCEPT
Summary: Duplicate of IBA annotation. FGFR2 promotes cell proliferation.
Reason: Correct - duplicates IBA with different evidence.
GO:0008543 fibroblast growth factor receptor signaling pathway
IEA
GO_REF:0000120
ACCEPT
Summary: Duplicate of IBA annotation. FGFR2 is a core component of FGF signaling.
Reason: Correct - duplicates IBA with different evidence.
GO:0016020 membrane
IEA
GO_REF:0000002
ACCEPT
Summary: Transmembrane FGFR2 isoforms are integral membrane proteins. This is a parent term of plasma membrane - overly general but not wrong.
Reason: Correct but general. More specific annotations (plasma membrane) exist.
GO:0016301 kinase activity
IEA
GO_REF:0000043
ACCEPT
Summary: FGFR2 has kinase activity. This is a parent of the more specific protein tyrosine kinase activity annotations.
Reason: Correct but overly general. More specific annotations exist.
GO:0016740 transferase activity
IEA
GO_REF:0000043
ACCEPT
Summary: Kinases are transferases (transfer phosphate groups). This is very general but technically correct.
Reason: Correct parent term. Very general but valid.
GO:0031410 cytoplasmic vesicle
IEA
GO_REF:0000120
ACCEPT
Summary: FGFR2 is found in cytoplasmic vesicles during internalization after ligand binding. UniProt notes "After ligand binding, the activated receptor is rapidly internalized and degraded."
Reason: Valid location during receptor trafficking/internalization.
Supporting Evidence:
UniProtKB:P21802
After ligand binding, the activated receptor is rapidly internalized and degraded
GO:0033688 regulation of osteoblast proliferation
IEA
GO_REF:0000117
ACCEPT
Summary: FGFR2 regulates osteoblast proliferation - it promotes proliferation in immature osteoblasts. This is relevant to craniosynostosis syndromes caused by FGFR2 mutations.
Reason: UniProt confirms FGFR2 "Promotes cell proliferation in keratinocytes and immature osteoblasts" and "Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis."
GO:0043009 chordate embryonic development
IEA
GO_REF:0000117
KEEP AS NON CORE
Summary: FGFR2 is required for normal embryonic development. UniProt confirms it is "Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development."
Reason: Valid but very general developmental term. More specific developmental processes (limb, lung, skeleton) are better descriptors of FGFR2 function.
GO:0043410 positive regulation of MAPK cascade
IEA
GO_REF:0000117
ACCEPT
Summary: Duplicate annotation (IBA already reviewed). MAPK cascade activation is a core downstream signaling output of FGFR2.
Reason: Duplicates IBA with different evidence. Core signaling function.
GO:0045595 regulation of cell differentiation
IEA
GO_REF:0000117
ACCEPT
Summary: FGFR2 regulates differentiation of multiple cell types including osteoblasts, keratinocytes, and epithelial cells. This is a core function.
Reason: UniProt confirms role in "regulation of cell proliferation, differentiation, migration and apoptosis." Applies to both IIIb (epithelial differentiation) and IIIc (mesenchymal differentiation) isoforms.
GO:0048562 embryonic organ morphogenesis
IEA
GO_REF:0000117
ACCEPT
Summary: FGFR2 is required for morphogenesis of multiple embryonic organs including limbs, lungs, and craniofacial structures. UniProt confirms it is "Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development."
Reason: Core developmental function. FGFR2 is essential for morphogenesis of multiple organs through epithelial-mesenchymal interactions. Consistent with ISS annotation for the same term.
Supporting Evidence:
UniProtKB:P21802
Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development
GO:0048705 skeletal system morphogenesis
IEA
GO_REF:0000117
ACCEPT
Summary: FGFR2 is critical for skeletal development. Mutations cause multiple craniosynostosis syndromes (Crouzon, Apert, Pfeiffer, Jackson-Weiss).
Reason: UniProt confirms "required for normal skeleton development" and documents multiple skeletal disorder phenotypes from FGFR2 mutations.
GO:1904888 cranial skeletal system development
IEA
GO_REF:0000117
ACCEPT
Summary: FGFR2 is critical for cranial skeleton development. Mutations cause craniosynostosis - premature fusion of cranial sutures.
Reason: Strong evidence from human genetics - FGFR2 mutations cause Crouzon syndrome, Apert syndrome, Pfeiffer syndrome, and other craniosynostoses.
GO:0005515 protein binding
IPI
PMID:10618369
Structural interactions of fibroblast growth factor receptor...
MODIFY
Summary: PMID:10618369 is a structural study of FGFR2-FGF1 complex. The term "protein binding" is uninformative - more specific terms like "fibroblast growth factor binding" are available and preferred.
Reason: "Protein binding" is too generic for GO annotation. This paper documents FGF binding which is already captured by GO:0017134.
Proposed replacements: fibroblast growth factor binding
Supporting Evidence:
PMID:10618369
Structural interactions of fibroblast growth factor receptor with its ligands.
GO:0005515 protein binding
IPI
PMID:10830168
Crystal structures of two FGF-FGFR complexes reveal the dete...
MODIFY
Summary: PMID:10830168 reports crystal structures of FGF-FGFR complexes. Shows determinants of ligand-receptor specificity. "Protein binding" is too generic.
Reason: Paper specifically documents FGF binding. Should use GO:0017134 fibroblast growth factor binding instead.
Proposed replacements: fibroblast growth factor binding
Supporting Evidence:
PMID:10830168
Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity.
GO:0005515 protein binding
IPI
PMID:11390973
Structural basis for fibroblast growth factor receptor 2 act...
MODIFY
Summary: PMID:11390973 describes structural basis for FGFR2 activation in Apert syndrome, examining FGF2 binding. "Protein binding" is too generic.
Reason: Paper documents FGF2 binding to FGFR2. Should use more specific term.
Proposed replacements: fibroblast growth factor binding
Supporting Evidence:
PMID:11390973
Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.
GO:0005515 protein binding
IPI
PMID:12591959
Structural basis by which alternative splicing confers speci...
MODIFY
Summary: PMID:12591959 examines structural basis by which alternative splicing confers specificity in FGF receptors. Shows FGF10 binding to FGFR2IIIb.
Reason: Paper documents isoform-specific FGF binding. Should use GO:0017134.
Proposed replacements: fibroblast growth factor binding
Supporting Evidence:
PMID:12591959
Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors.
GO:0005515 protein binding
IPI
PMID:1309608
Determination of ligand-binding specificity by alternative s...
MODIFY
Summary: PMID:1309608 is a seminal paper showing that alternative splicing creates two distinct growth factor receptors with different ligand specificities. Documents FGF1 and FGF7 binding differences between isoforms.
Reason: Classic paper on FGFR2 isoform-specific FGF binding. Should use GO:0017134.
Proposed replacements: fibroblast growth factor binding
Supporting Evidence:
PMID:1309608
Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene.
GO:0005515 protein binding
IPI
PMID:22726438
Inhibition of basal FGF receptor signaling by dimeric Grb2.
MODIFY
Summary: PMID:22726438 documents inhibition of basal FGF receptor signaling by dimeric Grb2. Shows GRB2 interaction with FGFR2.
Reason: Documents specific GRB2 binding. Should be annotated with a more specific term reflecting signaling adaptor interaction.
Supporting Evidence:
PMID:22726438
Inhibition of basal FGF receptor signaling by dimeric Grb2.
GO:0005515 protein binding
IPI
PMID:23597563
Molecular mechanism of SSR128129E, an extracellularly acting...
MARK AS OVER ANNOTATED
Summary: PMID:23597563 describes molecular mechanism of SSR128129E, an extracellularly acting small-molecule allosteric inhibitor. Documents drug-receptor interaction.
Reason: This paper is about drug binding, not protein-protein interaction. The "protein binding" annotation does not capture meaningful biology here.
Supporting Evidence:
PMID:23597563
Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling.
GO:0005515 protein binding
IPI
PMID:25241761
Using an in situ proximity ligation assay to systematically ...
MARK AS OVER ANNOTATED
Summary: PMID:25241761 uses in situ proximity ligation assay to profile endogenous protein-protein interactions. High-throughput interactome study.
Reason: High-throughput study without specific functional characterization. "Protein binding" is too generic to be informative.
Supporting Evidence:
PMID:25241761
Oct 9. Using an in situ proximity ligation assay to systematically profile endogenous protein-protein interactions in a pathway network.
GO:0005515 protein binding
IPI
PMID:26267536
Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for...
MARK AS OVER ANNOTATED
Summary: PMID:26267536 describes long-pentraxin 3 derivative as FGF trap for cancer therapy. Documents FGF sequestration rather than receptor binding.
Reason: Paper focuses on therapeutic FGF trapping, not native FGFR2 interactions. "Protein binding" is not informative here.
Supporting Evidence:
PMID:26267536
Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy.
GO:0005515 protein binding
IPI
PMID:33961781
Dual proteome-scale networks reveal cell-specific remodeling...
MARK AS OVER ANNOTATED
Summary: PMID:33961781 is a large-scale proteome study of the human interactome. High-throughput data without specific functional characterization.
Reason: High-throughput interactome study. "Protein binding" is too generic to be informative for specific gene annotation.
Supporting Evidence:
PMID:33961781
2021 May 6. Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.
GO:0005515 protein binding
IPI
PMID:35384245
Physical and functional interactome atlas of human receptor ...
MARK AS OVER ANNOTATED
Summary: PMID:35384245 is a physical interactome atlas of human receptor tyrosine kinases. Large-scale study of RTK interactions.
Reason: High-throughput interactome study. Generic "protein binding" annotations from such studies add little value.
Supporting Evidence:
PMID:35384245
Physical and functional interactome atlas of human receptor tyrosine kinases.
GO:0005515 protein binding
IPI
PMID:35922511
A physical wiring diagram for the human immune system.
MARK AS OVER ANNOTATED
Summary: PMID:35922511 is a physical wiring diagram for the human immune system. Large-scale protein interaction study.
Reason: High-throughput study. Generic "protein binding" from such studies is not informative for specific gene function.
Supporting Evidence:
PMID:35922511
Aug 3. A physical wiring diagram for the human immune system.
GO:0001837 epithelial to mesenchymal transition
IEA
GO_REF:0000107
KEEP AS NON CORE
Summary: ISOFORM-SPECIFIC CONCERN: FGFR2 isoform switching (IIIb to IIIc) is associated with EMT. IIIb is epithelial; IIIc is mesenchymal. This annotation conflates gene-level with isoform-specific biology.
Reason: The isoform switch from IIIb to IIIc accompanies EMT in cancer, but FGFR2 itself does not directly cause EMT. This is a correlative rather than causative role. The annotation may be valid but represents secondary biology.
GO:0003416 endochondral bone growth
IEA
GO_REF:0000107
ACCEPT
Summary: FGFR2 plays a role in bone development. Mutations cause craniosynostosis and affect skeletal growth.
Reason: Valid bone development function supported by disease phenotypes. UniProt documents FGFR2 role in osteogenesis and skeletal development.
GO:0009986 cell surface
IEA
GO_REF:0000107
ACCEPT
Summary: FGFR2 is a cell surface receptor. More specific than plasma membrane in indicating the exposed surface.
Reason: Valid localization. FGFR2 is a transmembrane receptor exposed at the cell surface for ligand binding.
GO:0017134 fibroblast growth factor binding
IEA
GO_REF:0000120
ACCEPT
Summary: Duplicate of IBA annotation. FGF binding is a core FGFR2 function.
Reason: Core function - duplicates IBA with different evidence.
GO:0032496 response to lipopolysaccharide
IEA
GO_REF:0000107
MARK AS OVER ANNOTATED
Summary: LPS response is not a characterized FGFR2 function. This annotation may reflect expression changes rather than direct function.
Reason: No clear evidence that FGFR2 has a direct role in LPS response. This is likely an ortholog transfer from expression data rather than functional data.
GO:0044344 cellular response to fibroblast growth factor stimulus
IEA
GO_REF:0000107
ACCEPT
Summary: FGFR2 mediates cellular response to FGF. This is its core function as an FGF receptor.
Reason: Core function. FGFR2 is the receptor that mediates cellular response to multiple FGFs.
GO:0045471 response to ethanol
IEA
GO_REF:0000107
MARK AS OVER ANNOTATED
Summary: Ethanol response is not a characterized FGFR2 function. This annotation likely reflects expression changes rather than direct function.
Reason: No evidence that FGFR2 has a direct role in ethanol response. Likely ortholog transfer from expression data.
GO:0048333 mesodermal cell differentiation
IEA
GO_REF:0000107
ACCEPT
Summary: FGFR2IIIc (mesenchymal isoform) is involved in mesenchymal/mesodermal cell biology. This annotation may be partially isoform-specific.
Reason: Valid for FGFR2IIIc isoform specifically. FGF signaling through IIIc supports mesenchymal cell differentiation.
GO:0050680 negative regulation of epithelial cell proliferation
IEA
GO_REF:0000120
UNDECIDED
Summary: This annotation seems contradictory to FGFR2's known role in promoting keratinocyte (epithelial) proliferation. The annotation may be context- specific or erroneous.
Reason: UniProt states FGFR2 "promotes cell proliferation in keratinocytes" which contradicts negative regulation. May apply to specific contexts but unclear.
GO:0071300 cellular response to retinoic acid
IEA
GO_REF:0000107
MARK AS OVER ANNOTATED
Summary: Retinoic acid response is not a characterized FGFR2 function. May reflect expression regulation rather than functional response.
Reason: No clear evidence for direct FGFR2 role in retinoic acid response. Likely ortholog transfer from expression data.
GO:0071456 cellular response to hypoxia
IEA
GO_REF:0000107
MARK AS OVER ANNOTATED
Summary: Hypoxia response is not a well-characterized FGFR2 function. May reflect expression changes in hypoxia.
Reason: No clear evidence for direct FGFR2 role in hypoxia response. Likely ortholog transfer from expression data.
GO:0071560 cellular response to transforming growth factor beta stimulus
IEA
GO_REF:0000107
KEEP AS NON CORE
Summary: TGF-beta response may involve FGFR2 in certain contexts, especially related to EMT where both pathways interact.
Reason: There is crosstalk between FGF and TGF-beta pathways in EMT and development, but this is not a primary FGFR2 function.
GO:1904707 positive regulation of vascular associated smooth muscle cell proliferation
IEA
GO_REF:0000107
KEEP AS NON CORE
Summary: FGF signaling can promote smooth muscle cell proliferation, potentially via FGFR2IIIc in mesenchymal cells.
Reason: Valid but not a primary FGFR2 function. FGF2 signaling through FGFR can promote VSMC proliferation but this is not unique to FGFR2.
GO:0009986 cell surface
IDA
PMID:17959718
Heparanase cleavage of perlecan heparan sulfate modulates FG...
ACCEPT
Summary: PMID:17959718 examines heparanase cleavage of perlecan and FGF10 activity in submandibular gland branching morphogenesis. Shows FGFR2 at cell surface.
Reason: Direct experimental evidence for cell surface localization during FGF10-FGFR2 signaling in branching morphogenesis.
Supporting Evidence:
PMID:17959718
Heparanase cleavage of perlecan heparan sulfate modulates FGF10 activity during ex vivo submandibular gland branching morphogenesis.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654748
ACCEPT
Summary: Reactome pathway annotation. Multiple Reactome entries document FGFR2 plasma membrane localization in various signaling contexts.
Reason: Plasma membrane localization is well established for transmembrane FGFR2 isoforms. Reactome pathway data supports this.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5655233
ACCEPT
Summary: Reactome pathway annotation for FGFR2 signaling. Duplicates other PM annotations.
Reason: Valid localization, consistent with other evidence.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5655241
ACCEPT
Summary: Reactome pathway annotation. Part of FGFR2 signaling pathway documentation.
Reason: Valid localization, consistent with other evidence.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5655245
ACCEPT
Summary: Reactome pathway annotation for FGFR2 at plasma membrane.
Reason: Valid localization, duplicates other evidence.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5655268
ACCEPT
Summary: Reactome pathway annotation for FGFR2 signaling.
Reason: Valid localization, consistent with established biology.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5655301
ACCEPT
Summary: Reactome pathway annotation for FGFR2 signaling.
Reason: Valid localization.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5655320
ACCEPT
Summary: Reactome pathway annotation for FGFR2 signaling.
Reason: Valid localization.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5655323
ACCEPT
Summary: Reactome pathway annotation for FGFR2 signaling.
Reason: Valid localization.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5655339
ACCEPT
Summary: Reactome pathway annotation for FGFR2 signaling.
Reason: Valid localization.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5655343
ACCEPT
Summary: Reactome pathway annotation for FGFR2 signaling.
Reason: Valid localization.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-8853313
ACCEPT
Summary: Reactome pathway annotation for FGFR2 fusions autophosphorylation. Documents aberrant signaling in cancer.
Reason: Valid localization for wild-type and fusion FGFR2.
GO:0010839 negative regulation of keratinocyte proliferation
IMP
PMID:21412257
MiR-125b, a microRNA downregulated in psoriasis, modulates k...
REMOVE
Summary: PMID:21412257 shows miR-125b modulates keratinocyte proliferation by targeting FGFR2. Knockdown of FGFR2 by miRNA reduces proliferation, suggesting FGFR2 normally promotes (not inhibits) keratinocyte proliferation.
Reason: This annotation appears incorrect. The paper shows that FGFR2 knockdown reduces keratinocyte proliferation, meaning FGFR2 positively regulates proliferation. The annotation should be GO:0050679 (positive regulation of epithelial cell proliferation) rather than negative regulation.
Supporting Evidence:
PMID:21412257
Mar 17. MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-8853319
ACCEPT
Summary: Reactome pathway annotation for plasma membrane localization. FGFR2 transmembrane isoforms are plasma membrane receptors. Multiple Reactome pathways include FGFR2 at the plasma membrane.
Reason: Correct localization for transmembrane FGFR2 isoforms. Duplicate entries from different Reactome pathways reflect FGFR2 participation in multiple signaling contexts at the plasma membrane.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-2029989
ACCEPT
Summary: Reactome pathway annotation duplicate. Plasma membrane localization is well established for transmembrane FGFR2 isoforms.
Reason: Duplicate of other plasma membrane annotations from different Reactome pathway contexts. Valid for transmembrane isoforms.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-2029983
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-2029984
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-2033472
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-2033474
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-2033479
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-2033486
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-2033488
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-2033490
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-2077424
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-109699
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-190413
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-2316434
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-2400009
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654147
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654157
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654159
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654397
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654399
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654402
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654404
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654406
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654407
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654562
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654603
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654605
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654607
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654608
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654612
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654614
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654615
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654618
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654620
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654622
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654677
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654697
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654701
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5654729
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-5672965
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-190258
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-190260
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-190408
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-NUL-8853328
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-2029988
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-2029992
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0005886 plasma membrane
TAS
Reactome:R-HSA-2067713
ACCEPT
Summary: Reactome pathway annotation duplicate for plasma membrane localization.
Reason: Valid duplicate annotation from different Reactome pathway.
GO:0048701 embryonic cranial skeleton morphogenesis
IMP
PMID:7874170
Jackson-Weiss and Crouzon syndromes are allelic with mutatio...
ACCEPT
Summary: Mutations in FGFR2 cause Jackson-Weiss and Crouzon syndromes, which feature craniosynostosis (premature fusion of cranial sutures). This demonstrates FGFR2 role in cranial skeleton development. PMID:7874170 identified FGFR2 mutations in the IIIc domain in Jackson-Weiss syndrome families.
Reason: Strong genetic evidence linking FGFR2 mutations to craniosynostosis syndromes. FGFR2 is essential for normal cranial suture development; gain-of-function mutations cause premature suture fusion. This is a well-established core developmental function particularly for the IIIc isoform in mesenchyme.
Supporting Evidence:
PMID:7874170
We now report an FGFR2 mutation in the conserved region of the immunoglobulin IIIc domain in the Jackson-Weiss syndrome family in which the syndrome was originally described.
GO:0048701 embryonic cranial skeleton morphogenesis
IMP
PMID:7987400
Mutations in the fibroblast growth factor receptor 2 gene ca...
ACCEPT
Summary: PMID:7987400 demonstrates that mutations in FGFR2 cause Crouzon syndrome, providing additional genetic evidence for FGFR2 role in cranial skeleton development. Multiple mutations in the B exon (IIIc domain) were identified.
Reason: Complements PMID:7874170 evidence. Crouzon syndrome is autosomal dominant craniosynostosis caused by FGFR2 mutations, including cysteine substitutions in the Ig-like domain. Core developmental function.
Supporting Evidence:
PMID:7987400
We now present evidence that mutations in the fibroblast growth factor receptor 2 gene (FGFR2) cause Crouzon syndrome.
GO:0005634 nucleus
IDA
PMID:16597614
FGF-10 and its receptor exhibit bidirectional paracrine targ...
KEEP AS NON CORE
Summary: PMID:16597614 observed FGF-10 receptor (FGFR2IIIb/KGFR) in nucleus of urothelial cells by microscopy. This is an intriguing finding suggesting nuclear translocation of activated receptor, though unconventional.
Reason: Nuclear localization of FGFRs has been reported but is non-canonical and represents a specialized signaling mechanism rather than the primary localization. The main function of FGFR2 is at the plasma membrane.
Supporting Evidence:
PMID:16597614
Deconvolution, light and transmission electron microscopic studies captured FGF-10 and its receptor in association with the urothelial cell surface, in cytoplasm, and within nuclei
GO:0005737 cytoplasm
IDA
PMID:16597614
FGF-10 and its receptor exhibit bidirectional paracrine targ...
ACCEPT
Summary: PMID:16597614 showed FGFR2 (FGF-10 receptor) localizes to cytoplasm during its trafficking and signaling in urothelial cells.
Reason: FGFR2 is found in cytoplasm during biosynthesis, trafficking to plasma membrane, and after receptor internalization. Valid localization.
Supporting Evidence:
PMID:16597614
Deconvolution, light and transmission electron microscopic studies captured FGF-10 and its receptor in association with the urothelial cell surface, in cytoplasm, and within nuclei
GO:0009986 cell surface
IDA
PMID:16597614
FGF-10 and its receptor exhibit bidirectional paracrine targ...
ACCEPT
Summary: PMID:16597614 localized FGFR2 (FGF-10 receptor) to the urothelial cell surface, consistent with its function as a transmembrane receptor.
Reason: Cell surface localization is expected for transmembrane receptor tyrosine kinases. This is functionally equivalent to plasma membrane localization.
Supporting Evidence:
PMID:16597614
Deconvolution, light and transmission electron microscopic studies captured FGF-10 and its receptor in association with the urothelial cell surface
GO:0005007 fibroblast growth factor receptor activity
IDA
PMID:15629145
Tyrosine 769 of the keratinocyte growth factor receptor is r...
ACCEPT
Summary: PMID:15629145 studied KGFR (FGFR2IIIb) signaling through autophosphorylation and downstream pathway activation. The study demonstrated functional FGF receptor activity through tyrosine phosphorylation assays.
Reason: Direct experimental demonstration of FGFR2 (KGFR isoform) receptor activity including autophosphorylation and signaling. Core molecular function.
Supporting Evidence:
PMID:15629145
KGFR is rapidly autophosphorylated on specific tyrosine residues in the intracellular domain, recruits substrate proteins
GO:0005007 fibroblast growth factor receptor activity
IDA
PMID:8663044
Receptor specificity of the fibroblast growth factor family.
ACCEPT
Summary: PMID:8663044 systematically tested FGF receptor splice variants for ligand specificity and mitogenic activity. This landmark study established FGFR2 isoform-specific ligand binding and receptor activation.
Reason: Comprehensive biochemical characterization of FGFR2 splice variants as functional FGF receptors. Demonstrated mitogenic activity with multiple FGF ligands. Foundational study for FGFR2 biology.
Supporting Evidence:
PMID:8663044
we have engineered mitogenically responsive cell lines expressing the major splice variants of all the known FGF receptors. We have assayed the mitogenic activity of the nine known FGF ligands on these cell lines.
GO:0005886 plasma membrane
IDA
PMID:15629145
Tyrosine 769 of the keratinocyte growth factor receptor is r...
ACCEPT
Summary: PMID:15629145 studied KGFR (FGFR2IIIb) at the plasma membrane where it undergoes ligand-induced internalization.
Reason: Plasma membrane localization is the primary site of FGFR2 function as a transmembrane receptor.
Supporting Evidence:
PMID:15629145
Tyrosine 769 of the keratinocyte growth factor receptor is required for receptor signaling but not endocytosis.
GO:0005886 plasma membrane
IDA
PMID:16844695
Intracellular retention, degradation, and signaling of glyco...
ACCEPT
Summary: PMID:16844695 studied FGFR2 trafficking and localization, showing wild-type FGFR2 localizes to plasma membrane while glycosylation-deficient and mutant forms show altered localization.
Reason: Demonstrates plasma membrane is the normal localization for properly processed FGFR2, while mutations affecting glycosylation impair trafficking.
Supporting Evidence:
PMID:16844695
we show that trafficking and autoactivation of wild type FGFR2 is glycosylation-dependent
GO:0008284 positive regulation of cell population proliferation
IMP
PMID:15629145
Tyrosine 769 of the keratinocyte growth factor receptor is r...
ACCEPT
Summary: PMID:15629145 showed that KGFR Y769F mutation impairs cell proliferation, demonstrating that functional KGFR (FGFR2IIIb) signaling promotes proliferation.
Reason: Mutant phenotype analysis demonstrates FGFR2 promotes cell proliferation. Core biological process for FGFR signaling.
Supporting Evidence:
PMID:15629145
tyrosine 769 is required...for cell proliferation through the regulation of FRS2 tyrosine phosphorylation
GO:0008284 positive regulation of cell population proliferation
IDA
PMID:8663044
Receptor specificity of the fibroblast growth factor family.
ACCEPT
Summary: PMID:8663044 used mitogenic assays to demonstrate FGF-induced proliferation through FGFR2. Multiple FGF ligands activated FGFR2-expressing cells.
Reason: Direct mitogenic assays showing FGFR2 activation promotes cell proliferation. Foundational evidence for this core biological process.
Supporting Evidence:
PMID:8663044
Receptor specificity of the fibroblast growth factor family.
GO:0008543 fibroblast growth factor receptor signaling pathway
IDA
PMID:15629145
Tyrosine 769 of the keratinocyte growth factor receptor is r...
ACCEPT
Summary: PMID:15629145 characterized KGFR signaling pathway including PLCgamma recruitment, FRS2 phosphorylation, and MAPK activation. This directly demonstrates FGF receptor signaling.
Reason: Detailed characterization of FGFR2 (KGFR) signaling pathway components. Core biological process.
Supporting Evidence:
PMID:15629145
tyrosine 769 is required for the binding to KGFR and tyrosine phosphorylation of PLCgamma as well as for the full activation of MAPKs
GO:0008543 fibroblast growth factor receptor signaling pathway
IDA
PMID:8663044
Receptor specificity of the fibroblast growth factor family.
ACCEPT
Summary: PMID:8663044 demonstrated FGF signaling through FGFR2 using mitogenic assays as readout of pathway activation.
Reason: Functional demonstration of FGF signaling pathway activation through FGFR2.
Supporting Evidence:
PMID:8663044
Receptor specificity of the fibroblast growth factor family.
GO:0010518 positive regulation of phospholipase activity
IMP
PMID:16844695
Intracellular retention, degradation, and signaling of glyco...
ACCEPT
Summary: PMID:16844695 showed both wild-type and mutant FGFR2 signal through PLCgamma. The C278F mutation and unglycosylated FGFR2 signal through PLCgamma in a ligand-independent manner.
Reason: Demonstrates FGFR2 activates PLCgamma (phospholipase C gamma), which is a well-established downstream effector of FGFR signaling.
Supporting Evidence:
PMID:16844695
Both FGFR2C278F and unglycosylated wild type FGFR2 signal through phospholipase Cgamma in a ligand-independent manner
GO:0017134 fibroblast growth factor binding
IDA
PMID:8663044
Receptor specificity of the fibroblast growth factor family.
ACCEPT
Summary: PMID:8663044 systematically characterized FGF binding specificity of FGFR2 splice variants. FGF1 binds all variants; FGF2 binds IIIc; FGF7 binds IIIb.
Reason: Comprehensive biochemical characterization of FGF binding to FGFR2 isoforms. Core molecular function. Established isoform-specific ligand preferences.
Supporting Evidence:
PMID:8663044
FGF 1 is the only FGF that can activate all FGF receptor splice variants
GO:0018108 peptidyl-tyrosine phosphorylation
IDA
PMID:15629145
Tyrosine 769 of the keratinocyte growth factor receptor is r...
ACCEPT
Summary: PMID:15629145 demonstrated KGFR (FGFR2IIIb) phosphorylates tyrosine residues on PLCgamma and FRS2 substrates. The study showed Y769 is required for PLCgamma and FRS2 tyrosine phosphorylation.
Reason: Direct demonstration of FGFR2 tyrosine kinase activity phosphorylating substrates. Core enzymatic function of receptor tyrosine kinases.
Supporting Evidence:
PMID:15629145
tyrosine 769 is required for the binding to KGFR and tyrosine phosphorylation of PLCgamma...through the regulation of FRS2 tyrosine phosphorylation
GO:0018108 peptidyl-tyrosine phosphorylation
IDA
PMID:16844695
Intracellular retention, degradation, and signaling of glyco...
ACCEPT
Summary: PMID:16844695 showed FGFR2 phosphorylates itself and downstream substrates. Both wild-type and mutant FGFR2 exhibit tyrosine phosphorylation activity.
Reason: Confirms FGFR2 tyrosine kinase activity in phosphorylating substrates.
Supporting Evidence:
PMID:16844695
2006 Jul 14. Intracellular retention, degradation, and signaling of glycosylation-deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F.
GO:0033688 regulation of osteoblast proliferation
TAS
PMID:15190072
Cbl-mediated degradation of Lyn and Fyn induced by constitut...
ACCEPT
Summary: PMID:15190072 studied FGFR2 S252W gain-of-function mutation in osteoblasts. The study shows constitutive FGFR2 activation affects osteoblast proliferation through regulation of Src family kinases Lyn and Fyn.
Reason: Direct evidence that FGFR2 regulates osteoblast proliferation. This function is highly relevant to craniosynostosis syndromes caused by FGFR2 mutations.
Supporting Evidence:
PMID:15190072
Fibroblast growth factors (FGFs) play an important regulatory role in skeletal development and bone formation
GO:0042803 protein homodimerization activity
IPI
PMID:16844695
Intracellular retention, degradation, and signaling of glyco...
ACCEPT
Summary: PMID:16844695 studied FGFR2 homodimerization which is required for receptor activation. FGFR2 dimerizes upon ligand binding or constitutively in gain-of-function mutants.
Reason: FGFR2 homodimerization is essential for receptor activation. Documented by immunoprecipitation studies. Core mechanism of receptor activation.
Supporting Evidence:
PMID:16844695
2006 Jul 14. Intracellular retention, degradation, and signaling of glycosylation-deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F.
GO:0043410 positive regulation of MAPK cascade
IMP
PMID:15629145
Tyrosine 769 of the keratinocyte growth factor receptor is r...
ACCEPT
Summary: PMID:15629145 showed that KGFR Y769F mutation impairs MAPK activation, demonstrating that functional FGFR2 signaling is required for full MAPK cascade activation.
Reason: Mutant phenotype analysis confirms FGFR2 activates MAPK cascade. Core downstream signaling pathway.
Supporting Evidence:
PMID:15629145
tyrosine 769 is required...for the full activation of MAPKs
GO:0045667 regulation of osteoblast differentiation
TAS
PMID:15190072
Cbl-mediated degradation of Lyn and Fyn induced by constitut...
ACCEPT
Summary: PMID:15190072 demonstrated that constitutive FGFR2 activation promotes osteoblast differentiation through Cbl-mediated degradation of Src family kinases Lyn and Fyn.
Reason: Direct evidence that FGFR2 regulates osteoblast differentiation. The FGFR2 S252W mutation (Apert syndrome) increases ALP expression, a marker of osteoblast differentiation.
Supporting Evidence:
PMID:15190072
constitutive FGFR2 activation induces c-Cbl-dependent Lyn and Fyn proteasome degradation, resulting in...increased ALP expression
GO:0046777 protein autophosphorylation
IDA
PMID:15629145
Tyrosine 769 of the keratinocyte growth factor receptor is r...
ACCEPT
Summary: PMID:15629145 demonstrated KGFR (FGFR2IIIb) autophosphorylation on tyrosine residues including Y769 upon ligand binding.
Reason: Direct demonstration of FGFR2 autophosphorylation. Core mechanism of receptor tyrosine kinase activation.
Supporting Evidence:
PMID:15629145
KGFR is rapidly autophosphorylated on specific tyrosine residues in the intracellular domain
GO:0048705 skeletal system morphogenesis
TAS
PMID:15190072
Cbl-mediated degradation of Lyn and Fyn induced by constitut...
ACCEPT
Summary: PMID:15190072 discusses FGFR2 role in skeletal development. FGFR2 mutations cause skeletal abnormalities including craniosynostosis.
Reason: FGFR2 is essential for skeletal system development. Mutations cause multiple craniosynostosis syndromes affecting skull development.
Supporting Evidence:
PMID:15190072
Fibroblast growth factors (FGFs) play an important regulatory role in skeletal development and bone formation
GO:0035602 fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow cell
ISS
GO_REF:0000024
MARK AS OVER ANNOTATED
Summary: ISS annotation transferred from mouse ortholog. Overly specific term for a context-dependent function that is not a primary role for human FGFR2.
Reason: While FGF signaling can have anti-apoptotic effects, this highly specific term (bone marrow cell apoptosis) is not a core function of human FGFR2. Mouse knockout data may not directly translate to primary human function.
GO:0035603 fibroblast growth factor receptor signaling pathway involved in hemopoiesis
ISS
GO_REF:0000024
MARK AS OVER ANNOTATED
Summary: ISS annotation transferred from mouse ortholog. Hemopoiesis is not a primary function of FGFR2; this likely reflects pleiotropic effects in mouse models.
Reason: FGFR2 primary functions are in epithelial-mesenchymal signaling, skeletal development, and wound healing. Hemopoietic role is not a core function.
GO:0035604 fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow
ISS
GO_REF:0000024
MARK AS OVER ANNOTATED
Summary: ISS annotation transferred from mouse ortholog. Overly specific term for bone marrow context that is not a primary FGFR2 function.
Reason: While FGFR2 promotes proliferation generally, this bone marrow-specific context is not a core function for human FGFR2.
GO:0035607 fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog. FGFR2 has roles in brain development but this specific term for orbitofrontal cortex is highly specialized.
Reason: Brain development role is plausible given FGFR2 mutations cause Crouzon and Apert syndromes which can have CNS effects. However, this is a very specific developmental context, not a core function.
GO:0021769 orbitofrontal cortex development
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog for orbitofrontal cortex development. Related to the above signaling pathway annotation.
Reason: Specialized developmental context. FGFR2 contributes to brain development but this specific region is not a core function.
GO:0021847 ventricular zone neuroblast division
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog for neural progenitor division in the ventricular zone during brain development.
Reason: FGF signaling has roles in neural development but this is a specialized developmental function, not a core FGFR2 function.
GO:0021860 pyramidal neuron development
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog for pyramidal neuron development.
Reason: Specialized neuronal development context. Not a primary FGFR2 function.
GO:0045787 positive regulation of cell cycle
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2 promotes cell proliferation which involves positive regulation of the cell cycle.
Reason: Consistent with FGFR2 role in promoting cell proliferation. Mitogenic signaling through FRS2/MAPK pathway drives cell cycle progression.
GO:0060076 excitatory synapse
ISS
GO_REF:0000024
MARK AS OVER ANNOTATED
Summary: ISS annotation from mouse ortholog suggesting FGFR2 localization at excitatory synapses. Unusual localization for a growth factor receptor.
Reason: Synaptic localization is not a core function of FGFR2. May reflect specialized neuronal signaling in mouse models but not a primary human FGFR2 function.
GO:0000122 negative regulation of transcription by RNA polymerase II
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog. Indirect effect of FGFR2 signaling on transcription through downstream pathways.
Reason: FGFR2 signaling can affect transcription through MAPK and other pathways, but transcriptional regulation is an indirect downstream effect, not a core molecular function of the receptor.
GO:0001525 angiogenesis
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog. Duplicate of IBA annotation - FGF signaling has documented roles in angiogenesis.
Reason: Consistent with IBA annotation. Angiogenesis is a documented but non-core function for FGFR2; FGFR1 may be more prominent in vascular biology.
GO:0001657 ureteric bud development
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog. FGFR2 has roles in kidney development including ureteric bud branching morphogenesis.
Reason: UniProt notes FGFR2 is required for normal embryonic patterning including organogenesis. Kidney development is a documented but tissue-specific developmental function.
GO:0001701 in utero embryonic development
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog. FGFR2 is required for normal embryonic development as evidenced by embryonic lethality in knockout mice.
Reason: Very broad developmental term. FGFR2 is essential for development but more specific terms (limb, lung, skeletal) better capture core functions.
GO:0002053 positive regulation of mesenchymal cell proliferation
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2IIIc (mesenchymal isoform) promotes mesenchymal cell proliferation in response to FGF2/4 from epithelium.
Reason: Core function for FGFR2IIIc isoform. Mesenchymal proliferation is central to epithelial-mesenchymal signaling that FGFR2 mediates in development.
GO:0003148 outflow tract septum morphogenesis
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog. Cardiac outflow tract development involves FGFR signaling but is a specialized developmental context.
Reason: Cardiac development role is documented for FGFRs but this specific structure is not a core FGFR2 function.
GO:0003149 membranous septum morphogenesis
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog. Cardiac septum development is a specialized developmental context.
Reason: Specialized cardiac developmental function, not a core FGFR2 function.
GO:0007267 cell-cell signaling
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2 mediates paracrine signaling between epithelium and mesenchyme.
Reason: Core function. FGFR2 mediates paracrine FGF signaling between cell types, particularly epithelial-mesenchymal communication where IIIb receives signals from mesenchyme and IIIc receives signals from epithelium.
GO:0007409 axonogenesis
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog. FGF signaling has roles in axon guidance and neuronal development.
Reason: Neural development role is documented but not a primary FGFR2 function. More specialized than core epithelial-mesenchymal signaling roles.
GO:0008589 regulation of smoothened signaling pathway
ISS
GO_REF:0000024
MARK AS OVER ANNOTATED
Summary: ISS annotation from mouse ortholog. Cross-talk between FGF and Hedgehog (Smoothened) pathways has been reported in development.
Reason: While pathway cross-talk exists, direct regulation of Smoothened signaling is not a core FGFR2 function. This represents indirect developmental pathway interactions rather than a primary function.
GO:0009791 post-embryonic development
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog. FGFR2 has roles in tissue homeostasis and repair after embryonic development.
Reason: FGFR2 continues to function in adult tissue homeostasis and wound healing but this is a broad term. Embryonic roles are better documented.
GO:0009880 embryonic pattern specification
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2 contributes to embryonic patterning through epithelial-mesenchymal interactions.
Reason: UniProt confirms FGFR2 is required for normal embryonic patterning. FGF signaling through FGFR2 establishes tissue boundaries and patterns during development.
GO:0009887 animal organ morphogenesis
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2 is required for morphogenesis of multiple organs including limbs, lungs, and skeleton.
Reason: Core developmental function. FGFR2 is essential for branching morphogenesis and organ development, particularly lungs, limbs, and craniofacial skeleton.
GO:0016331 morphogenesis of embryonic epithelium
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2IIIb is expressed in epithelium and receives signals from mesenchyme to direct epithelial morphogenesis.
Reason: Core function for FGFR2IIIb isoform. Epithelial morphogenesis through FGF7/10 signaling is a primary developmental role.
GO:0022612 gland morphogenesis
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2 is required for salivary gland, lacrimal gland, and other gland development through branching morphogenesis.
Reason: Core developmental function. FGFR2-mediated branching morphogenesis is essential for gland development in multiple organ systems.
GO:0030177 positive regulation of Wnt signaling pathway
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog. Cross-talk between FGF and Wnt pathways occurs during development but this is indirect signaling.
Reason: FGF-Wnt pathway interactions exist during development but positive regulation of Wnt signaling is not a direct core function of FGFR2.
GO:0030282 bone mineralization
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog. FGFR2 regulates osteoblast differentiation and bone development; mineralization is a downstream effect.
Reason: Indirect effect of FGFR2 on osteoblast function. The core function is regulating osteoblast proliferation/differentiation rather than mineralization per se.
GO:0030324 lung development
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2 is essential for lung branching morphogenesis. UniProt confirms role in lung morphogenesis.
Reason: Core developmental function. FGFR2 (particularly IIIb/KGFR) is essential for lung epithelial branching morphogenesis through FGF10 signaling.
GO:0030855 epithelial cell differentiation
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2IIIb in epithelial cells regulates their differentiation in response to mesenchymal FGF signals.
Reason: Core function for FGFR2IIIb isoform. Epithelial differentiation is directed by FGF7/10 signaling through the epithelial FGFR2 isoform.
GO:0030901 midbrain development
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog for midbrain development.
Reason: Brain development is one of many developmental contexts where FGFR2 functions, but not a primary function.
GO:0030916 otic vesicle formation
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog for inner ear development.
Reason: Specialized developmental context. FGFR2 contributes to ear development but this is not a core function.
GO:0031069 hair follicle morphogenesis
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2 is required for skin development including hair follicles. UniProt notes role in skin development.
Reason: Documented role in skin development. FGF signaling through FGFR2IIIb contributes to epithelial appendage formation including hair follicles.
GO:0032808 lacrimal gland development
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog. Lacrimal gland develops through branching morphogenesis requiring FGFR2 signaling.
Reason: Example of gland morphogenesis role. More general gland morphogenesis term already captures this function.
GO:0035265 organ growth
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2 promotes cell proliferation which contributes to organ growth during development.
Reason: General term consistent with FGFR2 role in promoting proliferation during organ development.
GO:0042472 inner ear morphogenesis
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog for inner ear development.
Reason: Specialized developmental context for ear morphogenesis.
GO:0042476 odontogenesis
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog. FGF signaling is involved in tooth development through epithelial-mesenchymal interactions.
Reason: Tooth development involves FGFR2 but is a specialized developmental context rather than a core function.
GO:0045165 cell fate commitment
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog. FGFR2 signaling influences cell fate decisions during development.
Reason: Broad developmental term. FGFR2 influences cell fate but more specific terms better capture its functions.
GO:0045944 positive regulation of transcription by RNA polymerase II
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog. FGFR2 signaling can activate transcription through MAPK pathway and transcription factors.
Reason: Indirect downstream effect of FGFR2 signaling rather than a core molecular function of the receptor.
GO:0048286 lung alveolus development
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. Specific aspect of lung development where FGFR2 contributes to alveolar formation.
Reason: Part of core lung development function. FGFR2 is essential for lung morphogenesis including alveolar development.
GO:0048557 embryonic digestive tract morphogenesis
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog for GI tract development.
Reason: One of many organs where FGFR2 contributes to development but not a primary documented function.
GO:0048562 embryonic organ morphogenesis
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. General term for FGFR2 role in organ development during embryogenesis.
Reason: Core developmental function. FGFR2 is essential for morphogenesis of multiple organs through epithelial-mesenchymal interactions.
GO:0048565 digestive tract development
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog for GI tract development.
Reason: Digestive tract development is one of many developmental contexts.
GO:0048568 embryonic organ development
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. Broad term for embryonic organogenesis role of FGFR2.
Reason: Core developmental function consistent with FGFR2 role in multiple organ systems during development.
GO:0048608 reproductive structure development
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog for reproductive organ development.
Reason: Specialized developmental context not emphasized in human FGFR2 function.
GO:0048730 epidermis morphogenesis
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2 is required for skin development. UniProt confirms role in skin development.
Reason: Documented function. FGFR2IIIb in keratinocytes responds to FGF7/KGF from dermal fibroblasts to regulate epidermis.
GO:0048755 branching morphogenesis of a nerve
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog for nerve branching.
Reason: Specialized neural context not a primary FGFR2 function.
GO:0048762 mesenchymal cell differentiation
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2IIIc in mesenchyme responds to epithelial FGFs to promote mesenchymal differentiation.
Reason: Core function for FGFR2IIIc isoform. Mesenchymal differentiation is central to FGFR2 role in development.
GO:0050679 positive regulation of epithelial cell proliferation
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2IIIb promotes epithelial cell proliferation in response to FGF7/10. UniProt confirms proliferation in keratinocytes.
Reason: Core function for FGFR2IIIb isoform. Epithelial proliferation is a primary response to FGF7/10 signaling.
GO:0051150 regulation of smooth muscle cell differentiation
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog for smooth muscle differentiation.
Reason: Specialized context for FGFR2 function in mesenchymal differentiation.
GO:0051781 positive regulation of cell division
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2 promotes cell proliferation which involves cell division.
Reason: Consistent with core mitogenic function of FGFR2 signaling.
GO:0055010 ventricular cardiac muscle tissue morphogenesis
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog for cardiac development.
Reason: Cardiac development context is not a primary FGFR2 function.
GO:0060045 positive regulation of cardiac muscle cell proliferation
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog for cardiac muscle proliferation.
Reason: Specialized cardiac context not a primary FGFR2 function.
GO:0060174 limb bud formation
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2 is essential for limb bud development. UniProt confirms role in limb bud development.
Reason: Core developmental function. FGFR2 is required for limb bud outgrowth and patterning through FGF signaling.
GO:0060348 bone development
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2 is essential for bone development; mutations cause craniosynostosis syndromes.
Reason: Core developmental function. FGFR2 mutations in humans cause multiple skeletal syndromes demonstrating essential role in osteogenesis.
GO:0060349 bone morphogenesis
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2 regulates bone shape through effects on osteoblast function.
Reason: Core function evidenced by craniosynostosis syndromes where FGFR2 mutations cause abnormal skull bone morphology.
GO:0060442 branching involved in prostate gland morphogenesis
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog. Prostate gland develops through branching morphogenesis involving FGFR2.
Reason: Specific example of branching morphogenesis. General gland morphogenesis term captures this function.
GO:0060445 branching involved in salivary gland morphogenesis
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. Salivary gland develops through FGFR2-dependent branching morphogenesis.
Reason: Well-documented example of FGFR2-dependent branching morphogenesis. FGF10/FGFR2IIIb signaling is essential for salivary gland development.
GO:0060449 bud elongation involved in lung branching
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. Specific aspect of lung branching morphogenesis involving bud outgrowth.
Reason: Core lung development function. FGF10/FGFR2IIIb signaling drives epithelial bud elongation in lung branching.
GO:0060463 lung lobe morphogenesis
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog for lung lobe formation.
Reason: Part of core lung development function of FGFR2.
GO:0060484 lung-associated mesenchyme development
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2IIIc in lung mesenchyme responds to epithelial FGFs during development.
Reason: Core lung development function. Both epithelial (IIIb) and mesenchymal (IIIc) FGFR2 isoforms contribute to lung development.
GO:0060501 positive regulation of epithelial cell proliferation involved in lung morphogenesis
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGF10/FGFR2IIIb signaling promotes lung epithelial proliferation during branching morphogenesis.
Reason: Core function for lung development. FGFR2IIIb-mediated epithelial proliferation is essential for lung morphogenesis.
GO:0060512 prostate gland morphogenesis
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog for prostate development.
Reason: Specific gland development context. More general gland morphogenesis captures this function.
GO:0060523 prostate epithelial cord elongation
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog for prostate development.
Reason: Specific prostate developmental context. More general epithelial morphogenesis and gland development terms capture this function.
GO:0060527 prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog for highly specific prostate morphogenesis.
Reason: Overly specific developmental term. General gland morphogenesis captures FGFR2 role without this level of specificity.
GO:0060529 squamous basal epithelial stem cell differentiation involved in prostate gland acinus development
ISS
GO_REF:0000024
MARK AS OVER ANNOTATED
Summary: ISS annotation from mouse ortholog for very specific prostate stem cell context.
Reason: Extremely specific term that goes beyond core FGFR2 function. This level of specificity is not a primary FGFR2 function.
GO:0060601 lateral sprouting from an epithelium
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. Epithelial sprouting is part of branching morphogenesis that FGFR2 mediates.
Reason: Consistent with FGFR2 role in branching morphogenesis. Lateral sprouting is a core mechanism of epithelial branching in lungs and glands.
GO:0060615 mammary gland bud formation
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog. Mammary gland develops through FGFR2-dependent mechanisms similar to other glands.
Reason: Example of gland morphogenesis. General gland development terms capture this function.
GO:0060664 epithelial cell proliferation involved in salivary gland morphogenesis
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGF10/FGFR2IIIb signaling promotes epithelial proliferation in salivary gland development.
Reason: Core function for salivary gland development which is a well-documented FGFR2 function through epithelial-mesenchymal interactions.
GO:0060667 branch elongation involved in salivary gland morphogenesis
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. Branch elongation is a key aspect of salivary gland branching morphogenesis.
Reason: Core salivary gland development function. Consistent with FGFR2 role in branching morphogenesis.
GO:0060670 branching involved in labyrinthine layer morphogenesis
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog for placental labyrinthine layer.
Reason: Placental development context. UniProt notes trophoblast function but this specific aspect is not emphasized.
GO:0060688 regulation of morphogenesis of a branching structure
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2 is a key regulator of branching morphogenesis in multiple organs.
Reason: Core developmental function. FGFR2 regulates branching morphogenesis in lungs, glands, and other organs through epithelial-mesenchymal signaling.
GO:0060915 mesenchymal cell differentiation involved in lung development
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2IIIc in lung mesenchyme responds to epithelial signals to regulate mesenchymal differentiation.
Reason: Core lung development function. Both epithelial (IIIb) and mesenchymal (IIIc) FGFR2 isoforms contribute to lung development.
GO:0060916 mesenchymal cell proliferation involved in lung development
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2IIIc in lung mesenchyme promotes proliferation in response to epithelial FGFs.
Reason: Core lung development function for FGFR2IIIc isoform.
GO:0070372 regulation of ERK1 and ERK2 cascade
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2 activates ERK1/2 (MAPK3/MAPK1) through the RAS-MAPK pathway.
Reason: Core signaling function. ERK1/2 cascade activation is a primary downstream effect of FGFR2 signaling through FRS2/GRB2/SOS/RAS pathway.
GO:0070374 positive regulation of ERK1 and ERK2 cascade
ISS
GO_REF:0000024
ACCEPT
Summary: ISS annotation from mouse ortholog. FGFR2 positively regulates ERK1/2 cascade activation.
Reason: Core signaling function. More specific child term of MAPK cascade regulation that is well-documented for FGFR2.
GO:0090263 positive regulation of canonical Wnt signaling pathway
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: ISS annotation from mouse ortholog. Cross-talk between FGF and Wnt pathways occurs during development.
Reason: Indirect pathway cross-talk rather than a direct core function of FGFR2. More specific than general Wnt regulation annotation already reviewed.
GO:0016020 membrane
NAS
PMID:8676562
[Nucleotide sequences at intron 6 and exon 7 junction of fib...
ACCEPT
Summary: NAS annotation for membrane localization. FGFR2 is a transmembrane receptor.
Reason: Correct but general term. More specific plasma membrane annotations exist.
Supporting Evidence:
PMID:8676562
Apert syndrome, acrocephalosyndactyly Type I, is an autosomal dominant craniosynostosis comprising acrocephaly, facial dysmorphism and severe syndactyly of the hands and feet.
GO:0005634 nucleus
IDA
PMID:17471512
Translocation of fibroblast growth factor-10 and its recepto...
KEEP AS NON CORE
Summary: PMID:17471512 demonstrated nuclear localization of FGF-10 receptor (FGFR2IIIb) in urothelial cells along with its ligand FGF-10.
Reason: Nuclear localization represents a specialized signaling mechanism rather than the primary localization. Main FGFR2 function is at plasma membrane.
Supporting Evidence:
PMID:17471512
The FGF-10 receptor was observed in cell nuclei regardless of the presence or concentration of exogenous rFGF-10 ligand
GO:0005737 cytoplasm
IDA
PMID:17471512
Translocation of fibroblast growth factor-10 and its recepto...
ACCEPT
Summary: PMID:17471512 showed FGF-10 receptor (FGFR2IIIb) localizes to cytoplasm in urothelial cells during trafficking.
Reason: FGFR2 is found in cytoplasm during biosynthesis, trafficking, and after internalization.
Supporting Evidence:
PMID:17471512
rFGF-10(no NLS) was found in cytoplasm to a far greater degree than rFGF-10
GO:0005938 cell cortex
IDA
PMID:17471512
Translocation of fibroblast growth factor-10 and its recepto...
KEEP AS NON CORE
Summary: PMID:17471512 may have observed FGFR2 at the cell cortex during trafficking or at the plasma membrane interface.
Reason: Cell cortex localization is not a primary FGFR2 localization. May represent trafficking intermediate or plasma membrane-associated pool.
Supporting Evidence:
PMID:17471512
Translocation of fibroblast growth factor-10 and its receptor into nuclei of human urothelial cells.
GO:0008284 positive regulation of cell population proliferation
IGI
PMID:8663044
Receptor specificity of the fibroblast growth factor family.
ACCEPT
Summary: IGI (Inferred from Genetic Interaction) annotation from PMID:8663044 which tested multiple FGF-FGFR combinations for mitogenic activity.
Reason: Consistent with core mitogenic function. PMID:8663044 demonstrated proliferative activity of FGFR2 with various FGF ligands.
Supporting Evidence:
PMID:8663044
Receptor specificity of the fibroblast growth factor family.
GO:0008543 fibroblast growth factor receptor signaling pathway
IGI
PMID:8663044
Receptor specificity of the fibroblast growth factor family.
ACCEPT
Summary: IGI annotation from PMID:8663044 demonstrating FGF receptor signaling through FGFR2.
Reason: Core biological process. PMID:8663044 is foundational study for FGFR signaling specificity.
Supporting Evidence:
PMID:8663044
Receptor specificity of the fibroblast growth factor family.
GO:0005007 fibroblast growth factor receptor activity
IGI
PMID:10830168
Crystal structures of two FGF-FGFR complexes reveal the dete...
ACCEPT
Summary: IGI annotation from PMID:10830168 which determined crystal structures of FGF-FGFR complexes and characterized ligand-receptor specificity.
Reason: Core molecular function. PMID:10830168 provided structural basis for FGF receptor specificity through alternative splicing.
Supporting Evidence:
PMID:10830168
Specificity is achieved through interactions between the N-terminal and central regions of FGFs and two loop regions in D3 that are subject to alternative splicing
GO:0008543 fibroblast growth factor receptor signaling pathway
IPI
PMID:10830168
Crystal structures of two FGF-FGFR complexes reveal the dete...
ACCEPT
Summary: IPI annotation from PMID:10830168 based on physical interaction studies of FGF-FGFR complexes.
Reason: Core signaling pathway. Crystal structures revealed basis for ligand binding and receptor activation.
Supporting Evidence:
PMID:10830168
Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity.
GO:0017134 fibroblast growth factor binding
IPI
PMID:8386828
Activation of fibroblast growth factor (FGF) receptors by re...
ACCEPT
Summary: IPI annotation from PMID:8386828 demonstrating FGF-5 binding to FGFR2. Competition binding studies showed KD of 0.5-1.5 nM.
Reason: Core molecular function. Direct binding assays demonstrated FGF binding to FGFR2 with high affinity.
Supporting Evidence:
PMID:8386828
the KD for FGF-5-FGFR-1 and FGF-5-FGFR-2 interactions are both between 0.5 and 1.5 x 10(-9) M
GO:0005007 fibroblast growth factor receptor activity
NAS
PMID:8676562
[Nucleotide sequences at intron 6 and exon 7 junction of fib...
ACCEPT
Summary: NAS annotation for FGF receptor activity. Duplicate annotation with different evidence code.
Reason: Core molecular function supported by multiple evidence types.
Supporting Evidence:
PMID:8676562
Apert syndrome, acrocephalosyndactyly Type I, is an autosomal dominant craniosynostosis comprising acrocephaly, facial dysmorphism and severe syndactyly of the hands and feet.
GO:0004713 protein tyrosine kinase activity
NAS
PMID:1697263
Cloning and expression of two distinct high-affinity recepto...
ACCEPT
Summary: NAS annotation for protein tyrosine kinase activity. FGFR2 is a receptor tyrosine kinase.
Reason: Core molecular function. FGFR2 is a well-characterized receptor tyrosine kinase (EC 2.7.10.1).
Supporting Evidence:
PMID:1697263
Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors.
GO:0005007 fibroblast growth factor receptor activity
NAS
PMID:1400433
A novel form of fibroblast growth factor receptor 2. Alterna...
ACCEPT
Summary: NAS annotation from PMID:1400433 which identified alternative splicing creating isoforms with different ligand specificities.
Reason: Core molecular function. PMID:1400433 was important for understanding isoform-specific FGF binding.
Supporting Evidence:
PMID:1400433
A novel form of fibroblast growth factor receptor 2.
GO:0005007 fibroblast growth factor receptor activity
NAS
PMID:1697263
Cloning and expression of two distinct high-affinity recepto...
ACCEPT
Summary: NAS annotation for FGF receptor activity. Duplicate with different reference.
Reason: Core molecular function.
Supporting Evidence:
PMID:1697263
Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors.
GO:0016020 membrane
NAS
PMID:1697263
Cloning and expression of two distinct high-affinity recepto...
ACCEPT
Summary: NAS annotation for membrane localization. FGFR2 is a single-pass type I membrane protein.
Reason: Correct but general term. More specific plasma membrane annotations exist.
Supporting Evidence:
PMID:1697263
Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors.

Core Functions

References

file:human/FGFR2/FGFR2-deep-research-falcon.md
Deep research report on FGFR2 function, signaling, and clinical relevance
  • FGFR2 is a plasma membrane receptor tyrosine kinase with Ig-like extracellular domains whose IIIb/IIIc isoform switching determines epithelial vs mesenchymal ligand specificity.
  • Core signaling through FRS2/MAPK and PLCgamma pathways drives proliferation, differentiation, and branching morphogenesis in lungs, limbs, skeleton, and glands.
Gene Ontology annotation through association of InterPro records with GO terms
Gene Ontology annotation based on Enzyme Commission mapping
Manual transfer of experimentally-verified manual GO annotation data to orthologs by curator judgment of sequence similarity
Annotation inferences using phylogenetic trees
Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping
Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location vocabulary mapping, accompanied by conservative changes to GO terms applied by UniProt
Automatic transfer of experimentally verified manual GO annotation data to orthologs using Ensembl Compara
Electronic Gene Ontology annotations created by ARBA machine learning models
Combined Automated Annotation using Multiple IEA Methods
Structural interactions of fibroblast growth factor receptor with its ligands.
Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity.
Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.
Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors.
Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene.
A novel form of fibroblast growth factor receptor 2. Alternative splicing of the third immunoglobulin-like domain confers ligand binding specificity.
Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast growth factor receptor-2 activation supports osteoblast differentiation.
Tyrosine 769 of the keratinocyte growth factor receptor is required for receptor signaling but not endocytosis.
FGF-10 and its receptor exhibit bidirectional paracrine targeting to urothelial and smooth muscle cells in the lower urinary tract.
Intracellular retention, degradation, and signaling of glycosylation-deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F.
Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors.
Translocation of fibroblast growth factor-10 and its receptor into nuclei of human urothelial cells.
Heparanase cleavage of perlecan heparan sulfate modulates FGF10 activity during ex vivo submandibular gland branching morphogenesis.
MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2.
Inhibition of basal FGF receptor signaling by dimeric Grb2.
Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling.
Using an in situ proximity ligation assay to systematically profile endogenous protein-protein interactions in a pathway network.
Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy.
Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.
Physical and functional interactome atlas of human receptor tyrosine kinases.
A physical wiring diagram for the human immune system.
Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2.
Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome.
Activation of fibroblast growth factor (FGF) receptors by recombinant human FGF-5.
Receptor specificity of the fibroblast growth factor family.
[Nucleotide sequences at intron 6 and exon 7 junction of fibroblast growth factor receptor 2 and rapid mutational analysis in Apert syndrome].
Reactome:R-HSA-109699
PI3K-containing complexes phosphorylate PIP2 to PIP3
Reactome:R-HSA-190258
FGFR2c binds to FGF
Reactome:R-HSA-190260
FGFR2b binds to FGF
Reactome:R-HSA-190408
Autocatalytic phosphorylation of FGFR2b
Reactome:R-HSA-190413
Autocatalytic phosphorylation of FGFR2c
Reactome:R-HSA-2029983
Dimerization of FGFR2 ligand-independent mutants
Reactome:R-HSA-2029984
Autocatalytic phosphorylation of FGFR2 ligand-independent mutants
Reactome:R-HSA-2029988
Dimerization of overexpressed FGFR2
Reactome:R-HSA-2029989
Autocatalytic phosphorylation of overexpressed FGFR2 variants
Reactome:R-HSA-2029992
Tyrosine kinase inhibitors bind to overexpressed FGFR2 variants
Reactome:R-HSA-2033472
FGFR2c mutants bind an expanded range of ligands
Reactome:R-HSA-2033474
FGFR2b mutants bind an expanded range of ligands
Reactome:R-HSA-2033479
Dimerization of FGFR2 point mutants with enhanced kinase activity
Reactome:R-HSA-2033486
Autocatalytic phosphorylation of FGFR2c mutants with enhanced ligand binding
Reactome:R-HSA-2033488
Autocatalytic phosphorylation of FGFR2b mutants with enhanced ligand binding
Reactome:R-HSA-2033490
Autocatalytic phosphorylation of FGFR2 point mutants with enhanced kinase activity
Reactome:R-HSA-2067713
GP369 inhibits activation of amplified FGFR2 signaling
Reactome:R-HSA-2077424
Point mutants of FGFR2 bind and are inactivated by tyrosine kinase inhibitors
Reactome:R-HSA-2316434
PI3K phosphorylates PIP2 to PIP3
Reactome:R-HSA-2400009
PI3K inhibitors block PI3K catalytic activity
Reactome:R-HSA-5654147
Activated FGFR2 phosphorylates PLCG1
Reactome:R-HSA-5654157
p-4Y-PLCG1 dissociates from activated FGFR2
Reactome:R-HSA-5654159
Activated FGFR2 binds PLCG1
Reactome:R-HSA-5654397
Activated FGFR2 phosphorylates FRS2
Reactome:R-HSA-5654399
Activated FGFR2 binds FRS2
Reactome:R-HSA-5654402
Activated FGFR2:p-SHC1:GRB2:SOS1 activates RAS nucleotide exchange
Reactome:R-HSA-5654404
Activated FGFR2 binds SHC1
Reactome:R-HSA-5654406
Activated FGFR2:p-SHC1 binds GRB2:SOS1
Reactome:R-HSA-5654407
Activated FGFR2 phosphorylates SHC1
Reactome:R-HSA-5654562
Activated ERK1/2 threonine-phosphorylates FGFR2-associated FRS2
Reactome:R-HSA-5654603
Activated FGFR2 binds FRS3
Reactome:R-HSA-5654605
Activated FGFR2 phosphorylates FRS3
Reactome:R-HSA-5654607
Activated FGFR2 phosphorylates PPTN11
Reactome:R-HSA-5654608
Activated FGFR2:p-FRS bind to PPTN11
Reactome:R-HSA-5654612
Activated FGFR2:p-FRS2 binds GRB2:GAB1:PIK3R1
Reactome:R-HSA-5654614
Activated FGFR2:p-FRS2:GRB2:GAB1:PI3KR1 binds PIK3CA
Reactome:R-HSA-5654615
Activated FGFR2:pFRS binds GRB2:SOS1
Reactome:R-HSA-5654618
Activated FGFR2:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange
Reactome:R-HSA-5654620
Activated FGFR2:p-FRS2:p-PPTN11 binds GRB2:GAB1:PI3KR1
Reactome:R-HSA-5654622
Activated FGFR2:p-FRS2:p-PPTN11:GRB2:GAB1:PIK3R1 binds PIK3CA
Reactome:R-HSA-5654677
CBL ubiquitinates FRS2 and FGFR2
Reactome:R-HSA-5654697
FGFR2- and PTPN11- associated PI3K phosphorylates PIP2 to PIP3
Reactome:R-HSA-5654701
FGFR2-associated PI3K phosphorylates PIP2 to PIP3
Reactome:R-HSA-5654729
p-CBL:GRB2 binds p-FRS2:activated FGFR2
Reactome:R-HSA-5654748
p-4Y-PLCG1 dissociates from activated FGFR2 mutants
Reactome:R-HSA-5655233
Activated FGFR2 mutants:p-FRS2 binds GRB2-SOS1
Reactome:R-HSA-5655241
Activated FGFR2 mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange
Reactome:R-HSA-5655245
Activated FGFR2 mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA
Reactome:R-HSA-5655268
Activated FGFR2 mutants phosphorylate FRS2
Reactome:R-HSA-5655301
Activated FGFR2 mutants phosphorylate PLCG1
Reactome:R-HSA-5655320
Activated FGFR2 mutants:p-FRS2 binds GRB2:GAB1:PIK3R1
Reactome:R-HSA-5655323
Activated FGFR2 mutant-associated PI3K phosphorylates PIP2 to PIP3
Reactome:R-HSA-5655339
Activated FGFR2 mutants bind FRS2
Reactome:R-HSA-5655343
Activated FGFR2 mutants bind PLCG1
Reactome:R-HSA-5672965
RAS GEFs promote RAS nucleotide exchange
Reactome:R-HSA-8853313
FGFR2 fusions autophosphorylate
Reactome:R-HSA-8853319
FGFR2 fusions dimerize
Reactome:R-NUL-8853328
Mouse FGFR2 IIIa TM binds FGF1,2 and full-length receptors

📚 Additional Documentation

Deep Research Falcon

(FGFR2-deep-research-falcon.md)

provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-03-06T03:10:37.229091'
end_time: '2026-03-06T03:26:16.731636'
duration_seconds: 939.5
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: FGFR2
gene_symbol: FGFR2
uniprot_accession: P21802
protein_description: 'RecName: Full=Fibroblast growth factor receptor 2; Short=FGFR-2;
EC=2.7.10.1 {ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:18056630, ECO:0000269|PubMed:19410646,
ECO:0000269|PubMed:21454610}; AltName: Full=K-sam; Short=KGFR; AltName: Full=Keratinocyte
growth factor receptor; AltName: CD_antigen=CD332; Flags: Precursor;'
gene_info: Name=FGFR2; Synonyms=BEK, KGFR, KSAM;
organism_full: Homo sapiens (Human).
protein_family: Belongs to the protein kinase superfamily. Tyr protein
protein_domains: FGF_rcpt_fam. (IPR016248); Ig-like_dom. (IPR007110); Ig-like_dom_sf.
(IPR036179); Ig-like_fold. (IPR013783); Ig_I-set. (IPR013098)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
temperature: 0.1
citation_count: 33


Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

  • UniProt Accession: P21802
  • Protein Description: RecName: Full=Fibroblast growth factor receptor 2; Short=FGFR-2; EC=2.7.10.1 {ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:18056630, ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21454610}; AltName: Full=K-sam; Short=KGFR; AltName: Full=Keratinocyte growth factor receptor; AltName: CD_antigen=CD332; Flags: Precursor;
  • Gene Information: Name=FGFR2; Synonyms=BEK, KGFR, KSAM;
  • Organism (full): Homo sapiens (Human).
  • Protein Family: Belongs to the protein kinase superfamily. Tyr protein
  • Key Domains: FGF_rcpt_fam. (IPR016248); Ig-like_dom. (IPR007110); Ig-like_dom_sf. (IPR036179); Ig-like_fold. (IPR013783); Ig_I-set. (IPR013098)

MANDATORY VERIFICATION STEPS:

  1. Check if the gene symbol "FGFR2" matches the protein description above
  2. Verify the organism is correct: Homo sapiens (Human).
  3. Check if protein family/domains align with what you find in literature
  4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'FGFR2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene FGFR2 (gene ID: FGFR2, UniProt: P21802) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

  • UniProt Accession: P21802
  • Protein Description: RecName: Full=Fibroblast growth factor receptor 2; Short=FGFR-2; EC=2.7.10.1 {ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:18056630, ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21454610}; AltName: Full=K-sam; Short=KGFR; AltName: Full=Keratinocyte growth factor receptor; AltName: CD_antigen=CD332; Flags: Precursor;
  • Gene Information: Name=FGFR2; Synonyms=BEK, KGFR, KSAM;
  • Organism (full): Homo sapiens (Human).
  • Protein Family: Belongs to the protein kinase superfamily. Tyr protein
  • Key Domains: FGF_rcpt_fam. (IPR016248); Ig-like_dom. (IPR007110); Ig-like_dom_sf. (IPR036179); Ig-like_fold. (IPR013783); Ig_I-set. (IPR013098)

MANDATORY VERIFICATION STEPS:

  1. Check if the gene symbol "FGFR2" matches the protein description above
  2. Verify the organism is correct: Homo sapiens (Human).
  3. Check if protein family/domains align with what you find in literature
  4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'FGFR2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene FGFR2 (gene ID: FGFR2, UniProt: P21802) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research Report: Human FGFR2 (UniProt P21802) — Functional Annotation, Biology, and Translational Landscape (2023–2024-focused)

0. Target verification (critical identity check)

The requested target FGFR2 matches UniProt P21802 from Homo sapiens and is consistently described in authoritative literature as a single-pass transmembrane receptor tyrosine kinase with three extracellular immunoglobulin-like domains, a transmembrane helix, and an intracellular split tyrosine kinase domain. This aligns with UniProt’s “Fibroblast growth factor receptor 2 (FGFR-2; KGFR/K-sam/CD332)” and the kinase family/domain architecture expected for an RTK. (lau2024clinicaldevelopmentsand pages 2-4, guttieri2023emtautophagycrosstalkrole pages 10-15)

1. Key concepts and definitions (current understanding)

1.1 What FGFR2 is

FGFR2 is a member of the FGFR receptor tyrosine kinase family that transduces extracellular fibroblast growth factor (FGF) signals into intracellular phosphorylation-dependent signaling programs that control proliferation, survival, differentiation, and migration. Canonical activation is ligand-dependent dimerization followed by autophosphorylation of tyrosines in the intracellular region, which creates docking sites for adaptor/effector proteins. (lau2024clinicaldevelopmentsand pages 2-4, zhang2024targetingfgfrfor pages 1-3)

1.2 Domain architecture and cellular localization

FGFR2 is a plasma-membrane receptor with:
- Extracellular region containing three Ig-like domains (D1–D3) (ligand-binding largely mediated by D2/D3),
- Single transmembrane helix,
- Cytoplasmic tyrosine kinase domain (split TK1/TK2) plus C-terminal tail that becomes phosphorylated to recruit signaling proteins. (lau2024clinicaldevelopmentsand pages 2-4, guttieri2023emtautophagycrosstalkrole pages 10-15)

1.3 Ligand binding, co-factors, and isoform specificity (IIIb vs IIIc)

A central concept for FGFR2 functional annotation is alternative splicing of the ligand-binding region (commonly described for FGFR1–3 as exon 8/9 usage) producing IIIb and IIIc isoforms with different tissue expression and ligand specificity:
- FGFR2-IIIb: predominantly epithelial; binds FGF7 (KGF) and FGF10 (among others) and is often referred to as the keratinocyte growth factor receptor (KGFR). (guttieri2023emtautophagycrosstalkrole pages 10-15)
- FGFR2-IIIc: predominantly mesenchymal; binds ligands such as FGF2. (guttieri2023emtautophagycrosstalkrole pages 10-15)

Ligand binding is typically stabilized by heparan sulfate proteoglycans (HSPGs) (paracrine FGFs), while endocrine FGFs require Klotho co-receptors (family-level principle relevant to FGFR2). (lau2024clinicaldevelopmentsand pages 2-4)

1.4 Activation mechanism and phosphorylation-dependent signaling

Upon FGF engagement (with HSPG support), FGFR2 dimerizes, juxtaposing kinase domains and enabling intermolecular transphosphorylation (autophosphorylation). Review synthesis highlights multiple phosphorylated tyrosines (example residues listed in FGFR2 signaling summaries include Y653/Y654 as key activation loop regulators and additional phosphotyrosines that recruit adaptor proteins). (lau2024clinicaldevelopmentsand pages 2-4)

Two experimentally supported “first-layer” signaling nodes emphasized in mechanistic summaries include:
- FRS2α (FGF receptor substrate 2) as a major docking/scaffold protein; it recruits Grb2/SOS to activate RAS–MAPK and can recruit Gab1 to activate PI3K–AKT. (lau2024clinicaldevelopmentsand pages 2-4, guttieri2023emtautophagycrosstalkrole pages 10-15)
- PLCγ docking/activation (with a site noted for FGFR2b Y769 involvement in PLCγ binding), producing DAG/PKC signaling outputs. (guttieri2023emtautophagycrosstalkrole pages 10-15)

Downstream pathways repeatedly highlighted across 2023–2024 sources include:
- RAS–RAF–MEK–ERK (MAPK),
- PI3K–AKT,
- PLCγ → DAG/PKC,
- JAK/STAT (and additional stress/kinase branches such as p38/JNK in some contexts). (lau2024clinicaldevelopmentsand pages 2-4, guttieri2023emtautophagycrosstalkrole pages 10-15, zhang2024targetingfgfrfor pages 1-3)

1.5 Primary molecular function (functional annotation statement)

FGFR2’s primary biochemical activity is protein tyrosine kinase activity, catalyzing transfer of the γ-phosphate of ATP to tyrosine residues on substrate proteins (including the receptor itself via autophosphorylation), thereby generating phosphotyrosine docking sites that propagate signaling. This is supported by the repeated classification of FGFR2 as a receptor tyrosine kinase whose activation involves kinase-domain autophosphorylation and phosphorylation-dependent recruitment of FRS2/PLCγ and downstream pathways. (lau2024clinicaldevelopmentsand pages 2-4, guttieri2023emtautophagycrosstalkrole pages 10-15, zhang2024targetingfgfrfor pages 1-3)

2. Recent developments and latest research (prioritizing 2023–2024)

2.1 Isoform switching as a disease-relevant mechanism (FGFR2-IIIb ↔ IIIc)

A 2023 focused analysis emphasizes aberrant expression of the mesenchymal FGFR2c isoform as a mechanism that can promote autocrine signaling and phenotypes such as EMT (epithelial–mesenchymal transition), underscoring the importance of isoform-specific annotation (FGFR2b vs FGFR2c) rather than treating FGFR2 as a single uniform receptor in all tissues. (guttieri2023emtautophagycrosstalkrole pages 10-15)

2.2 2024: resistance biology becomes more precisely mapped (on-target vs off-target)

Two 2024 primary studies substantially refine the field’s understanding of resistance in FGFR2 fusion-positive cholangiocarcinoma:

1) Convergent MAPK pathway alterations as off-target resistance (MD Anderson; Journal of Hepatology, 2024): in 17 patients with repeat sequencing after FGFR inhibitor therapy, 11/17 (64.7%) acquired new FGFR2 mutations and 9/17 (52.9%) acquired MAPK pathway alterations, with many patients showing both categories. This supports a model in which tumors escape FGFR2 dependency through either on-target kinase alterations or reactivation of MAPK signaling. (diperi2024convergentmapkpathway pages 1-3)

2) Prospective molecular resistance profiling (UNLOCK; Clinical Cancer Research, 2024): in cholangiocarcinoma, polyclonal FGFR2 kinase-domain mutations were frequent at resistance (reported as 14/27 iCCA cases), and after irreversible inhibition (futibatinib), resistance mutations narrowed primarily to molecular brake N550 and gatekeeper V565 hotspots. Off-target PI3K/mTOR or MAPK alterations also occurred, sometimes co-existing with on-target mutations. (facchinetti2024understandingandovercoming pages 1-2)

2.3 2024: next-generation FGFR2-selective covalent inhibitors (structure/dynamics-enabled design)

A 2024 PNAS study reports the discovery of lirafugratinib (RLY-4008) as a highly FGFR2-selective irreversible inhibitor, designed by exploiting differential P-loop dynamics between FGFR1 and FGFR2 and covalently engaging an FGFR2 cysteine (Cys491 as described in the study). The work provides quantitative selectivity metrics (e.g., Caliper IC50s FGFR2 0.003 μM vs FGFR1 0.77 μM and FGFR4 15 μM) and emphasizes the translational rationale: sparing FGFR1/FGFR4 may reduce class-limiting toxicities (hyperphosphatemia and diarrhea). (schonherr2024discoveryoflirafugratinib pages 7-9, schonherr2024discoveryoflirafugratinib pages 1-2)

A visual table summarizing potency/selectivity from this work was retrieved (schonherr2024discoveryoflirafugratinib media 3bde7918).

3. Current applications and real-world implementations

3.1 Precision oncology: FGFR2 as a biomarker-defined therapeutic target

FGFR2 is a clinically actionable target in biomarker-defined subsets of cancer, notably:
- Intrahepatic cholangiocarcinoma (iCCA) where FGFR2 fusions occur in ~10–15% of cases (enabling selection for FGFR inhibitors). (facchinetti2024understandingandovercoming pages 1-2, gonzalezmedina2024clinicalvalueof pages 1-2)
- Gastric cancer where FGFR2 dysregulation frequently occurs via amplification (reported 4–7% overall in one review; other summaries mention broader ranges), and fusions occur less commonly (0.5–3%). (lau2024clinicaldevelopmentsand pages 2-4)

3.2 Targeted therapies in practice: pan-FGFR vs FGFR2-selective approaches

Clinical practice and late-stage development include:
- ATP-competitive FGFR inhibitors (e.g., pemigatinib) used in multiple FGFR-altered solid tumors; efficacy varies by alteration class (fusions tend to respond better than some mutation classes). (rodon2024pemigatinibinpreviously pages 1-2)
- Irreversible inhibitors (e.g., futibatinib), designed to retain activity against some resistance mutations via covalent engagement. (balasooriya2024theirreversiblefgfr pages 5-6)
- FGFR2-selective covalent inhibitors (lirafugratinib/RLY-4008) aiming to improve therapeutic index by avoiding FGFR1/FGFR4 toxicities and expanding coverage of FGFR2 resistance mutations. (schonherr2024discoveryoflirafugratinib pages 7-9, schonherr2024discoveryoflirafugratinib pages 1-2)

3.3 Liquid biopsy (ctDNA) implementation for FGFR2 fusion detection and monitoring

A 2024 Clinical Cancer Research study evaluated a hybrid-capture panel in 18 tissue-confirmed FGFR2-fusion iCCA patients and demonstrated:
- Baseline plasma fusion detection: 16/18 (88.9%) plasma-positive for FGFR2 fusion. (gonzalezmedina2024clinicalvalueof pages 1-2, gonzalezmedina2024clinicalvalueof pages 5-7)
- Clinical utility: longitudinal rises in ctDNA or emergence of resistance mutations enabled earlier detection of progression than standard imaging in reported cases. (gonzalezmedina2024clinicalvalueof pages 1-2)
- Lead time: appearance of FGFR2 resistance mutations and increased tumor fraction were detected months before clinical/radiologic progression in example cases, with median lead times reported around ~4.9–7 months in described patients, and an illustrative case with signal 8.4 months before imaging progression. (gonzalezmedina2024clinicalvalueof pages 10-11)

4. Expert opinions and analysis (authoritative synthesis)

4.1 Why fusions respond, and why resistance is common

Across 2024 clinical and translational sources, a consistent expert view is that FGFR2 fusions are strong oncogenic drivers and can confer dependency on FGFR signaling (hence sensitivity to FGFR inhibition), but clinical benefit is limited by:
- On-target kinase-domain mutations (including gatekeeper and molecular-brake mutations) that reduce inhibitor binding or increase ATP affinity, and
- Off-target bypass mechanisms, particularly MAPK pathway reactivation and sometimes PI3K/mTOR changes. (diperi2024convergentmapkpathway pages 1-3, facchinetti2024understandingandovercoming pages 1-2)

4.2 Sequential and combination strategies as an emerging paradigm

The 2024 resistance literature supports a strategy of molecularly guided sequencing (switching inhibitor class based on resistance mechanism) and rational combinations (e.g., FGFR inhibitor + MEK inhibitor) for tumors that escape through MAPK pathway changes, though not all bypass alterations are equally suppressible (e.g., KRAS-driven resistance can be difficult to overcome). (diperi2024convergentmapkpathway pages 1-3, facchinetti2024understandingandovercoming pages 1-2)

4.3 Toxicity-driven need for selectivity

The development of FGFR2-selective inhibitors is motivated by the expert interpretation that pan-FGFR inhibition produces dose-limiting toxicities partly mediated by FGFR1/FGFR4, constraining efficacy. The PNAS 2024 lirafugratinib study explicitly frames selectivity as a route to maintain efficacy while reducing hyperphosphatemia/diarrhea and improving dosing headroom. (schonherr2024discoveryoflirafugratinib pages 1-2)

5. Key statistics and data (recent studies)

Category Metric / Finding Quantitative Value Source
Prevalence (iCCA) FGFR2 fusions in Intrahepatic Cholangiocarcinoma 10–15% (fusions); ~12% (fusions/truncations) Facchinetti 2024 (facchinetti2024understandingandovercoming pages 1-2); Balasooriya 2024 (balasooriya2024theirreversiblefgfr pages 4-5)
Prevalence (Gastric) FGFR2 Amplifications / Fusions 4–7% (Amplification); 0.5–3% (Fusions) Lau 2024 (lau2024clinicaldevelopmentsand pages 2-4); Shan 2024 (shan2024moleculartargetingof pages 4-5)
Efficacy (Pemigatinib) FIGHT-207 Basket Trial (Solid Tumors) Cohort A (Fusions): ORR 26.5%, mPFS 4.5 mo, mOS 17.5 mo
Cohort B (Mutations): ORR 9.4%, mPFS 3.7 mo
Rodón 2024 (rodon2024pemigatinibinpreviously pages 1-2)
Efficacy (Futibatinib) FGFR2-fusion iCCA (Pivotal Study) ORR 42% Cited in DiPeri 2024 (diperi2024convergentmapkpathway pages 1-3)
Efficacy (Lirafugratinib) FGFR2-selective (RLY-4008) in naive iCCA ORR 73% (Early clinical data, doses ≥70 mg) Schönherr 2024 (schonherr2024discoveryoflirafugratinib pages 7-9, schonherr2024discoveryoflirafugratinib pages 1-2)
Resistance Mechanisms Polyclonal FGFR2 KD Mutations 50% frequency post-reversible inhibitors vs 23% post-futibatinib Facchinetti 2024 (facchinetti2024understandingandovercoming pages 5-6, facchinetti2024understandingandovercoming pages 1-2)
Resistance Mechanisms Acquired Alterations (DiPeri Cohort) New FGFR2 mutations: 64.7%; MAPK pathway alterations: 52.9% DiPeri 2024 (diperi2024convergentmapkpathway pages 1-3)
Resistance Hotspots Dominant On-Target Residues N550 (Molecular Brake) & V565/V564 (Gatekeeper) Facchinetti 2024 (facchinetti2024understandingandovercoming pages 5-6); Balasooriya 2024 (balasooriya2024theirreversiblefgfr pages 22-24)
Liquid Biopsy Plasma FGFR2 Fusion Detection Rate 88.9% (16/18 patients) in iCCA González-Medina 2024 (gonzalezmedina2024clinicalvalueof pages 1-2, gonzalezmedina2024clinicalvalueof pages 5-7)
Liquid Biopsy Molecular vs Radiologic Progression ctDNA detected progression median 3–7 months earlier than imaging González-Medina 2024 (gonzalezmedina2024clinicalvalueof pages 10-11)

Table: Key statistics extracted from recent literature regarding FGFR2 alteration prevalence, inhibitor efficacy, resistance mechanisms, and liquid biopsy performance.

5.1 Clinical outcomes snapshot: pemigatinib basket trial (Nature Medicine 2024)

In the phase 2 FIGHT-207 basket trial (previously treated solid tumors with FGFR1–FGFR3 alterations), the primary endpoint ORR was:
- 26.5% in the fusion/rearrangement cohort (13/49),
- 9.4% in the activating non-kinase domain mutation cohort (3/32).
Median PFS was 4.5 months and 3.7 months, respectively, with common TEAEs including hyperphosphatemia (84%) and stomatitis (53%). (rodon2024pemigatinibinpreviously pages 1-2)

5.2 Resistance frequencies and hotspots (Clinical Cancer Research 2024)

In a 2024 resistance profiling cohort, polyclonal FGFR2 kinase-domain mutations were common after reversible inhibitors (e.g., pemigatinib/erdafitinib), and resistance converged on N550 and V565 as dominant hotspots, especially after futibatinib where these remained the principal on-target residues. (facchinetti2024understandingandovercoming pages 5-6, facchinetti2024understandingandovercoming pages 1-2)

5.3 Liquid biopsy performance and prognostic associations (Clinical Cancer Research 2024)

In FGFR2-fusion iCCA, baseline and longitudinal ctDNA/cfDNA features were strongly associated with outcomes:
- Baseline plasma fusion detection: 88.9% (16/18). (gonzalezmedina2024clinicalvalueof pages 1-2, gonzalezmedina2024clinicalvalueof pages 5-7)
- High baseline ctDNA metrics were associated with substantially shorter median PFS and OS in reported stratifications (e.g., PFS 6.53 vs 13.3 months for high vs low baseline ctDNA, P=0.0018; OS 10.6 months vs not reached, P=0.0198). (gonzalezmedina2024clinicalvalueof pages 7-8)

6. Functional-annotation-ready summary (what FGFR2 does, where it acts, and in which pathways)

  • Molecular function: receptor protein tyrosine kinase; ATP-dependent phosphorylation of tyrosine residues (autophosphorylation and phosphorylation of docking substrates), enabling assembly of signaling complexes. (lau2024clinicaldevelopmentsand pages 2-4, guttieri2023emtautophagycrosstalkrole pages 10-15)
  • Cellular component / localization: plasma membrane single-pass transmembrane receptor with extracellular Ig-like ligand-binding domains and cytoplasmic TK domain. (lau2024clinicaldevelopmentsand pages 2-4, guttieri2023emtautophagycrosstalkrole pages 10-15)
  • Upstream inputs: FGFs, with HSPG cofactor dependence for paracrine ligands; isoform-specific ligand binding via IIIb/IIIc splice variants (epithelial IIIb vs mesenchymal IIIc). (lau2024clinicaldevelopmentsand pages 2-4, guttieri2023emtautophagycrosstalkrole pages 10-15)
  • Immediate downstream effectors: FRS2α (major docking/scaffold), PLCγ (including a noted PLCγ-binding requirement involving Y769 in FGFR2b), plus recruitment of other adaptors. (lau2024clinicaldevelopmentsand pages 2-4, guttieri2023emtautophagycrosstalkrole pages 10-15)
  • Core signaling pathways: RAS–MAPK, PI3K–AKT, PLCγ/PKC, and JAK/STAT (context-dependent). (lau2024clinicaldevelopmentsand pages 2-4, guttieri2023emtautophagycrosstalkrole pages 10-15, zhang2024targetingfgfrfor pages 1-3)

7. URLs and publication dates (for major sources used)

  • Lau et al. BiomedicinesMay 2024 — https://doi.org/10.3390/biomedicines12051117 (lau2024clinicaldevelopmentsand pages 2-4)
  • Zhang et al. Journal of Hematology & OncologyJun 2024 — https://doi.org/10.1186/s13045-024-01558-1 (zhang2024targetingfgfrfor pages 1-3)
  • Rodón et al. Nature MedicineMay 2024 — https://doi.org/10.1038/s41591-024-02934-7 (rodon2024pemigatinibinpreviously pages 1-2)
  • DiPeri et al. Journal of HepatologyFeb 2024 — https://doi.org/10.1016/j.jhep.2023.10.041 (diperi2024convergentmapkpathway pages 1-3)
  • Facchinetti et al. Clinical Cancer ResearchSep 2024 — https://doi.org/10.1158/1078-0432.ccr-24-1834 (facchinetti2024understandingandovercoming pages 1-2)
  • González-Medina et al. Clinical Cancer ResearchJul 2024 — https://doi.org/10.1158/1078-0432.ccr-23-3780 (gonzalezmedina2024clinicalvalueof pages 1-2)
  • Schönherr et al. PNASFeb 2024 — https://doi.org/10.1073/pnas.2317756121 (schonherr2024discoveryoflirafugratinib pages 1-2)

8. Notes on scope and evidence limits

This report focuses on experimentally supported receptor biology and 2024 translational evidence. Some classical FGFR2 developmental biology and older foundational signaling work is not exhaustively reviewed here because the user requested prioritization of 2023–2024 sources; however, the mechanistic framework summarized above is consistent across the modern reviews and primary clinical/translational studies cited.

References

  1. (lau2024clinicaldevelopmentsand pages 2-4): David K. Lau, Jack P. Collin, and John M. Mariadason. Clinical developments and challenges in treating fgfr2-driven gastric cancer. Biomedicines, 12:1117, May 2024. URL: https://doi.org/10.3390/biomedicines12051117, doi:10.3390/biomedicines12051117. This article has 19 citations.

  2. (guttieri2023emtautophagycrosstalkrole pages 10-15): L Guttieri. Emt/autophagy crosstalk: role of the aberrant expression of the mesenchymal fgfr2c isoform. Unknown journal, 2023.

  3. (zhang2024targetingfgfrfor pages 1-3): Pei Zhang, Lin Yue, QingQing Leng, Chen Chang, Cailing Gan, Tinghong Ye, and Dan Cao. Targeting fgfr for cancer therapy. Journal of Hematology & Oncology, Jun 2024. URL: https://doi.org/10.1186/s13045-024-01558-1, doi:10.1186/s13045-024-01558-1. This article has 89 citations and is from a domain leading peer-reviewed journal.

  4. (diperi2024convergentmapkpathway pages 1-3): Timothy P. DiPeri, Ming Zhao, Kurt W. Evans, Kaushik Varadarajan, Tyler Moss, Stephen Scott, Michael P. Kahle, Charnel C. Byrnes, Huiqin Chen, Sunyoung S. Lee, Abdel-Baset Halim, Hiroshi Hirai, Volker Wacheck, Lawrence N. Kwong, Jordi Rodon, Milind Javle, and Funda Meric-Bernstam. Convergent mapk pathway alterations mediate acquired resistance to fgfr inhibitors in fgfr2 fusion-positive cholangiocarcinoma. Journal of Hepatology, 80:322-334, Feb 2024. URL: https://doi.org/10.1016/j.jhep.2023.10.041, doi:10.1016/j.jhep.2023.10.041. This article has 34 citations and is from a highest quality peer-reviewed journal.

  5. (facchinetti2024understandingandovercoming pages 1-2): Francesco Facchinetti, Yohann Loriot, Floriane Brayé, Damien Vasseur, Rastislav Bahleda, Ludovic Bigot, Rémy Barbé, Catline Nobre, David Combarel, Stefan Michiels, Antoine Italiano, Cristina Smolenschi, Lambros Tselikas, Jean-Yves Scoazec, Santiago Ponce-Aix, Benjamin Besse, Fabrice André, Ken A. Olaussen, Antoine Hollebecque, and Luc Friboulet. Understanding and overcoming resistance to selective fgfr inhibitors across fgfr2-driven malignancies. Clinical Cancer Research, 30:4943-4956, Sep 2024. URL: https://doi.org/10.1158/1078-0432.ccr-24-1834, doi:10.1158/1078-0432.ccr-24-1834. This article has 32 citations and is from a highest quality peer-reviewed journal.

  6. (schonherr2024discoveryoflirafugratinib pages 7-9): Heike Schönherr, Pelin Ayaz, Alexander M. Taylor, Jessica B. Casaletto, B. Barry Touré, Demetri T. Moustakas, Brandi M. Hudson, Roberto Valverde, Songping Zhao, Patrick J. O’Hearn, Lindsey Foster, Dina A. Sharon, Sam Garfinkle, Fabrizio Giordanetto, André Lescarbeau, Ravi Kurukulasuriya, Nastaran Gerami-Moayed, Dejan Maglic, Kamil Bruderek, Gaauri Naik, Hakan Gunaydin, Mary M. Mader, Alessandro A. Boezio, Thomas H. McLean, Rongfeng Chen, Yanxia Wang, David E. Shaw, James Watters, and Donald A. Bergstrom. Discovery of lirafugratinib (rly-4008), a highly selective irreversible small-molecule inhibitor of fgfr2. Proceedings of the National Academy of Sciences of the United States of America, Feb 2024. URL: https://doi.org/10.1073/pnas.2317756121, doi:10.1073/pnas.2317756121. This article has 57 citations and is from a highest quality peer-reviewed journal.

  7. (schonherr2024discoveryoflirafugratinib pages 1-2): Heike Schönherr, Pelin Ayaz, Alexander M. Taylor, Jessica B. Casaletto, B. Barry Touré, Demetri T. Moustakas, Brandi M. Hudson, Roberto Valverde, Songping Zhao, Patrick J. O’Hearn, Lindsey Foster, Dina A. Sharon, Sam Garfinkle, Fabrizio Giordanetto, André Lescarbeau, Ravi Kurukulasuriya, Nastaran Gerami-Moayed, Dejan Maglic, Kamil Bruderek, Gaauri Naik, Hakan Gunaydin, Mary M. Mader, Alessandro A. Boezio, Thomas H. McLean, Rongfeng Chen, Yanxia Wang, David E. Shaw, James Watters, and Donald A. Bergstrom. Discovery of lirafugratinib (rly-4008), a highly selective irreversible small-molecule inhibitor of fgfr2. Proceedings of the National Academy of Sciences of the United States of America, Feb 2024. URL: https://doi.org/10.1073/pnas.2317756121, doi:10.1073/pnas.2317756121. This article has 57 citations and is from a highest quality peer-reviewed journal.

  8. (schonherr2024discoveryoflirafugratinib media 3bde7918): Heike Schönherr, Pelin Ayaz, Alexander M. Taylor, Jessica B. Casaletto, B. Barry Touré, Demetri T. Moustakas, Brandi M. Hudson, Roberto Valverde, Songping Zhao, Patrick J. O’Hearn, Lindsey Foster, Dina A. Sharon, Sam Garfinkle, Fabrizio Giordanetto, André Lescarbeau, Ravi Kurukulasuriya, Nastaran Gerami-Moayed, Dejan Maglic, Kamil Bruderek, Gaauri Naik, Hakan Gunaydin, Mary M. Mader, Alessandro A. Boezio, Thomas H. McLean, Rongfeng Chen, Yanxia Wang, David E. Shaw, James Watters, and Donald A. Bergstrom. Discovery of lirafugratinib (rly-4008), a highly selective irreversible small-molecule inhibitor of fgfr2. Proceedings of the National Academy of Sciences of the United States of America, Feb 2024. URL: https://doi.org/10.1073/pnas.2317756121, doi:10.1073/pnas.2317756121. This article has 57 citations and is from a highest quality peer-reviewed journal.

  9. (gonzalezmedina2024clinicalvalueof pages 1-2): Alberto González-Medina, Maria Vila-Casadesús, Marina Gomez-Rey, Carles Fabregat-Franco, Alexandre Sierra, Tian V. Tian, Florian Castet, Gloria Castillo, Judit Matito, Paola Martinez, Josep M. Miquel, Paolo Nuciforo, Raquel Pérez-López, Teresa Macarulla, and Ana Vivancos. Clinical value of liquid biopsy in patients with fgfr2 fusion–positive cholangiocarcinoma during targeted therapy. Clinical Cancer Research, 30:4491-4504, Jul 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-3780, doi:10.1158/1078-0432.ccr-23-3780. This article has 21 citations and is from a highest quality peer-reviewed journal.

  10. (rodon2024pemigatinibinpreviously pages 1-2): Jordi Rodón, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, and Lipika Goyal. Pemigatinib in previously treated solid tumors with activating fgfr1–fgfr3 alterations: phase 2 fight-207 basket trial. Nature Medicine, 30:1645-1654, May 2024. URL: https://doi.org/10.1038/s41591-024-02934-7, doi:10.1038/s41591-024-02934-7. This article has 61 citations and is from a highest quality peer-reviewed journal.

  11. (balasooriya2024theirreversiblefgfr pages 5-6): Eranga R. Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L. Norden, Ryan B. Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John Tyhonas, Matthew Lardy, Kathryn B. Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa S. Silveira, and Nabeel Bardeesy. The irreversible fgfr inhibitor kin-3248 overcomes fgfr2 kinase domain mutations. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2181-2192, Mar 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-3588, doi:10.1158/1078-0432.ccr-23-3588. This article has 18 citations.

  12. (gonzalezmedina2024clinicalvalueof pages 5-7): Alberto González-Medina, Maria Vila-Casadesús, Marina Gomez-Rey, Carles Fabregat-Franco, Alexandre Sierra, Tian V. Tian, Florian Castet, Gloria Castillo, Judit Matito, Paola Martinez, Josep M. Miquel, Paolo Nuciforo, Raquel Pérez-López, Teresa Macarulla, and Ana Vivancos. Clinical value of liquid biopsy in patients with fgfr2 fusion–positive cholangiocarcinoma during targeted therapy. Clinical Cancer Research, 30:4491-4504, Jul 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-3780, doi:10.1158/1078-0432.ccr-23-3780. This article has 21 citations and is from a highest quality peer-reviewed journal.

  13. (gonzalezmedina2024clinicalvalueof pages 10-11): Alberto González-Medina, Maria Vila-Casadesús, Marina Gomez-Rey, Carles Fabregat-Franco, Alexandre Sierra, Tian V. Tian, Florian Castet, Gloria Castillo, Judit Matito, Paola Martinez, Josep M. Miquel, Paolo Nuciforo, Raquel Pérez-López, Teresa Macarulla, and Ana Vivancos. Clinical value of liquid biopsy in patients with fgfr2 fusion–positive cholangiocarcinoma during targeted therapy. Clinical Cancer Research, 30:4491-4504, Jul 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-3780, doi:10.1158/1078-0432.ccr-23-3780. This article has 21 citations and is from a highest quality peer-reviewed journal.

  14. (balasooriya2024theirreversiblefgfr pages 4-5): Eranga R. Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L. Norden, Ryan B. Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John Tyhonas, Matthew Lardy, Kathryn B. Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa S. Silveira, and Nabeel Bardeesy. The irreversible fgfr inhibitor kin-3248 overcomes fgfr2 kinase domain mutations. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2181-2192, Mar 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-3588, doi:10.1158/1078-0432.ccr-23-3588. This article has 18 citations.

  15. (shan2024moleculartargetingof pages 4-5): Khine S. Shan, Shivani Dalal, Nyein Nyein Thaw Dar, Omani McLish, Matthew Salzberg, and Brian A. Pico. Molecular targeting of the fibroblast growth factor receptor pathway across various cancers. International Journal of Molecular Sciences, 25:849, Jan 2024. URL: https://doi.org/10.3390/ijms25020849, doi:10.3390/ijms25020849. This article has 24 citations.

  16. (facchinetti2024understandingandovercoming pages 5-6): Francesco Facchinetti, Yohann Loriot, Floriane Brayé, Damien Vasseur, Rastislav Bahleda, Ludovic Bigot, Rémy Barbé, Catline Nobre, David Combarel, Stefan Michiels, Antoine Italiano, Cristina Smolenschi, Lambros Tselikas, Jean-Yves Scoazec, Santiago Ponce-Aix, Benjamin Besse, Fabrice André, Ken A. Olaussen, Antoine Hollebecque, and Luc Friboulet. Understanding and overcoming resistance to selective fgfr inhibitors across fgfr2-driven malignancies. Clinical Cancer Research, 30:4943-4956, Sep 2024. URL: https://doi.org/10.1158/1078-0432.ccr-24-1834, doi:10.1158/1078-0432.ccr-24-1834. This article has 32 citations and is from a highest quality peer-reviewed journal.

  17. (balasooriya2024theirreversiblefgfr pages 22-24): Eranga R. Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L. Norden, Ryan B. Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John Tyhonas, Matthew Lardy, Kathryn B. Grandinetti, Robert Pelham, Liliana Soroceanu, Vanessa S. Silveira, and Nabeel Bardeesy. The irreversible fgfr inhibitor kin-3248 overcomes fgfr2 kinase domain mutations. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2181-2192, Mar 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-3588, doi:10.1158/1078-0432.ccr-23-3588. This article has 18 citations.

  18. (gonzalezmedina2024clinicalvalueof pages 7-8): Alberto González-Medina, Maria Vila-Casadesús, Marina Gomez-Rey, Carles Fabregat-Franco, Alexandre Sierra, Tian V. Tian, Florian Castet, Gloria Castillo, Judit Matito, Paola Martinez, Josep M. Miquel, Paolo Nuciforo, Raquel Pérez-López, Teresa Macarulla, and Ana Vivancos. Clinical value of liquid biopsy in patients with fgfr2 fusion–positive cholangiocarcinoma during targeted therapy. Clinical Cancer Research, 30:4491-4504, Jul 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-3780, doi:10.1158/1078-0432.ccr-23-3780. This article has 21 citations and is from a highest quality peer-reviewed journal.

Citations

  1. guttieri2023emtautophagycrosstalkrole pages 10-15
  2. lau2024clinicaldevelopmentsand pages 2-4
  3. diperi2024convergentmapkpathway pages 1-3
  4. facchinetti2024understandingandovercoming pages 1-2
  5. rodon2024pemigatinibinpreviously pages 1-2
  6. balasooriya2024theirreversiblefgfr pages 5-6
  7. gonzalezmedina2024clinicalvalueof pages 1-2
  8. gonzalezmedina2024clinicalvalueof pages 10-11
  9. schonherr2024discoveryoflirafugratinib pages 1-2
  10. balasooriya2024theirreversiblefgfr pages 4-5
  11. shan2024moleculartargetingof pages 4-5
  12. facchinetti2024understandingandovercoming pages 5-6
  13. balasooriya2024theirreversiblefgfr pages 22-24
  14. gonzalezmedina2024clinicalvalueof pages 7-8
  15. zhang2024targetingfgfrfor pages 1-3
  16. schonherr2024discoveryoflirafugratinib pages 7-9
  17. gonzalezmedina2024clinicalvalueof pages 5-7
  18. https://doi.org/10.3390/biomedicines12051117
  19. https://doi.org/10.1186/s13045-024-01558-1
  20. https://doi.org/10.1038/s41591-024-02934-7
  21. https://doi.org/10.1016/j.jhep.2023.10.041
  22. https://doi.org/10.1158/1078-0432.ccr-24-1834
  23. https://doi.org/10.1158/1078-0432.ccr-23-3780
  24. https://doi.org/10.1073/pnas.2317756121
  25. https://doi.org/10.3390/biomedicines12051117,
  26. https://doi.org/10.1186/s13045-024-01558-1,
  27. https://doi.org/10.1016/j.jhep.2023.10.041,
  28. https://doi.org/10.1158/1078-0432.ccr-24-1834,
  29. https://doi.org/10.1073/pnas.2317756121,
  30. https://doi.org/10.1158/1078-0432.ccr-23-3780,
  31. https://doi.org/10.1038/s41591-024-02934-7,
  32. https://doi.org/10.1158/1078-0432.ccr-23-3588,
  33. https://doi.org/10.3390/ijms25020849,

Notes

(FGFR2-notes.md)

FGFR2 (Fibroblast Growth Factor Receptor 2) Notes - ISOFORMS Project

Key Isoform Biology

FGFR2 encodes a receptor tyrosine kinase with tissue-specific isoform switching that determines ligand specificity.

Critical Isoforms: IIIb vs IIIc

Isoform UniProt ID Exon Usage Ligand Specificity Tissue Expression
FGFR2IIIb P21802-1 Exon IIIb FGF1, FGF3, FGF7 (KGF), FGF10 EPITHELIAL
FGFR2IIIc P21802-3 Exon IIIc FGF1, FGF2, FGF4, FGF6, FGF9 MESENCHYMAL

The IIIb vs IIIc Switch

The Ig-like domain III is alternatively spliced:
- Exon IIIb encodes epithelial-specific splice variant
- Exon IIIc encodes mesenchymal-specific splice variant

This creates mutually exclusive ligand binding:
- FGF7 (KGF) binds ONLY to IIIb (epithelial)
- FGF2 binds preferentially to IIIc (mesenchymal)

Biological Significance: Epithelial-Mesenchymal Communication

The IIIb/IIIc isoform switching enables paracrine signaling:
- Mesenchyme produces FGF7/10 → signals to epithelium (IIIb)
- Epithelium produces FGF2/4 → signals to mesenchyme (IIIc)

This is critical for:
- Limb development
- Lung branching morphogenesis
- Prostate development
- Wound healing

Soluble/Secreted Isoforms

  • Isoform 8 (P21802-8): Secreted
  • Isoform 13 (P21802-13): Secreted

These may act as decoy receptors, similar to soluble FAS.

Cancer Relevance

Isoform switching in cancer:
- Epithelial-to-mesenchymal transition (EMT) includes IIIb→IIIc switch
- Some cancers inappropriately express IIIc in epithelial contexts
- Mis-splicing correlates with metastatic potential

GOA Annotation Status

  • 250 annotations fetched, 229 seeded
  • NO isoform-specific annotations - all annotated to P21802 gene level

Expected Annotation Issues

  1. "FGF receptor signaling pathway" - applies to both isoforms but with different ligands
  2. "fibroblast growth factor binding" - TRUE for both, but DIFFERENT FGFs
  3. Epithelial morphogenesis terms may be IIIb-specific
  4. Mesenchymal development terms may be IIIc-specific
  5. Any FGF7 (KGF) signaling annotations should be IIIb-specific
  6. Any FGF2 signaling annotations should be preferentially IIIc

Key References

  • UniProt P21802 function annotation distinguishes IIIb and IIIc ligand binding
  • PMID:1309608 - FGFR2 cloning and splice variants
  • PMID:7987400 - FGF receptor ligand specificities

📄 View Raw YAML

id: P21802
gene_symbol: FGFR2
product_type: PROTEIN
status: COMPLETE
taxon:
  id: NCBITaxon:9606
  label: Homo sapiens
description: >-
  FGFR2 (Fibroblast Growth Factor Receptor 2) encodes a receptor tyrosine kinase
  that mediates FGF signaling in development, tissue repair, and homeostasis.

  CRITICAL ISOFORM BIOLOGY: Alternative splicing of exon IIIb vs IIIc in the third
  Ig-like domain creates isoforms with MUTUALLY EXCLUSIVE ligand specificities:

  (1) FGFR2IIIb (P21802-3, KGFR) is expressed in EPITHELIAL cells and binds FGF1,
  FGF3, FGF7 (KGF), and FGF10. FGF7 and FGF10 bind ONLY to IIIb.

  (2) FGFR2IIIc (P21802-1, BEK) is expressed in MESENCHYMAL cells and binds FGF1,
  FGF2, FGF4, FGF6, and FGF9. FGF2 binds preferentially to IIIc.

  This isoform switching enables PARACRINE signaling between epithelium and mesenchyme:
  mesenchyme produces FGF7/10 to signal to epithelial IIIb, while epithelium produces
  FGF2/4 to signal to mesenchymal IIIc. Critical for limb development, lung branching
  morphogenesis, and wound healing.

  Additional isoforms: Secreted/soluble forms (P21802-14, P21802-19) may act as
  decoy receptors. Numerous other splice variants exist with various domain combinations.

  Cancer relevance: IIIb-to-IIIc isoform switching accompanies epithelial-mesenchymal
  transition (EMT) and correlates with metastatic potential in some cancers.
alternative_products:
  - name: 1 (BEK, FGFR2IIIc)
    id: P21802-1
  - name: 2 (Short)
    id: P21802-2
    sequence_note: VSP_002978
  - name: 3 (BFR-1, FGFR2IIIb, KGFR)
    id: P21802-3
    sequence_note: VSP_002969, VSP_002970, VSP_002971,
  - name: 4 (K-sam)
    id: P21802-4
    sequence_note: VSP_002964, VSP_002969, VSP_002970,
  - name: 5 (K-sam-I, BEK, IgIIIc)
    id: P21802-5
    sequence_note: VSP_002975
  - name: 6 (K-sam-IIC2)
    id: P21802-6
    sequence_note: VSP_002975, VSP_002984
  - name: 7 (K-sam-IIC3)
    id: P21802-8
    sequence_note: VSP_002975, VSP_002978
  - name: 8 (K-sam-IV, Soluble KGFR)
    id: P21802-14
    sequence_note: VSP_002965, VSP_002966
  - name: 9 (K-sam-III)
    id: P21802-15
    sequence_note: VSP_002968
  - name: 10 (TK14)
    id: P21802-16
    sequence_note: VSP_002967, VSP_002975
  - name: '11'
    id: P21802-17
    sequence_note: VSP_002969, VSP_002970, VSP_002971,
  - name: 12 (K-sam-IIC1, KGFR, IgIIIb)
    id: P21802-18
    sequence_note: VSP_002969, VSP_002970, VSP_002971,
  - name: 13 (Soluble KGFR)
    id: P21802-19
    sequence_note: VSP_002969, VSP_002970, VSP_002971,
  - name: '14'
    id: P21802-20
    sequence_note: VSP_019608, VSP_019609
  - name: '15'
    id: P21802-21
    sequence_note: VSP_002964, VSP_041915
  - name: '16'
    id: P21802-22
    sequence_note: VSP_002964, VSP_002969, VSP_002970,
  - name: '17'
    id: P21802-23
    sequence_note: VSP_041914
existing_annotations:
  - term:
      id: GO:0005007
      label: fibroblast growth factor receptor activity
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: >-
        FGFR2 is unambiguously a fibroblast growth factor receptor. UniProt confirms
        it is a "Tyrosine-protein kinase that acts as a cell-surface receptor for
        fibroblast growth factors." This applies to all transmembrane isoforms (both
        IIIb/KGFR and IIIc/BEK), though with different ligand specificities. Deep
        research confirms FGFR2 as a receptor tyrosine kinase whose primary function
        is transducing FGF signals via autophosphorylation and downstream pathway
        activation.
      action: ACCEPT
      reason: >-
        Core molecular function of FGFR2. Extensive experimental evidence from multiple
        studies (PMID:8663044, PMID:16597617, PMID:15629145) demonstrates FGF receptor
        activity. The IBA annotation appropriately captures the conserved function.
      supported_by:
        - reference_id: UniProtKB:P21802
          supporting_text: "Tyrosine-protein kinase that acts as a cell-surface receptor
            for fibroblast growth factors"
        - reference_id: file:human/FGFR2/FGFR2-deep-research-falcon.md
          supporting_text: "FGFR2 is a member of the FGFR receptor tyrosine kinase family
            that transduces extracellular fibroblast growth factor (FGF) signals into
            intracellular phosphorylation-dependent signaling programs that control
            proliferation, survival, differentiation, and migration."
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: >-
        Plasma membrane localization is confirmed for all transmembrane FGFR2 isoforms
        (IIIb and IIIc). However, secreted isoforms (P21802-14, P21802-19) are not
        plasma membrane-localized. The annotation is appropriate at the gene level
        since most functional isoforms are transmembrane.
      action: ACCEPT
      reason: >-
        UniProt confirms "Cell membrane; Single-pass type I membrane protein" for
        main
        isoforms. Extensive localization data supports plasma membrane localization
        for functional receptor isoforms.
      supported_by:
        - reference_id: UniProtKB:P21802
          supporting_text: "SUBCELLULAR LOCATION: Cell membrane; Single-pass type
            I membrane protein"
  - term:
      id: GO:0008284
      label: positive regulation of cell population proliferation
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: >-
        FGFR2 signaling promotes cell proliferation in keratinocytes and immature
        osteoblasts. UniProt notes it "Promotes cell proliferation in keratinocytes
        and immature osteoblasts." This is a well-established downstream effect of
        FGF signaling through both IIIb and IIIc isoforms.
      action: ACCEPT
      reason: >-
        Core biological process for FGFR2. Multiple studies demonstrate proliferative
        effects (PMID:8663044, PMID:15629145, PMID:16597617). This applies to both
        major splice variants with different ligands driving the same outcome.
      supported_by:
        - reference_id: UniProtKB:P21802
          supporting_text: "Promotes cell proliferation in keratinocytes and immature
            osteoblasts"
  - term:
      id: GO:0008543
      label: fibroblast growth factor receptor signaling pathway
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: >-
        FGFR2 is a core component of FGF receptor signaling. Ligand binding leads
        to
        receptor dimerization, autophosphorylation, and activation of downstream
        cascades including PLCG1, MAPK, and PI3K/AKT pathways.
      action: ACCEPT
      reason: >-
        Fundamental role of FGFR2. UniProt extensively documents signaling mechanism
        including phosphorylation of PLCG1, FRS2, and activation of RAS-MAPK and
        AKT pathways. Both IIIb and IIIc isoforms signal through these pathways.
      supported_by:
        - reference_id: UniProtKB:P21802
          supporting_text: "Phosphorylation of FRS2 triggers recruitment of GRB2,
            GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1
            and the MAP kinase signaling pathway"
  - term:
      id: GO:0001525
      label: angiogenesis
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: >-
        FGF signaling through FGFRs is known to promote angiogenesis, particularly
        FGF2 signaling through FGFR2IIIc (mesenchymal isoform). However, this may
        be more prominent for FGFR1 in endothelial cells. The annotation is reasonable
        but likely represents a non-core function.
      action: KEEP_AS_NON_CORE
      reason: >-
        Angiogenesis is documented for FGF/FGFR signaling generally, but FGFR2's
        primary roles are in epithelial-mesenchymal signaling for organ development
        rather than vascular biology. This is a secondary rather than core function.
  - term:
      id: GO:0043410
      label: positive regulation of MAPK cascade
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: >-
        MAPK cascade activation is a core downstream signaling event for FGFR2.
        UniProt confirms that FRS2 phosphorylation leads to recruitment of GRB2/SOS1
        and activation of RAS-MAPK signaling.
      action: ACCEPT
      reason: >-
        Core signaling output of FGFR2. Well-documented in UniProt and multiple
        publications (PMID:15629145, PMID:17623664). Both IIIb and IIIc isoforms
        activate MAPK upon ligand binding.
      supported_by:
        - reference_id: UniProtKB:P21802
          supporting_text: "mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and
            the MAP kinase signaling pathway"
  - term:
      id: GO:0043235
      label: receptor complex
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: >-
        FGFR2 forms homodimers upon ligand binding and also forms complexes with
        heparan sulfate proteoglycan co-receptors. UniProt confirms "Homodimer after
        ligand binding."
      action: ACCEPT
      reason: >-
        FGFR2 functions as part of a receptor complex including FGF ligands, heparan
        sulfate, and in some cases KLB (for FGF19/21). Dimerization is required for
        receptor activation.
      supported_by:
        - reference_id: UniProtKB:P21802
          supporting_text: "Monomer. Homodimer after ligand binding."
  - term:
      id: GO:0017134
      label: fibroblast growth factor binding
    evidence_type: IBA
    original_reference_id: GO_REF:0000033
    review:
      summary: >-
        FGFR2 binds multiple FGFs with isoform-specific preferences. IIIc (P21802-1)
        has high affinity for FGF1, FGF2; IIIb (P21802-3) has high affinity for FGF1,
        FGF7. CRITICAL ISOFORM NOTE - FGF7 binds ONLY to IIIb (epithelial); FGF2 binds
        preferentially to IIIc (mesenchymal).
      action: ACCEPT
      reason: >-
        Core molecular function. Extensive structural and biochemical data (PMID:8663044,
        PMID:10830168, PMID:12591959) document FGF binding. The annotation at gene
        level is appropriate though ligand specificity differs by isoform.
      supported_by:
        - reference_id: UniProtKB:P21802
          supporting_text: "Isoform 1 has high affinity for FGF1 and FGF2, but low
            affinity for FGF7. Isoform 3 has high affinity for FGF1 and FGF7"
  - term:
      id: GO:0000166
      label: nucleotide binding
    evidence_type: IEA
    original_reference_id: GO_REF:0000043
    review:
      summary: >-
        FGFR2 is a tyrosine kinase that binds ATP for its catalytic activity.
        Nucleotide binding is accurate but overly general - ATP binding is more specific.
      action: ACCEPT
      reason: >-
        True but general. FGFR2 has a kinase domain that binds ATP. The more specific
        term "ATP binding" is also annotated and preferred.
  - term:
      id: GO:0004672
      label: protein kinase activity
    evidence_type: IEA
    original_reference_id: GO_REF:0000002
    review:
      summary: >-
        FGFR2 is a protein kinase. The annotation is correct but "protein tyrosine
        kinase activity" is more specific and preferred.
      action: ACCEPT
      reason: >-
        Correct parent term. FGFR2 has documented kinase activity (EC 2.7.10.1).
        More specific child term annotations also exist.
  - term:
      id: GO:0004713
      label: protein tyrosine kinase activity
    evidence_type: IEA
    original_reference_id: GO_REF:0000120
    review:
      summary: >-
        FGFR2 is a receptor tyrosine kinase that autophosphorylates and phosphorylates
        substrates including PLCG1, FRS2, and PAK4 on tyrosine residues.
      action: ACCEPT
      reason: >-
        Core molecular function. UniProt confirms EC 2.7.10.1 classification and
        documents phosphorylation of multiple substrates. Applies to all kinase-
        containing isoforms.
      supported_by:
        - reference_id: UniProtKB:P21802
          supporting_text: "Phosphorylates PLCG1, FRS2 and PAK4"
  - term:
      id: GO:0004714
      label: transmembrane receptor protein tyrosine kinase activity
    evidence_type: IEA
    original_reference_id: GO_REF:0000003
    review:
      summary: >-
        FGFR2 is a single-pass type I transmembrane receptor tyrosine kinase. This
        is the most specific and appropriate molecular function term for membrane-
        bound isoforms.
      action: ACCEPT
      reason: >-
        Most specific appropriate MF term for transmembrane FGFR2 isoforms. Note
        that secreted isoforms (P21802-14, P21802-19) lack transmembrane domain
        and kinase activity.
  - term:
      id: GO:0005007
      label: fibroblast growth factor receptor activity
    evidence_type: IEA
    original_reference_id: GO_REF:0000120
    review:
      summary: >-
        Duplicate of IBA annotation. FGFR2 is unambiguously an FGF receptor.
      action: ACCEPT
      reason: >-
        Core function - duplicates IBA annotation with different evidence. Correct.
  - term:
      id: GO:0005524
      label: ATP binding
    evidence_type: IEA
    original_reference_id: GO_REF:0000120
    review:
      summary: >-
        FGFR2 kinase domain binds ATP. Crystal structures confirm ATP binding
        (PDB entries with ATP analogs).
      action: ACCEPT
      reason: >-
        Core function for kinase activity. Structural data confirms ATP binding site.
  - term:
      id: GO:0005576
      label: extracellular region
    evidence_type: IEA
    original_reference_id: GO_REF:0000044
    review:
      summary: >-
        The secreted/soluble isoforms (P21802-14 soluble KGFR, P21802-19 soluble KGFR)
        are found in the extracellular region. For transmembrane isoforms, the
        N-terminal region including Ig-like domains is extracellular.
      action: ACCEPT
      reason: >-
        Appropriate for secreted isoforms. UniProt confirms isoforms 8 (K-sam-IV,
        Soluble KGFR) and 13 (Soluble KGFR) are secreted forms that would localize
        to the extracellular region.
  - term:
      id: GO:0005794
      label: Golgi apparatus
    evidence_type: IEA
    original_reference_id: GO_REF:0000044
    review:
      summary: >-
        FGFR2 is N-glycosylated and transits through the Golgi. UniProt notes
        "N-glycan chains undergo further maturation to an Endo H-resistant form
        in the Golgi apparatus."
      action: ACCEPT
      reason: >-
        FGFR2 passes through Golgi during maturation. Also documented as
        "Golgi apparatus" in subcellular location. Represents trafficking intermediate.
      supported_by:
        - reference_id: UniProtKB:P21802
          supporting_text: "SUBCELLULAR LOCATION: Cell membrane; Single-pass type
            I membrane protein. Golgi apparatus."
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: IEA
    original_reference_id: GO_REF:0000044
    review:
      summary: >-
        Duplicate of IBA annotation. Plasma membrane localization for transmembrane
        isoforms is well established.
      action: ACCEPT
      reason: >-
        Correct - duplicates IBA with different evidence.
  - term:
      id: GO:0006915
      label: apoptotic process
    evidence_type: IEA
    original_reference_id: GO_REF:0000043
    review:
      summary: >-
        FGFR2 has complex effects on apoptosis - it can promote apoptosis in
        differentiated osteoblasts but inhibit it in keratinocytes and immature
        osteoblasts. The UniProt keyword may be too general.
      action: KEEP_AS_NON_CORE
      reason: >-
        UniProt notes FGFR2 "promotes apoptosis in differentiated osteoblasts" but
        this is context-dependent and not a primary function. The annotation is
        valid but represents a secondary/context-specific role.
      supported_by:
        - reference_id: UniProtKB:P21802
          supporting_text: "Promotes cell proliferation in keratinocytes and immature
            osteoblasts, but promotes apoptosis in differentiated osteoblasts"
  - term:
      id: GO:0008201
      label: heparin binding
    evidence_type: IEA
    original_reference_id: GO_REF:0000043
    review:
      summary: >-
        FGFR2 binds heparan sulfate glycosaminoglycans which serve as coreceptors.
        Heparin (a highly sulfated heparan sulfate) is used experimentally.
      action: ACCEPT
      reason: >-
        Documented function. UniProt confirms "Affinity for fibroblast growth factors
        (FGFs) is increased by heparan sulfate glycosaminoglycans that function as
        coreceptors." Crystal structures show heparin binding (PMID:11069186).
      supported_by:
        - reference_id: UniProtKB:P21802
          supporting_text: "Affinity for fibroblast growth factors (FGFs) is increased
            by heparan sulfate glycosaminoglycans that function as coreceptors"
  - term:
      id: GO:0008284
      label: positive regulation of cell population proliferation
    evidence_type: IEA
    original_reference_id: GO_REF:0000120
    review:
      summary: >-
        Duplicate of IBA annotation. FGFR2 promotes cell proliferation.
      action: ACCEPT
      reason: >-
        Correct - duplicates IBA with different evidence.
  - term:
      id: GO:0008543
      label: fibroblast growth factor receptor signaling pathway
    evidence_type: IEA
    original_reference_id: GO_REF:0000120
    review:
      summary: >-
        Duplicate of IBA annotation. FGFR2 is a core component of FGF signaling.
      action: ACCEPT
      reason: >-
        Correct - duplicates IBA with different evidence.
  - term:
      id: GO:0016020
      label: membrane
    evidence_type: IEA
    original_reference_id: GO_REF:0000002
    review:
      summary: >-
        Transmembrane FGFR2 isoforms are integral membrane proteins. This is a
        parent term of plasma membrane - overly general but not wrong.
      action: ACCEPT
      reason: >-
        Correct but general. More specific annotations (plasma membrane) exist.
  - term:
      id: GO:0016301
      label: kinase activity
    evidence_type: IEA
    original_reference_id: GO_REF:0000043
    review:
      summary: >-
        FGFR2 has kinase activity. This is a parent of the more specific protein
        tyrosine kinase activity annotations.
      action: ACCEPT
      reason: >-
        Correct but overly general. More specific annotations exist.
  - term:
      id: GO:0016740
      label: transferase activity
    evidence_type: IEA
    original_reference_id: GO_REF:0000043
    review:
      summary: >-
        Kinases are transferases (transfer phosphate groups). This is very general
        but technically correct.
      action: ACCEPT
      reason: >-
        Correct parent term. Very general but valid.
  - term:
      id: GO:0031410
      label: cytoplasmic vesicle
    evidence_type: IEA
    original_reference_id: GO_REF:0000120
    review:
      summary: >-
        FGFR2 is found in cytoplasmic vesicles during internalization after ligand
        binding. UniProt notes "After ligand binding, the activated receptor is
        rapidly internalized and degraded."
      action: ACCEPT
      reason: >-
        Valid location during receptor trafficking/internalization.
      supported_by:
        - reference_id: UniProtKB:P21802
          supporting_text: "After ligand binding, the activated receptor is rapidly
            internalized and degraded"
  - term:
      id: GO:0033688
      label: regulation of osteoblast proliferation
    evidence_type: IEA
    original_reference_id: GO_REF:0000117
    review:
      summary: >-
        FGFR2 regulates osteoblast proliferation - it promotes proliferation in
        immature osteoblasts. This is relevant to craniosynostosis syndromes caused
        by FGFR2 mutations.
      action: ACCEPT
      reason: >-
        UniProt confirms FGFR2 "Promotes cell proliferation in keratinocytes and
        immature osteoblasts" and "Plays an essential role in the regulation of
        osteoblast differentiation, proliferation and apoptosis."
  - term:
      id: GO:0043009
      label: chordate embryonic development
    evidence_type: IEA
    original_reference_id: GO_REF:0000117
    review:
      summary: >-
        FGFR2 is required for normal embryonic development. UniProt confirms it is
        "Required for normal embryonic patterning, trophoblast function, limb bud
        development, lung morphogenesis, osteogenesis and skin development."
      action: KEEP_AS_NON_CORE
      reason: >-
        Valid but very general developmental term. More specific developmental
        processes (limb, lung, skeleton) are better descriptors of FGFR2 function.
  - term:
      id: GO:0043410
      label: positive regulation of MAPK cascade
    evidence_type: IEA
    original_reference_id: GO_REF:0000117
    review:
      summary: >-
        Duplicate annotation (IBA already reviewed). MAPK cascade activation is a
        core downstream signaling output of FGFR2.
      action: ACCEPT
      reason: >-
        Duplicates IBA with different evidence. Core signaling function.
  - term:
      id: GO:0045595
      label: regulation of cell differentiation
    evidence_type: IEA
    original_reference_id: GO_REF:0000117
    review:
      summary: >-
        FGFR2 regulates differentiation of multiple cell types including osteoblasts,
        keratinocytes, and epithelial cells. This is a core function.
      action: ACCEPT
      reason: >-
        UniProt confirms role in "regulation of cell proliferation, differentiation,
        migration and apoptosis." Applies to both IIIb (epithelial differentiation)
        and IIIc (mesenchymal differentiation) isoforms.
  - term:
      id: GO:0048562
      label: embryonic organ morphogenesis
    evidence_type: IEA
    original_reference_id: GO_REF:0000117
    review:
      summary: >-
        FGFR2 is required for morphogenesis of multiple embryonic organs including
        limbs, lungs, and craniofacial structures. UniProt confirms it is "Required
        for normal embryonic patterning, trophoblast function, limb bud development,
        lung morphogenesis, osteogenesis and skin development."
      action: ACCEPT
      reason: >-
        Core developmental function. FGFR2 is essential for morphogenesis of
        multiple organs through epithelial-mesenchymal interactions. Consistent
        with ISS annotation for the same term.
      supported_by:
        - reference_id: UniProtKB:P21802
          supporting_text: "Required for normal embryonic patterning, trophoblast
            function, limb bud development, lung morphogenesis, osteogenesis and
            skin development"
  - term:
      id: GO:0048705
      label: skeletal system morphogenesis
    evidence_type: IEA
    original_reference_id: GO_REF:0000117
    review:
      summary: >-
        FGFR2 is critical for skeletal development. Mutations cause multiple
        craniosynostosis syndromes (Crouzon, Apert, Pfeiffer, Jackson-Weiss).
      action: ACCEPT
      reason: >-
        UniProt confirms "required for normal skeleton development" and documents
        multiple skeletal disorder phenotypes from FGFR2 mutations.
  - term:
      id: GO:1904888
      label: cranial skeletal system development
    evidence_type: IEA
    original_reference_id: GO_REF:0000117
    review:
      summary: >-
        FGFR2 is critical for cranial skeleton development. Mutations cause
        craniosynostosis - premature fusion of cranial sutures.
      action: ACCEPT
      reason: >-
        Strong evidence from human genetics - FGFR2 mutations cause Crouzon syndrome,
        Apert syndrome, Pfeiffer syndrome, and other craniosynostoses.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:10618369
    review:
      summary: >-
        PMID:10618369 is a structural study of FGFR2-FGF1 complex. The term
        "protein binding" is uninformative - more specific terms like "fibroblast
        growth factor binding" are available and preferred.
      action: MODIFY
      reason: >-
        "Protein binding" is too generic for GO annotation. This paper documents
        FGF binding which is already captured by GO:0017134.
      proposed_replacement_terms:
        - id: GO:0017134
          label: fibroblast growth factor binding
      supported_by:
        - reference_id: PMID:10618369
          supporting_text: Structural interactions of fibroblast growth factor 
            receptor with its ligands.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:10830168
    review:
      summary: >-
        PMID:10830168 reports crystal structures of FGF-FGFR complexes. Shows
        determinants of ligand-receptor specificity. "Protein binding" is too generic.
      action: MODIFY
      reason: >-
        Paper specifically documents FGF binding. Should use GO:0017134 fibroblast
        growth factor binding instead.
      proposed_replacement_terms:
        - id: GO:0017134
          label: fibroblast growth factor binding
      supported_by:
        - reference_id: PMID:10830168
          supporting_text: Crystal structures of two FGF-FGFR complexes reveal 
            the determinants of ligand-receptor specificity.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:11390973
    review:
      summary: >-
        PMID:11390973 describes structural basis for FGFR2 activation in Apert
        syndrome, examining FGF2 binding. "Protein binding" is too generic.
      action: MODIFY
      reason: >-
        Paper documents FGF2 binding to FGFR2. Should use more specific term.
      proposed_replacement_terms:
        - id: GO:0017134
          label: fibroblast growth factor binding
      supported_by:
        - reference_id: PMID:11390973
          supporting_text: Structural basis for fibroblast growth factor 
            receptor 2 activation in Apert syndrome.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:12591959
    review:
      summary: >-
        PMID:12591959 examines structural basis by which alternative splicing confers
        specificity in FGF receptors. Shows FGF10 binding to FGFR2IIIb.
      action: MODIFY
      reason: >-
        Paper documents isoform-specific FGF binding. Should use GO:0017134.
      proposed_replacement_terms:
        - id: GO:0017134
          label: fibroblast growth factor binding
      supported_by:
        - reference_id: PMID:12591959
          supporting_text: Structural basis by which alternative splicing 
            confers specificity in fibroblast growth factor receptors.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:1309608
    review:
      summary: >-
        PMID:1309608 is a seminal paper showing that alternative splicing creates
        two distinct growth factor receptors with different ligand specificities.
        Documents FGF1 and FGF7 binding differences between isoforms.
      action: MODIFY
      reason: >-
        Classic paper on FGFR2 isoform-specific FGF binding. Should use GO:0017134.
      proposed_replacement_terms:
        - id: GO:0017134
          label: fibroblast growth factor binding
      supported_by:
        - reference_id: PMID:1309608
          supporting_text: 'Determination of ligand-binding specificity by alternative
            splicing: two distinct growth factor receptors encoded by a single gene.'
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:22726438
    review:
      summary: >-
        PMID:22726438 documents inhibition of basal FGF receptor signaling by
        dimeric Grb2. Shows GRB2 interaction with FGFR2.
      action: MODIFY
      reason: >-
        Documents specific GRB2 binding. Should be annotated with a more specific
        term reflecting signaling adaptor interaction.
      proposed_replacement_terms:
        - id: GO:0005068
          label: transmembrane receptor protein tyrosine kinase adaptor activity
      supported_by:
        - reference_id: PMID:22726438
          supporting_text: Inhibition of basal FGF receptor signaling by dimeric
            Grb2.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:23597563
    review:
      summary: >-
        PMID:23597563 describes molecular mechanism of SSR128129E, an extracellularly
        acting small-molecule allosteric inhibitor. Documents drug-receptor interaction.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        This paper is about drug binding, not protein-protein interaction. The
        "protein binding" annotation does not capture meaningful biology here.
      supported_by:
        - reference_id: PMID:23597563
          supporting_text: Molecular mechanism of SSR128129E, an extracellularly
            acting, small-molecule, allosteric inhibitor of FGF receptor 
            signaling.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:25241761
    review:
      summary: >-
        PMID:25241761 uses in situ proximity ligation assay to profile endogenous
        protein-protein interactions. High-throughput interactome study.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        High-throughput study without specific functional characterization. "Protein
        binding" is too generic to be informative.
      supported_by:
        - reference_id: PMID:25241761
          supporting_text: Oct 9. Using an in situ proximity ligation assay to 
            systematically profile endogenous protein-protein interactions in a 
            pathway network.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:26267536
    review:
      summary: >-
        PMID:26267536 describes long-pentraxin 3 derivative as FGF trap for cancer
        therapy. Documents FGF sequestration rather than receptor binding.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Paper focuses on therapeutic FGF trapping, not native FGFR2 interactions.
        "Protein binding" is not informative here.
      supported_by:
        - reference_id: PMID:26267536
          supporting_text: Long-Pentraxin 3 Derivative as a Small-Molecule FGF 
            Trap for Cancer Therapy.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:33961781
    review:
      summary: >-
        PMID:33961781 is a large-scale proteome study of the human interactome.
        High-throughput data without specific functional characterization.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        High-throughput interactome study. "Protein binding" is too generic to be
        informative for specific gene annotation.
      supported_by:
        - reference_id: PMID:33961781
          supporting_text: 2021 May 6. Dual proteome-scale networks reveal 
            cell-specific remodeling of the human interactome.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:35384245
    review:
      summary: >-
        PMID:35384245 is a physical interactome atlas of human receptor tyrosine
        kinases. Large-scale study of RTK interactions.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        High-throughput interactome study. Generic "protein binding" annotations
        from such studies add little value.
      supported_by:
        - reference_id: PMID:35384245
          supporting_text: Physical and functional interactome atlas of human 
            receptor tyrosine kinases.
  - term:
      id: GO:0005515
      label: protein binding
    evidence_type: IPI
    original_reference_id: PMID:35922511
    review:
      summary: >-
        PMID:35922511 is a physical wiring diagram for the human immune system.
        Large-scale protein interaction study.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        High-throughput study. Generic "protein binding" from such studies is
        not informative for specific gene function.
      supported_by:
        - reference_id: PMID:35922511
          supporting_text: Aug 3. A physical wiring diagram for the human immune
            system.
  - term:
      id: GO:0001837
      label: epithelial to mesenchymal transition
    evidence_type: IEA
    original_reference_id: GO_REF:0000107
    review:
      summary: >-
        ISOFORM-SPECIFIC CONCERN: FGFR2 isoform switching (IIIb to IIIc) is
        associated with EMT. IIIb is epithelial; IIIc is mesenchymal. This
        annotation conflates gene-level with isoform-specific biology.
      action: KEEP_AS_NON_CORE
      reason: >-
        The isoform switch from IIIb to IIIc accompanies EMT in cancer, but FGFR2
        itself does not directly cause EMT. This is a correlative rather than
        causative role. The annotation may be valid but represents secondary biology.
  - term:
      id: GO:0003416
      label: endochondral bone growth
    evidence_type: IEA
    original_reference_id: GO_REF:0000107
    review:
      summary: >-
        FGFR2 plays a role in bone development. Mutations cause craniosynostosis
        and affect skeletal growth.
      action: ACCEPT
      reason: >-
        Valid bone development function supported by disease phenotypes. UniProt
        documents FGFR2 role in osteogenesis and skeletal development.
  - term:
      id: GO:0009986
      label: cell surface
    evidence_type: IEA
    original_reference_id: GO_REF:0000107
    review:
      summary: >-
        FGFR2 is a cell surface receptor. More specific than plasma membrane in
        indicating the exposed surface.
      action: ACCEPT
      reason: >-
        Valid localization. FGFR2 is a transmembrane receptor exposed at the cell
        surface for ligand binding.
  - term:
      id: GO:0017134
      label: fibroblast growth factor binding
    evidence_type: IEA
    original_reference_id: GO_REF:0000120
    review:
      summary: >-
        Duplicate of IBA annotation. FGF binding is a core FGFR2 function.
      action: ACCEPT
      reason: >-
        Core function - duplicates IBA with different evidence.
  - term:
      id: GO:0032496
      label: response to lipopolysaccharide
    evidence_type: IEA
    original_reference_id: GO_REF:0000107
    review:
      summary: >-
        LPS response is not a characterized FGFR2 function. This annotation may
        reflect expression changes rather than direct function.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        No clear evidence that FGFR2 has a direct role in LPS response. This is
        likely an ortholog transfer from expression data rather than functional data.
  - term:
      id: GO:0044344
      label: cellular response to fibroblast growth factor stimulus
    evidence_type: IEA
    original_reference_id: GO_REF:0000107
    review:
      summary: >-
        FGFR2 mediates cellular response to FGF. This is its core function as an
        FGF receptor.
      action: ACCEPT
      reason: >-
        Core function. FGFR2 is the receptor that mediates cellular response to
        multiple FGFs.
  - term:
      id: GO:0045471
      label: response to ethanol
    evidence_type: IEA
    original_reference_id: GO_REF:0000107
    review:
      summary: >-
        Ethanol response is not a characterized FGFR2 function. This annotation
        likely reflects expression changes rather than direct function.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        No evidence that FGFR2 has a direct role in ethanol response. Likely
        ortholog transfer from expression data.
  - term:
      id: GO:0048333
      label: mesodermal cell differentiation
    evidence_type: IEA
    original_reference_id: GO_REF:0000107
    review:
      summary: >-
        FGFR2IIIc (mesenchymal isoform) is involved in mesenchymal/mesodermal cell
        biology. This annotation may be partially isoform-specific.
      action: ACCEPT
      reason: >-
        Valid for FGFR2IIIc isoform specifically. FGF signaling through IIIc supports
        mesenchymal cell differentiation.
  - term:
      id: GO:0050680
      label: negative regulation of epithelial cell proliferation
    evidence_type: IEA
    original_reference_id: GO_REF:0000120
    review:
      summary: >-
        This annotation seems contradictory to FGFR2's known role in promoting
        keratinocyte (epithelial) proliferation. The annotation may be context-
        specific or erroneous.
      action: UNDECIDED
      reason: >-
        UniProt states FGFR2 "promotes cell proliferation in keratinocytes" which
        contradicts negative regulation. May apply to specific contexts but unclear.
  - term:
      id: GO:0071300
      label: cellular response to retinoic acid
    evidence_type: IEA
    original_reference_id: GO_REF:0000107
    review:
      summary: >-
        Retinoic acid response is not a characterized FGFR2 function. May reflect
        expression regulation rather than functional response.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        No clear evidence for direct FGFR2 role in retinoic acid response. Likely
        ortholog transfer from expression data.
  - term:
      id: GO:0071456
      label: cellular response to hypoxia
    evidence_type: IEA
    original_reference_id: GO_REF:0000107
    review:
      summary: >-
        Hypoxia response is not a well-characterized FGFR2 function. May reflect
        expression changes in hypoxia.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        No clear evidence for direct FGFR2 role in hypoxia response. Likely ortholog
        transfer from expression data.
  - term:
      id: GO:0071560
      label: cellular response to transforming growth factor beta stimulus
    evidence_type: IEA
    original_reference_id: GO_REF:0000107
    review:
      summary: >-
        TGF-beta response may involve FGFR2 in certain contexts, especially related
        to EMT where both pathways interact.
      action: KEEP_AS_NON_CORE
      reason: >-
        There is crosstalk between FGF and TGF-beta pathways in EMT and development,
        but this is not a primary FGFR2 function.
  - term:
      id: GO:1904707
      label: positive regulation of vascular associated smooth muscle cell 
        proliferation
    evidence_type: IEA
    original_reference_id: GO_REF:0000107
    review:
      summary: >-
        FGF signaling can promote smooth muscle cell proliferation, potentially via
        FGFR2IIIc in mesenchymal cells.
      action: KEEP_AS_NON_CORE
      reason: >-
        Valid but not a primary FGFR2 function. FGF2 signaling through FGFR can
        promote VSMC proliferation but this is not unique to FGFR2.
  - term:
      id: GO:0009986
      label: cell surface
    evidence_type: IDA
    original_reference_id: PMID:17959718
    review:
      summary: >-
        PMID:17959718 examines heparanase cleavage of perlecan and FGF10 activity
        in submandibular gland branching morphogenesis. Shows FGFR2 at cell surface.
      action: ACCEPT
      reason: >-
        Direct experimental evidence for cell surface localization during
        FGF10-FGFR2 signaling in branching morphogenesis.
      supported_by:
        - reference_id: PMID:17959718
          supporting_text: Heparanase cleavage of perlecan heparan sulfate 
            modulates FGF10 activity during ex vivo submandibular gland 
            branching morphogenesis.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654748
    review:
      summary: >-
        Reactome pathway annotation. Multiple Reactome entries document FGFR2
        plasma membrane localization in various signaling contexts.
      action: ACCEPT
      reason: >-
        Plasma membrane localization is well established for transmembrane FGFR2
        isoforms. Reactome pathway data supports this.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5655233
    review:
      summary: >-
        Reactome pathway annotation for FGFR2 signaling. Duplicates other PM annotations.
      action: ACCEPT
      reason: >-
        Valid localization, consistent with other evidence.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5655241
    review:
      summary: >-
        Reactome pathway annotation. Part of FGFR2 signaling pathway documentation.
      action: ACCEPT
      reason: >-
        Valid localization, consistent with other evidence.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5655245
    review:
      summary: >-
        Reactome pathway annotation for FGFR2 at plasma membrane.
      action: ACCEPT
      reason: >-
        Valid localization, duplicates other evidence.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5655268
    review:
      summary: >-
        Reactome pathway annotation for FGFR2 signaling.
      action: ACCEPT
      reason: >-
        Valid localization, consistent with established biology.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5655301
    review:
      summary: >-
        Reactome pathway annotation for FGFR2 signaling.
      action: ACCEPT
      reason: >-
        Valid localization.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5655320
    review:
      summary: >-
        Reactome pathway annotation for FGFR2 signaling.
      action: ACCEPT
      reason: >-
        Valid localization.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5655323
    review:
      summary: >-
        Reactome pathway annotation for FGFR2 signaling.
      action: ACCEPT
      reason: >-
        Valid localization.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5655339
    review:
      summary: >-
        Reactome pathway annotation for FGFR2 signaling.
      action: ACCEPT
      reason: >-
        Valid localization.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5655343
    review:
      summary: >-
        Reactome pathway annotation for FGFR2 signaling.
      action: ACCEPT
      reason: >-
        Valid localization.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-8853313
    review:
      summary: >-
        Reactome pathway annotation for FGFR2 fusions autophosphorylation. Documents
        aberrant signaling in cancer.
      action: ACCEPT
      reason: >-
        Valid localization for wild-type and fusion FGFR2.
  - term:
      id: GO:0010839
      label: negative regulation of keratinocyte proliferation
    evidence_type: IMP
    original_reference_id: PMID:21412257
    review:
      summary: >-
        PMID:21412257 shows miR-125b modulates keratinocyte proliferation by
        targeting FGFR2. Knockdown of FGFR2 by miRNA reduces proliferation,
        suggesting FGFR2 normally promotes (not inhibits) keratinocyte proliferation.
      action: REMOVE
      reason: >-
        This annotation appears incorrect. The paper shows that FGFR2 knockdown
        reduces keratinocyte proliferation, meaning FGFR2 positively regulates
        proliferation. The annotation should be GO:0050679 (positive regulation
        of epithelial cell proliferation) rather than negative regulation.
      supported_by:
        - reference_id: PMID:21412257
          supporting_text: Mar 17. MiR-125b, a microRNA downregulated in 
            psoriasis, modulates keratinocyte proliferation by targeting FGFR2.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-8853319
    review:
      summary: >-
        Reactome pathway annotation for plasma membrane localization. FGFR2
        transmembrane isoforms are plasma membrane receptors. Multiple Reactome
        pathways include FGFR2 at the plasma membrane.
      action: ACCEPT
      reason: >-
        Correct localization for transmembrane FGFR2 isoforms. Duplicate entries
        from different Reactome pathways reflect FGFR2 participation in multiple
        signaling contexts at the plasma membrane.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2029989
    review:
      summary: >-
        Reactome pathway annotation duplicate. Plasma membrane localization is
        well established for transmembrane FGFR2 isoforms.
      action: ACCEPT
      reason: >-
        Duplicate of other plasma membrane annotations from different Reactome
        pathway contexts. Valid for transmembrane isoforms.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2029983
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2029984
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2033472
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2033474
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2033479
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2033486
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2033488
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2033490
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2077424
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-109699
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-190413
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2316434
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2400009
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654147
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654157
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654159
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654397
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654399
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654402
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654404
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654406
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654407
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654562
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654603
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654605
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654607
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654608
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654612
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654614
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654615
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654618
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654620
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654622
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654677
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654697
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654701
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5654729
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-5672965
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-190258
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-190260
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-190408
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-NUL-8853328
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2029988
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2029992
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: TAS
    original_reference_id: Reactome:R-HSA-2067713
    review:
      summary: >-
        Reactome pathway annotation duplicate for plasma membrane localization.
      action: ACCEPT
      reason: >-
        Valid duplicate annotation from different Reactome pathway.
  - term:
      id: GO:0048701
      label: embryonic cranial skeleton morphogenesis
    evidence_type: IMP
    original_reference_id: PMID:7874170
    review:
      summary: >-
        Mutations in FGFR2 cause Jackson-Weiss and Crouzon syndromes, which feature
        craniosynostosis (premature fusion of cranial sutures). This demonstrates
        FGFR2 role in cranial skeleton development. PMID:7874170 identified FGFR2
        mutations in the IIIc domain in Jackson-Weiss syndrome families.
      action: ACCEPT
      reason: >-
        Strong genetic evidence linking FGFR2 mutations to craniosynostosis syndromes.
        FGFR2 is essential for normal cranial suture development; gain-of-function
        mutations cause premature suture fusion. This is a well-established core
        developmental function particularly for the IIIc isoform in mesenchyme.
      supported_by:
        - reference_id: PMID:7874170
          supporting_text: "We now report an FGFR2 mutation in the conserved region
            of the immunoglobulin IIIc domain in the Jackson-Weiss syndrome family
            in which the syndrome was originally described."
  - term:
      id: GO:0048701
      label: embryonic cranial skeleton morphogenesis
    evidence_type: IMP
    original_reference_id: PMID:7987400
    review:
      summary: >-
        PMID:7987400 demonstrates that mutations in FGFR2 cause Crouzon syndrome,
        providing additional genetic evidence for FGFR2 role in cranial skeleton
        development. Multiple mutations in the B exon (IIIc domain) were identified.
      action: ACCEPT
      reason: >-
        Complements PMID:7874170 evidence. Crouzon syndrome is autosomal dominant
        craniosynostosis caused by FGFR2 mutations, including cysteine substitutions
        in the Ig-like domain. Core developmental function.
      supported_by:
        - reference_id: PMID:7987400
          supporting_text: "We now present evidence that mutations in the fibroblast
            growth factor receptor 2 gene (FGFR2) cause Crouzon syndrome."
  - term:
      id: GO:0005634
      label: nucleus
    evidence_type: IDA
    original_reference_id: PMID:16597614
    review:
      summary: >-
        PMID:16597614 observed FGF-10 receptor (FGFR2IIIb/KGFR) in nucleus of
        urothelial cells by microscopy. This is an intriguing finding suggesting
        nuclear translocation of activated receptor, though unconventional.
      action: KEEP_AS_NON_CORE
      reason: >-
        Nuclear localization of FGFRs has been reported but is non-canonical and
        represents a specialized signaling mechanism rather than the primary
        localization. The main function of FGFR2 is at the plasma membrane.
      supported_by:
        - reference_id: PMID:16597614
          supporting_text: "Deconvolution, light and transmission electron microscopic
            studies captured FGF-10 and its receptor in association with the urothelial
            cell surface, in cytoplasm, and within nuclei"
  - term:
      id: GO:0005737
      label: cytoplasm
    evidence_type: IDA
    original_reference_id: PMID:16597614
    review:
      summary: >-
        PMID:16597614 showed FGFR2 (FGF-10 receptor) localizes to cytoplasm during
        its trafficking and signaling in urothelial cells.
      action: ACCEPT
      reason: >-
        FGFR2 is found in cytoplasm during biosynthesis, trafficking to plasma
        membrane, and after receptor internalization. Valid localization.
      supported_by:
        - reference_id: PMID:16597614
          supporting_text: "Deconvolution, light and transmission electron microscopic
            studies captured FGF-10 and its receptor in association with the urothelial
            cell surface, in cytoplasm, and within nuclei"
  - term:
      id: GO:0009986
      label: cell surface
    evidence_type: IDA
    original_reference_id: PMID:16597614
    review:
      summary: >-
        PMID:16597614 localized FGFR2 (FGF-10 receptor) to the urothelial cell
        surface, consistent with its function as a transmembrane receptor.
      action: ACCEPT
      reason: >-
        Cell surface localization is expected for transmembrane receptor tyrosine
        kinases. This is functionally equivalent to plasma membrane localization.
      supported_by:
        - reference_id: PMID:16597614
          supporting_text: "Deconvolution, light and transmission electron microscopic
            studies captured FGF-10 and its receptor in association with the urothelial
            cell surface"
  - term:
      id: GO:0005007
      label: fibroblast growth factor receptor activity
    evidence_type: IDA
    original_reference_id: PMID:15629145
    review:
      summary: >-
        PMID:15629145 studied KGFR (FGFR2IIIb) signaling through autophosphorylation
        and downstream pathway activation. The study demonstrated functional FGF
        receptor activity through tyrosine phosphorylation assays.
      action: ACCEPT
      reason: >-
        Direct experimental demonstration of FGFR2 (KGFR isoform) receptor activity
        including autophosphorylation and signaling. Core molecular function.
      supported_by:
        - reference_id: PMID:15629145
          supporting_text: "KGFR is rapidly autophosphorylated on specific tyrosine
            residues in the intracellular domain, recruits substrate proteins"
  - term:
      id: GO:0005007
      label: fibroblast growth factor receptor activity
    evidence_type: IDA
    original_reference_id: PMID:8663044
    review:
      summary: >-
        PMID:8663044 systematically tested FGF receptor splice variants for ligand
        specificity and mitogenic activity. This landmark study established FGFR2
        isoform-specific ligand binding and receptor activation.
      action: ACCEPT
      reason: >-
        Comprehensive biochemical characterization of FGFR2 splice variants as
        functional FGF receptors. Demonstrated mitogenic activity with multiple
        FGF ligands. Foundational study for FGFR2 biology.
      supported_by:
        - reference_id: PMID:8663044
          supporting_text: "we have engineered mitogenically responsive cell lines
            expressing the major splice variants of all the known FGF receptors. We
            have assayed the mitogenic activity of the nine known FGF ligands on these
            cell lines."
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: IDA
    original_reference_id: PMID:15629145
    review:
      summary: >-
        PMID:15629145 studied KGFR (FGFR2IIIb) at the plasma membrane where it
        undergoes ligand-induced internalization.
      action: ACCEPT
      reason: >-
        Plasma membrane localization is the primary site of FGFR2 function as a
        transmembrane receptor.
      supported_by:
        - reference_id: PMID:15629145
          supporting_text: Tyrosine 769 of the keratinocyte growth factor 
            receptor is required for receptor signaling but not endocytosis.
  - term:
      id: GO:0005886
      label: plasma membrane
    evidence_type: IDA
    original_reference_id: PMID:16844695
    review:
      summary: >-
        PMID:16844695 studied FGFR2 trafficking and localization, showing wild-type
        FGFR2 localizes to plasma membrane while glycosylation-deficient and
        mutant forms show altered localization.
      action: ACCEPT
      reason: >-
        Demonstrates plasma membrane is the normal localization for properly
        processed FGFR2, while mutations affecting glycosylation impair trafficking.
      supported_by:
        - reference_id: PMID:16844695
          supporting_text: "we show that trafficking and autoactivation of wild type
            FGFR2 is glycosylation-dependent"
  - term:
      id: GO:0008284
      label: positive regulation of cell population proliferation
    evidence_type: IMP
    original_reference_id: PMID:15629145
    review:
      summary: >-
        PMID:15629145 showed that KGFR Y769F mutation impairs cell proliferation,
        demonstrating that functional KGFR (FGFR2IIIb) signaling promotes
        proliferation.
      action: ACCEPT
      reason: >-
        Mutant phenotype analysis demonstrates FGFR2 promotes cell proliferation.
        Core biological process for FGFR signaling.
      supported_by:
        - reference_id: PMID:15629145
          supporting_text: "tyrosine 769 is required...for cell proliferation through
            the regulation of FRS2 tyrosine phosphorylation"
  - term:
      id: GO:0008284
      label: positive regulation of cell population proliferation
    evidence_type: IDA
    original_reference_id: PMID:8663044
    review:
      summary: >-
        PMID:8663044 used mitogenic assays to demonstrate FGF-induced proliferation
        through FGFR2. Multiple FGF ligands activated FGFR2-expressing cells.
      action: ACCEPT
      reason: >-
        Direct mitogenic assays showing FGFR2 activation promotes cell proliferation.
        Foundational evidence for this core biological process.
      supported_by:
        - reference_id: PMID:8663044
          supporting_text: Receptor specificity of the fibroblast growth factor 
            family.
  - term:
      id: GO:0008543
      label: fibroblast growth factor receptor signaling pathway
    evidence_type: IDA
    original_reference_id: PMID:15629145
    review:
      summary: >-
        PMID:15629145 characterized KGFR signaling pathway including PLCgamma
        recruitment, FRS2 phosphorylation, and MAPK activation. This directly
        demonstrates FGF receptor signaling.
      action: ACCEPT
      reason: >-
        Detailed characterization of FGFR2 (KGFR) signaling pathway components.
        Core biological process.
      supported_by:
        - reference_id: PMID:15629145
          supporting_text: "tyrosine 769 is required for the binding to KGFR and tyrosine
            phosphorylation of PLCgamma as well as for the full activation of MAPKs"
  - term:
      id: GO:0008543
      label: fibroblast growth factor receptor signaling pathway
    evidence_type: IDA
    original_reference_id: PMID:8663044
    review:
      summary: >-
        PMID:8663044 demonstrated FGF signaling through FGFR2 using mitogenic
        assays as readout of pathway activation.
      action: ACCEPT
      reason: >-
        Functional demonstration of FGF signaling pathway activation through FGFR2.
      supported_by:
        - reference_id: PMID:8663044
          supporting_text: Receptor specificity of the fibroblast growth factor 
            family.
  - term:
      id: GO:0010518
      label: positive regulation of phospholipase activity
    evidence_type: IMP
    original_reference_id: PMID:16844695
    review:
      summary: >-
        PMID:16844695 showed both wild-type and mutant FGFR2 signal through PLCgamma.
        The C278F mutation and unglycosylated FGFR2 signal through PLCgamma in a
        ligand-independent manner.
      action: ACCEPT
      reason: >-
        Demonstrates FGFR2 activates PLCgamma (phospholipase C gamma), which is a
        well-established downstream effector of FGFR signaling.
      supported_by:
        - reference_id: PMID:16844695
          supporting_text: "Both FGFR2C278F and unglycosylated wild type FGFR2 signal
            through phospholipase Cgamma in a ligand-independent manner"
  - term:
      id: GO:0017134
      label: fibroblast growth factor binding
    evidence_type: IDA
    original_reference_id: PMID:8663044
    review:
      summary: >-
        PMID:8663044 systematically characterized FGF binding specificity of FGFR2
        splice variants. FGF1 binds all variants; FGF2 binds IIIc; FGF7 binds IIIb.
      action: ACCEPT
      reason: >-
        Comprehensive biochemical characterization of FGF binding to FGFR2 isoforms.
        Core molecular function. Established isoform-specific ligand preferences.
      supported_by:
        - reference_id: PMID:8663044
          supporting_text: "FGF 1 is the only FGF that can activate all FGF receptor
            splice variants"
  - term:
      id: GO:0018108
      label: peptidyl-tyrosine phosphorylation
    evidence_type: IDA
    original_reference_id: PMID:15629145
    review:
      summary: >-
        PMID:15629145 demonstrated KGFR (FGFR2IIIb) phosphorylates tyrosine residues
        on PLCgamma and FRS2 substrates. The study showed Y769 is required for
        PLCgamma and FRS2 tyrosine phosphorylation.
      action: ACCEPT
      reason: >-
        Direct demonstration of FGFR2 tyrosine kinase activity phosphorylating
        substrates. Core enzymatic function of receptor tyrosine kinases.
      supported_by:
        - reference_id: PMID:15629145
          supporting_text: "tyrosine 769 is required for the binding to KGFR and tyrosine
            phosphorylation of PLCgamma...through the regulation of FRS2 tyrosine
            phosphorylation"
  - term:
      id: GO:0018108
      label: peptidyl-tyrosine phosphorylation
    evidence_type: IDA
    original_reference_id: PMID:16844695
    review:
      summary: >-
        PMID:16844695 showed FGFR2 phosphorylates itself and downstream substrates.
        Both wild-type and mutant FGFR2 exhibit tyrosine phosphorylation activity.
      action: ACCEPT
      reason: >-
        Confirms FGFR2 tyrosine kinase activity in phosphorylating substrates.
      supported_by:
        - reference_id: PMID:16844695
          supporting_text: 2006 Jul 14. Intracellular retention, degradation, 
            and signaling of glycosylation-deficient FGFR2 and craniosynostosis 
            syndrome-associated FGFR2C278F.
  - term:
      id: GO:0033688
      label: regulation of osteoblast proliferation
    evidence_type: TAS
    original_reference_id: PMID:15190072
    review:
      summary: >-
        PMID:15190072 studied FGFR2 S252W gain-of-function mutation in osteoblasts.
        The study shows constitutive FGFR2 activation affects osteoblast
        proliferation through regulation of Src family kinases Lyn and Fyn.
      action: ACCEPT
      reason: >-
        Direct evidence that FGFR2 regulates osteoblast proliferation. This function
        is highly relevant to craniosynostosis syndromes caused by FGFR2 mutations.
      supported_by:
        - reference_id: PMID:15190072
          supporting_text: "Fibroblast growth factors (FGFs) play an important regulatory
            role in skeletal development and bone formation"
  - term:
      id: GO:0042803
      label: protein homodimerization activity
    evidence_type: IPI
    original_reference_id: PMID:16844695
    review:
      summary: >-
        PMID:16844695 studied FGFR2 homodimerization which is required for receptor
        activation. FGFR2 dimerizes upon ligand binding or constitutively in
        gain-of-function mutants.
      action: ACCEPT
      reason: >-
        FGFR2 homodimerization is essential for receptor activation. Documented
        by immunoprecipitation studies. Core mechanism of receptor activation.
      supported_by:
        - reference_id: PMID:16844695
          supporting_text: 2006 Jul 14. Intracellular retention, degradation, 
            and signaling of glycosylation-deficient FGFR2 and craniosynostosis 
            syndrome-associated FGFR2C278F.
  - term:
      id: GO:0043410
      label: positive regulation of MAPK cascade
    evidence_type: IMP
    original_reference_id: PMID:15629145
    review:
      summary: >-
        PMID:15629145 showed that KGFR Y769F mutation impairs MAPK activation,
        demonstrating that functional FGFR2 signaling is required for full MAPK
        cascade activation.
      action: ACCEPT
      reason: >-
        Mutant phenotype analysis confirms FGFR2 activates MAPK cascade. Core
        downstream signaling pathway.
      supported_by:
        - reference_id: PMID:15629145
          supporting_text: "tyrosine 769 is required...for the full activation of
            MAPKs"
  - term:
      id: GO:0045667
      label: regulation of osteoblast differentiation
    evidence_type: TAS
    original_reference_id: PMID:15190072
    review:
      summary: >-
        PMID:15190072 demonstrated that constitutive FGFR2 activation promotes
        osteoblast differentiation through Cbl-mediated degradation of Src family
        kinases Lyn and Fyn.
      action: ACCEPT
      reason: >-
        Direct evidence that FGFR2 regulates osteoblast differentiation. The
        FGFR2 S252W mutation (Apert syndrome) increases ALP expression, a marker
        of osteoblast differentiation.
      supported_by:
        - reference_id: PMID:15190072
          supporting_text: "constitutive FGFR2 activation induces c-Cbl-dependent
            Lyn and Fyn proteasome degradation, resulting in...increased ALP expression"
  - term:
      id: GO:0046777
      label: protein autophosphorylation
    evidence_type: IDA
    original_reference_id: PMID:15629145
    review:
      summary: >-
        PMID:15629145 demonstrated KGFR (FGFR2IIIb) autophosphorylation on tyrosine
        residues including Y769 upon ligand binding.
      action: ACCEPT
      reason: >-
        Direct demonstration of FGFR2 autophosphorylation. Core mechanism of
        receptor tyrosine kinase activation.
      supported_by:
        - reference_id: PMID:15629145
          supporting_text: "KGFR is rapidly autophosphorylated on specific tyrosine
            residues in the intracellular domain"
  - term:
      id: GO:0048705
      label: skeletal system morphogenesis
    evidence_type: TAS
    original_reference_id: PMID:15190072
    review:
      summary: >-
        PMID:15190072 discusses FGFR2 role in skeletal development. FGFR2 mutations
        cause skeletal abnormalities including craniosynostosis.
      action: ACCEPT
      reason: >-
        FGFR2 is essential for skeletal system development. Mutations cause
        multiple craniosynostosis syndromes affecting skull development.
      supported_by:
        - reference_id: PMID:15190072
          supporting_text: "Fibroblast growth factors (FGFs) play an important regulatory
            role in skeletal development and bone formation"
  - term:
      id: GO:0035602
      label: fibroblast growth factor receptor signaling pathway involved in 
        negative regulation of apoptotic process in bone marrow cell
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation transferred from mouse ortholog. Overly specific term for
        a context-dependent function that is not a primary role for human FGFR2.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        While FGF signaling can have anti-apoptotic effects, this highly specific
        term (bone marrow cell apoptosis) is not a core function of human FGFR2.
        Mouse knockout data may not directly translate to primary human function.
  - term:
      id: GO:0035603
      label: fibroblast growth factor receptor signaling pathway involved in 
        hemopoiesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation transferred from mouse ortholog. Hemopoiesis is not a primary
        function of FGFR2; this likely reflects pleiotropic effects in mouse models.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        FGFR2 primary functions are in epithelial-mesenchymal signaling, skeletal
        development, and wound healing. Hemopoietic role is not a core function.
  - term:
      id: GO:0035604
      label: fibroblast growth factor receptor signaling pathway involved in 
        positive regulation of cell proliferation in bone marrow
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation transferred from mouse ortholog. Overly specific term for
        bone marrow context that is not a primary FGFR2 function.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        While FGFR2 promotes proliferation generally, this bone marrow-specific
        context is not a core function for human FGFR2.
  - term:
      id: GO:0035607
      label: fibroblast growth factor receptor signaling pathway involved in 
        orbitofrontal cortex development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 has roles in brain development
        but this specific term for orbitofrontal cortex is highly specialized.
      action: KEEP_AS_NON_CORE
      reason: >-
        Brain development role is plausible given FGFR2 mutations cause Crouzon
        and Apert syndromes which can have CNS effects. However, this is a very
        specific developmental context, not a core function.
  - term:
      id: GO:0021769
      label: orbitofrontal cortex development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for orbitofrontal cortex development.
        Related to the above signaling pathway annotation.
      action: KEEP_AS_NON_CORE
      reason: >-
        Specialized developmental context. FGFR2 contributes to brain development
        but this specific region is not a core function.
  - term:
      id: GO:0021847
      label: ventricular zone neuroblast division
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for neural progenitor division in the
        ventricular zone during brain development.
      action: KEEP_AS_NON_CORE
      reason: >-
        FGF signaling has roles in neural development but this is a specialized
        developmental function, not a core FGFR2 function.
  - term:
      id: GO:0021860
      label: pyramidal neuron development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for pyramidal neuron development.
      action: KEEP_AS_NON_CORE
      reason: >-
        Specialized neuronal development context. Not a primary FGFR2 function.
  - term:
      id: GO:0045787
      label: positive regulation of cell cycle
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 promotes cell proliferation which
        involves positive regulation of the cell cycle.
      action: ACCEPT
      reason: >-
        Consistent with FGFR2 role in promoting cell proliferation. Mitogenic
        signaling through FRS2/MAPK pathway drives cell cycle progression.
  - term:
      id: GO:0060076
      label: excitatory synapse
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog suggesting FGFR2 localization at
        excitatory synapses. Unusual localization for a growth factor receptor.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Synaptic localization is not a core function of FGFR2. May reflect
        specialized neuronal signaling in mouse models but not a primary
        human FGFR2 function.
  - term:
      id: GO:0000122
      label: negative regulation of transcription by RNA polymerase II
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. Indirect effect of FGFR2 signaling
        on transcription through downstream pathways.
      action: KEEP_AS_NON_CORE
      reason: >-
        FGFR2 signaling can affect transcription through MAPK and other pathways,
        but transcriptional regulation is an indirect downstream effect, not
        a core molecular function of the receptor.
  - term:
      id: GO:0001525
      label: angiogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. Duplicate of IBA annotation - FGF
        signaling has documented roles in angiogenesis.
      action: KEEP_AS_NON_CORE
      reason: >-
        Consistent with IBA annotation. Angiogenesis is a documented but non-core
        function for FGFR2; FGFR1 may be more prominent in vascular biology.
  - term:
      id: GO:0001657
      label: ureteric bud development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 has roles in kidney development
        including ureteric bud branching morphogenesis.
      action: KEEP_AS_NON_CORE
      reason: >-
        UniProt notes FGFR2 is required for normal embryonic patterning including
        organogenesis. Kidney development is a documented but tissue-specific
        developmental function.
  - term:
      id: GO:0001701
      label: in utero embryonic development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 is required for normal embryonic
        development as evidenced by embryonic lethality in knockout mice.
      action: KEEP_AS_NON_CORE
      reason: >-
        Very broad developmental term. FGFR2 is essential for development but
        more specific terms (limb, lung, skeletal) better capture core functions.
  - term:
      id: GO:0002053
      label: positive regulation of mesenchymal cell proliferation
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2IIIc (mesenchymal isoform) promotes
        mesenchymal cell proliferation in response to FGF2/4 from epithelium.
      action: ACCEPT
      reason: >-
        Core function for FGFR2IIIc isoform. Mesenchymal proliferation is central
        to epithelial-mesenchymal signaling that FGFR2 mediates in development.
  - term:
      id: GO:0003148
      label: outflow tract septum morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. Cardiac outflow tract development
        involves FGFR signaling but is a specialized developmental context.
      action: KEEP_AS_NON_CORE
      reason: >-
        Cardiac development role is documented for FGFRs but this specific
        structure is not a core FGFR2 function.
  - term:
      id: GO:0003149
      label: membranous septum morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. Cardiac septum development is a
        specialized developmental context.
      action: KEEP_AS_NON_CORE
      reason: >-
        Specialized cardiac developmental function, not a core FGFR2 function.
  - term:
      id: GO:0007267
      label: cell-cell signaling
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 mediates paracrine signaling
        between epithelium and mesenchyme.
      action: ACCEPT
      reason: >-
        Core function. FGFR2 mediates paracrine FGF signaling between cell types,
        particularly epithelial-mesenchymal communication where IIIb receives
        signals from mesenchyme and IIIc receives signals from epithelium.
  - term:
      id: GO:0007409
      label: axonogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGF signaling has roles in axon
        guidance and neuronal development.
      action: KEEP_AS_NON_CORE
      reason: >-
        Neural development role is documented but not a primary FGFR2 function.
        More specialized than core epithelial-mesenchymal signaling roles.
  - term:
      id: GO:0008589
      label: regulation of smoothened signaling pathway
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. Cross-talk between FGF and Hedgehog
        (Smoothened) pathways has been reported in development.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        While pathway cross-talk exists, direct regulation of Smoothened signaling
        is not a core FGFR2 function. This represents indirect developmental
        pathway interactions rather than a primary function.
  - term:
      id: GO:0009791
      label: post-embryonic development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 has roles in tissue homeostasis
        and repair after embryonic development.
      action: KEEP_AS_NON_CORE
      reason: >-
        FGFR2 continues to function in adult tissue homeostasis and wound healing
        but this is a broad term. Embryonic roles are better documented.
  - term:
      id: GO:0009880
      label: embryonic pattern specification
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 contributes to embryonic patterning
        through epithelial-mesenchymal interactions.
      action: ACCEPT
      reason: >-
        UniProt confirms FGFR2 is required for normal embryonic patterning. FGF
        signaling through FGFR2 establishes tissue boundaries and patterns during
        development.
  - term:
      id: GO:0009887
      label: animal organ morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 is required for morphogenesis
        of multiple organs including limbs, lungs, and skeleton.
      action: ACCEPT
      reason: >-
        Core developmental function. FGFR2 is essential for branching morphogenesis
        and organ development, particularly lungs, limbs, and craniofacial skeleton.
  - term:
      id: GO:0016331
      label: morphogenesis of embryonic epithelium
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2IIIb is expressed in epithelium
        and receives signals from mesenchyme to direct epithelial morphogenesis.
      action: ACCEPT
      reason: >-
        Core function for FGFR2IIIb isoform. Epithelial morphogenesis through
        FGF7/10 signaling is a primary developmental role.
  - term:
      id: GO:0022612
      label: gland morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 is required for salivary gland,
        lacrimal gland, and other gland development through branching morphogenesis.
      action: ACCEPT
      reason: >-
        Core developmental function. FGFR2-mediated branching morphogenesis is
        essential for gland development in multiple organ systems.
  - term:
      id: GO:0030177
      label: positive regulation of Wnt signaling pathway
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. Cross-talk between FGF and Wnt pathways
        occurs during development but this is indirect signaling.
      action: KEEP_AS_NON_CORE
      reason: >-
        FGF-Wnt pathway interactions exist during development but positive regulation
        of Wnt signaling is not a direct core function of FGFR2.
  - term:
      id: GO:0030282
      label: bone mineralization
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 regulates osteoblast differentiation
        and bone development; mineralization is a downstream effect.
      action: KEEP_AS_NON_CORE
      reason: >-
        Indirect effect of FGFR2 on osteoblast function. The core function is
        regulating osteoblast proliferation/differentiation rather than
        mineralization per se.
  - term:
      id: GO:0030324
      label: lung development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 is essential for lung branching
        morphogenesis. UniProt confirms role in lung morphogenesis.
      action: ACCEPT
      reason: >-
        Core developmental function. FGFR2 (particularly IIIb/KGFR) is essential
        for lung epithelial branching morphogenesis through FGF10 signaling.
  - term:
      id: GO:0030855
      label: epithelial cell differentiation
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2IIIb in epithelial cells regulates
        their differentiation in response to mesenchymal FGF signals.
      action: ACCEPT
      reason: >-
        Core function for FGFR2IIIb isoform. Epithelial differentiation is directed
        by FGF7/10 signaling through the epithelial FGFR2 isoform.
  - term:
      id: GO:0030901
      label: midbrain development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for midbrain development.
      action: KEEP_AS_NON_CORE
      reason: >-
        Brain development is one of many developmental contexts where FGFR2
        functions, but not a primary function.
  - term:
      id: GO:0030916
      label: otic vesicle formation
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for inner ear development.
      action: KEEP_AS_NON_CORE
      reason: >-
        Specialized developmental context. FGFR2 contributes to ear development
        but this is not a core function.
  - term:
      id: GO:0031069
      label: hair follicle morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 is required for skin development
        including hair follicles. UniProt notes role in skin development.
      action: ACCEPT
      reason: >-
        Documented role in skin development. FGF signaling through FGFR2IIIb
        contributes to epithelial appendage formation including hair follicles.
  - term:
      id: GO:0032808
      label: lacrimal gland development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. Lacrimal gland develops through
        branching morphogenesis requiring FGFR2 signaling.
      action: KEEP_AS_NON_CORE
      reason: >-
        Example of gland morphogenesis role. More general gland morphogenesis
        term already captures this function.
  - term:
      id: GO:0035265
      label: organ growth
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 promotes cell proliferation
        which contributes to organ growth during development.
      action: ACCEPT
      reason: >-
        General term consistent with FGFR2 role in promoting proliferation
        during organ development.
  - term:
      id: GO:0042472
      label: inner ear morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for inner ear development.
      action: KEEP_AS_NON_CORE
      reason: >-
        Specialized developmental context for ear morphogenesis.
  - term:
      id: GO:0042476
      label: odontogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGF signaling is involved in tooth
        development through epithelial-mesenchymal interactions.
      action: KEEP_AS_NON_CORE
      reason: >-
        Tooth development involves FGFR2 but is a specialized developmental
        context rather than a core function.
  - term:
      id: GO:0045165
      label: cell fate commitment
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 signaling influences cell fate
        decisions during development.
      action: KEEP_AS_NON_CORE
      reason: >-
        Broad developmental term. FGFR2 influences cell fate but more specific
        terms better capture its functions.
  - term:
      id: GO:0045944
      label: positive regulation of transcription by RNA polymerase II
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 signaling can activate
        transcription through MAPK pathway and transcription factors.
      action: KEEP_AS_NON_CORE
      reason: >-
        Indirect downstream effect of FGFR2 signaling rather than a core
        molecular function of the receptor.
  - term:
      id: GO:0048286
      label: lung alveolus development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. Specific aspect of lung development
        where FGFR2 contributes to alveolar formation.
      action: ACCEPT
      reason: >-
        Part of core lung development function. FGFR2 is essential for lung
        morphogenesis including alveolar development.
  - term:
      id: GO:0048557
      label: embryonic digestive tract morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for GI tract development.
      action: KEEP_AS_NON_CORE
      reason: >-
        One of many organs where FGFR2 contributes to development but not
        a primary documented function.
  - term:
      id: GO:0048562
      label: embryonic organ morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. General term for FGFR2 role in
        organ development during embryogenesis.
      action: ACCEPT
      reason: >-
        Core developmental function. FGFR2 is essential for morphogenesis of
        multiple organs through epithelial-mesenchymal interactions.
  - term:
      id: GO:0048565
      label: digestive tract development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for GI tract development.
      action: KEEP_AS_NON_CORE
      reason: >-
        Digestive tract development is one of many developmental contexts.
  - term:
      id: GO:0048568
      label: embryonic organ development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. Broad term for embryonic
        organogenesis role of FGFR2.
      action: ACCEPT
      reason: >-
        Core developmental function consistent with FGFR2 role in multiple
        organ systems during development.
  - term:
      id: GO:0048608
      label: reproductive structure development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for reproductive organ development.
      action: KEEP_AS_NON_CORE
      reason: >-
        Specialized developmental context not emphasized in human FGFR2 function.
  - term:
      id: GO:0048730
      label: epidermis morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 is required for skin
        development. UniProt confirms role in skin development.
      action: ACCEPT
      reason: >-
        Documented function. FGFR2IIIb in keratinocytes responds to FGF7/KGF
        from dermal fibroblasts to regulate epidermis.
  - term:
      id: GO:0048755
      label: branching morphogenesis of a nerve
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for nerve branching.
      action: KEEP_AS_NON_CORE
      reason: >-
        Specialized neural context not a primary FGFR2 function.
  - term:
      id: GO:0048762
      label: mesenchymal cell differentiation
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2IIIc in mesenchyme responds
        to epithelial FGFs to promote mesenchymal differentiation.
      action: ACCEPT
      reason: >-
        Core function for FGFR2IIIc isoform. Mesenchymal differentiation is
        central to FGFR2 role in development.
  - term:
      id: GO:0050679
      label: positive regulation of epithelial cell proliferation
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2IIIb promotes epithelial cell
        proliferation in response to FGF7/10. UniProt confirms proliferation
        in keratinocytes.
      action: ACCEPT
      reason: >-
        Core function for FGFR2IIIb isoform. Epithelial proliferation is a
        primary response to FGF7/10 signaling.
  - term:
      id: GO:0051150
      label: regulation of smooth muscle cell differentiation
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for smooth muscle differentiation.
      action: KEEP_AS_NON_CORE
      reason: >-
        Specialized context for FGFR2 function in mesenchymal differentiation.
  - term:
      id: GO:0051781
      label: positive regulation of cell division
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 promotes cell proliferation
        which involves cell division.
      action: ACCEPT
      reason: >-
        Consistent with core mitogenic function of FGFR2 signaling.
  - term:
      id: GO:0055010
      label: ventricular cardiac muscle tissue morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for cardiac development.
      action: KEEP_AS_NON_CORE
      reason: >-
        Cardiac development context is not a primary FGFR2 function.
  - term:
      id: GO:0060045
      label: positive regulation of cardiac muscle cell proliferation
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for cardiac muscle proliferation.
      action: KEEP_AS_NON_CORE
      reason: >-
        Specialized cardiac context not a primary FGFR2 function.
  - term:
      id: GO:0060174
      label: limb bud formation
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 is essential for limb bud
        development. UniProt confirms role in limb bud development.
      action: ACCEPT
      reason: >-
        Core developmental function. FGFR2 is required for limb bud outgrowth
        and patterning through FGF signaling.
  - term:
      id: GO:0060348
      label: bone development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 is essential for bone
        development; mutations cause craniosynostosis syndromes.
      action: ACCEPT
      reason: >-
        Core developmental function. FGFR2 mutations in humans cause multiple
        skeletal syndromes demonstrating essential role in osteogenesis.
  - term:
      id: GO:0060349
      label: bone morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 regulates bone shape through
        effects on osteoblast function.
      action: ACCEPT
      reason: >-
        Core function evidenced by craniosynostosis syndromes where FGFR2
        mutations cause abnormal skull bone morphology.
  - term:
      id: GO:0060442
      label: branching involved in prostate gland morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. Prostate gland develops through
        branching morphogenesis involving FGFR2.
      action: KEEP_AS_NON_CORE
      reason: >-
        Specific example of branching morphogenesis. General gland morphogenesis
        term captures this function.
  - term:
      id: GO:0060445
      label: branching involved in salivary gland morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. Salivary gland develops through
        FGFR2-dependent branching morphogenesis.
      action: ACCEPT
      reason: >-
        Well-documented example of FGFR2-dependent branching morphogenesis.
        FGF10/FGFR2IIIb signaling is essential for salivary gland development.
  - term:
      id: GO:0060449
      label: bud elongation involved in lung branching
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. Specific aspect of lung branching
        morphogenesis involving bud outgrowth.
      action: ACCEPT
      reason: >-
        Core lung development function. FGF10/FGFR2IIIb signaling drives
        epithelial bud elongation in lung branching.
  - term:
      id: GO:0060463
      label: lung lobe morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for lung lobe formation.
      action: ACCEPT
      reason: >-
        Part of core lung development function of FGFR2.
  - term:
      id: GO:0060484
      label: lung-associated mesenchyme development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2IIIc in lung mesenchyme
        responds to epithelial FGFs during development.
      action: ACCEPT
      reason: >-
        Core lung development function. Both epithelial (IIIb) and mesenchymal
        (IIIc) FGFR2 isoforms contribute to lung development.
  - term:
      id: GO:0060501
      label: positive regulation of epithelial cell proliferation involved in 
        lung morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGF10/FGFR2IIIb signaling promotes
        lung epithelial proliferation during branching morphogenesis.
      action: ACCEPT
      reason: >-
        Core function for lung development. FGFR2IIIb-mediated epithelial
        proliferation is essential for lung morphogenesis.
  - term:
      id: GO:0060512
      label: prostate gland morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for prostate development.
      action: KEEP_AS_NON_CORE
      reason: >-
        Specific gland development context. More general gland morphogenesis
        captures this function.
  - term:
      id: GO:0060523
      label: prostate epithelial cord elongation
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for prostate development.
      action: KEEP_AS_NON_CORE
      reason: >-
        Specific prostate developmental context. More general epithelial
        morphogenesis and gland development terms capture this function.
  - term:
      id: GO:0060527
      label: prostate epithelial cord arborization involved in prostate 
        glandular acinus morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for highly specific prostate morphogenesis.
      action: KEEP_AS_NON_CORE
      reason: >-
        Overly specific developmental term. General gland morphogenesis captures
        FGFR2 role without this level of specificity.
  - term:
      id: GO:0060529
      label: squamous basal epithelial stem cell differentiation involved in 
        prostate gland acinus development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for very specific prostate stem cell context.
      action: MARK_AS_OVER_ANNOTATED
      reason: >-
        Extremely specific term that goes beyond core FGFR2 function. This level
        of specificity is not a primary FGFR2 function.
  - term:
      id: GO:0060601
      label: lateral sprouting from an epithelium
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. Epithelial sprouting is part of
        branching morphogenesis that FGFR2 mediates.
      action: ACCEPT
      reason: >-
        Consistent with FGFR2 role in branching morphogenesis. Lateral sprouting
        is a core mechanism of epithelial branching in lungs and glands.
  - term:
      id: GO:0060615
      label: mammary gland bud formation
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. Mammary gland develops through
        FGFR2-dependent mechanisms similar to other glands.
      action: KEEP_AS_NON_CORE
      reason: >-
        Example of gland morphogenesis. General gland development terms capture
        this function.
  - term:
      id: GO:0060664
      label: epithelial cell proliferation involved in salivary gland 
        morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGF10/FGFR2IIIb signaling promotes
        epithelial proliferation in salivary gland development.
      action: ACCEPT
      reason: >-
        Core function for salivary gland development which is a well-documented
        FGFR2 function through epithelial-mesenchymal interactions.
  - term:
      id: GO:0060667
      label: branch elongation involved in salivary gland morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. Branch elongation is a key aspect
        of salivary gland branching morphogenesis.
      action: ACCEPT
      reason: >-
        Core salivary gland development function. Consistent with FGFR2 role
        in branching morphogenesis.
  - term:
      id: GO:0060670
      label: branching involved in labyrinthine layer morphogenesis
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog for placental labyrinthine layer.
      action: KEEP_AS_NON_CORE
      reason: >-
        Placental development context. UniProt notes trophoblast function but
        this specific aspect is not emphasized.
  - term:
      id: GO:0060688
      label: regulation of morphogenesis of a branching structure
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 is a key regulator of branching
        morphogenesis in multiple organs.
      action: ACCEPT
      reason: >-
        Core developmental function. FGFR2 regulates branching morphogenesis in
        lungs, glands, and other organs through epithelial-mesenchymal signaling.
  - term:
      id: GO:0060915
      label: mesenchymal cell differentiation involved in lung development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2IIIc in lung mesenchyme responds
        to epithelial signals to regulate mesenchymal differentiation.
      action: ACCEPT
      reason: >-
        Core lung development function. Both epithelial (IIIb) and mesenchymal
        (IIIc) FGFR2 isoforms contribute to lung development.
  - term:
      id: GO:0060916
      label: mesenchymal cell proliferation involved in lung development
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2IIIc in lung mesenchyme promotes
        proliferation in response to epithelial FGFs.
      action: ACCEPT
      reason: >-
        Core lung development function for FGFR2IIIc isoform.
  - term:
      id: GO:0070372
      label: regulation of ERK1 and ERK2 cascade
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 activates ERK1/2 (MAPK3/MAPK1)
        through the RAS-MAPK pathway.
      action: ACCEPT
      reason: >-
        Core signaling function. ERK1/2 cascade activation is a primary downstream
        effect of FGFR2 signaling through FRS2/GRB2/SOS/RAS pathway.
  - term:
      id: GO:0070374
      label: positive regulation of ERK1 and ERK2 cascade
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. FGFR2 positively regulates ERK1/2
        cascade activation.
      action: ACCEPT
      reason: >-
        Core signaling function. More specific child term of MAPK cascade
        regulation that is well-documented for FGFR2.
  - term:
      id: GO:0090263
      label: positive regulation of canonical Wnt signaling pathway
    evidence_type: ISS
    original_reference_id: GO_REF:0000024
    review:
      summary: >-
        ISS annotation from mouse ortholog. Cross-talk between FGF and Wnt
        pathways occurs during development.
      action: KEEP_AS_NON_CORE
      reason: >-
        Indirect pathway cross-talk rather than a direct core function of FGFR2.
        More specific than general Wnt regulation annotation already reviewed.
  - term:
      id: GO:0016020
      label: membrane
    evidence_type: NAS
    original_reference_id: PMID:8676562
    review:
      summary: >-
        NAS annotation for membrane localization. FGFR2 is a transmembrane
        receptor.
      action: ACCEPT
      reason: >-
        Correct but general term. More specific plasma membrane annotations exist.
      supported_by:
        - reference_id: PMID:8676562
          supporting_text: 'Apert syndrome, acrocephalosyndactyly Type I, is an autosomal
            dominant craniosynostosis comprising acrocephaly, facial dysmorphism and
            severe syndactyly of the hands and feet.'
  - term:
      id: GO:0005634
      label: nucleus
    evidence_type: IDA
    original_reference_id: PMID:17471512
    review:
      summary: >-
        PMID:17471512 demonstrated nuclear localization of FGF-10 receptor
        (FGFR2IIIb) in urothelial cells along with its ligand FGF-10.
      action: KEEP_AS_NON_CORE
      reason: >-
        Nuclear localization represents a specialized signaling mechanism rather
        than the primary localization. Main FGFR2 function is at plasma membrane.
      supported_by:
        - reference_id: PMID:17471512
          supporting_text: "The FGF-10 receptor was observed in cell nuclei regardless
            of the presence or concentration of exogenous rFGF-10 ligand"
  - term:
      id: GO:0005737
      label: cytoplasm
    evidence_type: IDA
    original_reference_id: PMID:17471512
    review:
      summary: >-
        PMID:17471512 showed FGF-10 receptor (FGFR2IIIb) localizes to cytoplasm
        in urothelial cells during trafficking.
      action: ACCEPT
      reason: >-
        FGFR2 is found in cytoplasm during biosynthesis, trafficking, and after
        internalization.
      supported_by:
        - reference_id: PMID:17471512
          supporting_text: "rFGF-10(no NLS) was found in cytoplasm to a far greater
            degree than rFGF-10"
  - term:
      id: GO:0005938
      label: cell cortex
    evidence_type: IDA
    original_reference_id: PMID:17471512
    review:
      summary: >-
        PMID:17471512 may have observed FGFR2 at the cell cortex during trafficking
        or at the plasma membrane interface.
      action: KEEP_AS_NON_CORE
      reason: >-
        Cell cortex localization is not a primary FGFR2 localization. May represent
        trafficking intermediate or plasma membrane-associated pool.
      supported_by:
        - reference_id: PMID:17471512
          supporting_text: Translocation of fibroblast growth factor-10 and its 
            receptor into nuclei of human urothelial cells.
  - term:
      id: GO:0008284
      label: positive regulation of cell population proliferation
    evidence_type: IGI
    original_reference_id: PMID:8663044
    review:
      summary: >-
        IGI (Inferred from Genetic Interaction) annotation from PMID:8663044 which
        tested multiple FGF-FGFR combinations for mitogenic activity.
      action: ACCEPT
      reason: >-
        Consistent with core mitogenic function. PMID:8663044 demonstrated
        proliferative activity of FGFR2 with various FGF ligands.
      supported_by:
        - reference_id: PMID:8663044
          supporting_text: Receptor specificity of the fibroblast growth factor 
            family.
  - term:
      id: GO:0008543
      label: fibroblast growth factor receptor signaling pathway
    evidence_type: IGI
    original_reference_id: PMID:8663044
    review:
      summary: >-
        IGI annotation from PMID:8663044 demonstrating FGF receptor signaling
        through FGFR2.
      action: ACCEPT
      reason: >-
        Core biological process. PMID:8663044 is foundational study for FGFR
        signaling specificity.
      supported_by:
        - reference_id: PMID:8663044
          supporting_text: Receptor specificity of the fibroblast growth factor 
            family.
  - term:
      id: GO:0005007
      label: fibroblast growth factor receptor activity
    evidence_type: IGI
    original_reference_id: PMID:10830168
    review:
      summary: >-
        IGI annotation from PMID:10830168 which determined crystal structures
        of FGF-FGFR complexes and characterized ligand-receptor specificity.
      action: ACCEPT
      reason: >-
        Core molecular function. PMID:10830168 provided structural basis for
        FGF receptor specificity through alternative splicing.
      supported_by:
        - reference_id: PMID:10830168
          supporting_text: "Specificity is achieved through interactions between the
            N-terminal and central regions of FGFs and two loop regions in D3 that
            are subject to alternative splicing"
  - term:
      id: GO:0008543
      label: fibroblast growth factor receptor signaling pathway
    evidence_type: IPI
    original_reference_id: PMID:10830168
    review:
      summary: >-
        IPI annotation from PMID:10830168 based on physical interaction studies
        of FGF-FGFR complexes.
      action: ACCEPT
      reason: >-
        Core signaling pathway. Crystal structures revealed basis for ligand
        binding and receptor activation.
      supported_by:
        - reference_id: PMID:10830168
          supporting_text: Crystal structures of two FGF-FGFR complexes reveal 
            the determinants of ligand-receptor specificity.
  - term:
      id: GO:0017134
      label: fibroblast growth factor binding
    evidence_type: IPI
    original_reference_id: PMID:8386828
    review:
      summary: >-
        IPI annotation from PMID:8386828 demonstrating FGF-5 binding to FGFR2.
        Competition binding studies showed KD of 0.5-1.5 nM.
      action: ACCEPT
      reason: >-
        Core molecular function. Direct binding assays demonstrated FGF binding
        to FGFR2 with high affinity.
      supported_by:
        - reference_id: PMID:8386828
          supporting_text: "the KD for FGF-5-FGFR-1 and FGF-5-FGFR-2 interactions
            are both between 0.5 and 1.5 x 10(-9) M"
  - term:
      id: GO:0005007
      label: fibroblast growth factor receptor activity
    evidence_type: NAS
    original_reference_id: PMID:8676562
    review:
      summary: >-
        NAS annotation for FGF receptor activity. Duplicate annotation with
        different evidence code.
      action: ACCEPT
      reason: >-
        Core molecular function supported by multiple evidence types.
      supported_by:
        - reference_id: PMID:8676562
          supporting_text: 'Apert syndrome, acrocephalosyndactyly Type I, is an autosomal
            dominant craniosynostosis comprising acrocephaly, facial dysmorphism and
            severe syndactyly of the hands and feet.'
  - term:
      id: GO:0004713
      label: protein tyrosine kinase activity
    evidence_type: NAS
    original_reference_id: PMID:1697263
    review:
      summary: >-
        NAS annotation for protein tyrosine kinase activity. FGFR2 is a receptor
        tyrosine kinase.
      action: ACCEPT
      reason: >-
        Core molecular function. FGFR2 is a well-characterized receptor tyrosine
        kinase (EC 2.7.10.1).
      supported_by:
        - reference_id: PMID:1697263
          supporting_text: Cloning and expression of two distinct high-affinity 
            receptors cross-reacting with acidic and basic fibroblast growth 
            factors.
  - term:
      id: GO:0005007
      label: fibroblast growth factor receptor activity
    evidence_type: NAS
    original_reference_id: PMID:1400433
    review:
      summary: >-
        NAS annotation from PMID:1400433 which identified alternative splicing
        creating isoforms with different ligand specificities.
      action: ACCEPT
      reason: >-
        Core molecular function. PMID:1400433 was important for understanding
        isoform-specific FGF binding.
      supported_by:
        - reference_id: PMID:1400433
          supporting_text: A novel form of fibroblast growth factor receptor 2.
  - term:
      id: GO:0005007
      label: fibroblast growth factor receptor activity
    evidence_type: NAS
    original_reference_id: PMID:1697263
    review:
      summary: >-
        NAS annotation for FGF receptor activity. Duplicate with different reference.
      action: ACCEPT
      reason: >-
        Core molecular function.
      supported_by:
        - reference_id: PMID:1697263
          supporting_text: Cloning and expression of two distinct high-affinity 
            receptors cross-reacting with acidic and basic fibroblast growth 
            factors.
  - term:
      id: GO:0016020
      label: membrane
    evidence_type: NAS
    original_reference_id: PMID:1697263
    review:
      summary: >-
        NAS annotation for membrane localization. FGFR2 is a single-pass type I
        membrane protein.
      action: ACCEPT
      reason: >-
        Correct but general term. More specific plasma membrane annotations exist.
      supported_by:
        - reference_id: PMID:1697263
          supporting_text: Cloning and expression of two distinct high-affinity 
            receptors cross-reacting with acidic and basic fibroblast growth 
            factors.
core_functions:
  - molecular_function:
      id: GO:0005007
      label: fibroblast growth factor receptor activity
    directly_involved_in:
      - id: GO:0008543
        label: fibroblast growth factor receptor signaling pathway
      - id: GO:0008284
        label: positive regulation of cell population proliferation
      - id: GO:0070374
        label: positive regulation of ERK1 and ERK2 cascade
      - id: GO:0060348
        label: bone development
      - id: GO:0060688
        label: regulation of morphogenesis of a branching structure
      - id: GO:0048701
        label: embryonic cranial skeleton morphogenesis
      - id: GO:0030324
        label: lung development
    locations:
      - id: GO:0005886
        label: plasma membrane
references:
  - id: file:human/FGFR2/FGFR2-deep-research-falcon.md
    title: Deep research report on FGFR2 function, signaling, and clinical relevance
    findings:
      - statement: >-
          FGFR2 is a plasma membrane receptor tyrosine kinase with Ig-like
          extracellular domains whose IIIb/IIIc isoform switching determines
          epithelial vs mesenchymal ligand specificity.
      - statement: >-
          Core signaling through FRS2/MAPK and PLCgamma pathways drives
          proliferation, differentiation, and branching morphogenesis in lungs,
          limbs, skeleton, and glands.
  - id: GO_REF:0000002
    title: Gene Ontology annotation through association of InterPro records with
      GO terms
    findings: []
  - id: GO_REF:0000003
    title: Gene Ontology annotation based on Enzyme Commission mapping
    findings: []
  - id: GO_REF:0000024
    title: Manual transfer of experimentally-verified manual GO annotation data 
      to orthologs by curator judgment of sequence similarity
    findings: []
  - id: GO_REF:0000033
    title: Annotation inferences using phylogenetic trees
    findings: []
  - id: GO_REF:0000043
    title: Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword 
      mapping
    findings: []
  - id: GO_REF:0000044
    title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular 
      Location vocabulary mapping, accompanied by conservative changes to GO 
      terms applied by UniProt
    findings: []
  - id: GO_REF:0000107
    title: Automatic transfer of experimentally verified manual GO annotation 
      data to orthologs using Ensembl Compara
    findings: []
  - id: GO_REF:0000117
    title: Electronic Gene Ontology annotations created by ARBA machine learning
      models
    findings: []
  - id: GO_REF:0000120
    title: Combined Automated Annotation using Multiple IEA Methods
    findings: []
  - id: PMID:10618369
    title: Structural interactions of fibroblast growth factor receptor with its
      ligands.
    findings: []
  - id: PMID:10830168
    title: Crystal structures of two FGF-FGFR complexes reveal the determinants 
      of ligand-receptor specificity.
    findings: []
  - id: PMID:11390973
    title: Structural basis for fibroblast growth factor receptor 2 activation 
      in Apert syndrome.
    findings: []
  - id: PMID:12591959
    title: Structural basis by which alternative splicing confers specificity in
      fibroblast growth factor receptors.
    findings: []
  - id: PMID:1309608
    title: 'Determination of ligand-binding specificity by alternative splicing: two
      distinct growth factor receptors encoded by a single gene.'
    findings: []
  - id: PMID:1400433
    title: A novel form of fibroblast growth factor receptor 2. Alternative 
      splicing of the third immunoglobulin-like domain confers ligand binding 
      specificity.
    findings: []
  - id: PMID:15190072
    title: Cbl-mediated degradation of Lyn and Fyn induced by constitutive 
      fibroblast growth factor receptor-2 activation supports osteoblast 
      differentiation.
    findings: []
  - id: PMID:15629145
    title: Tyrosine 769 of the keratinocyte growth factor receptor is required 
      for receptor signaling but not endocytosis.
    findings: []
  - id: PMID:16597614
    title: FGF-10 and its receptor exhibit bidirectional paracrine targeting to 
      urothelial and smooth muscle cells in the lower urinary tract.
    findings: []
  - id: PMID:16844695
    title: Intracellular retention, degradation, and signaling of 
      glycosylation-deficient FGFR2 and craniosynostosis syndrome-associated 
      FGFR2C278F.
    findings: []
  - id: PMID:1697263
    title: Cloning and expression of two distinct high-affinity receptors 
      cross-reacting with acidic and basic fibroblast growth factors.
    findings: []
  - id: PMID:17471512
    title: Translocation of fibroblast growth factor-10 and its receptor into 
      nuclei of human urothelial cells.
    findings: []
  - id: PMID:17959718
    title: Heparanase cleavage of perlecan heparan sulfate modulates FGF10 
      activity during ex vivo submandibular gland branching morphogenesis.
    findings: []
  - id: PMID:21412257
    title: MiR-125b, a microRNA downregulated in psoriasis, modulates 
      keratinocyte proliferation by targeting FGFR2.
    findings: []
  - id: PMID:22726438
    title: Inhibition of basal FGF receptor signaling by dimeric Grb2.
    findings: []
  - id: PMID:23597563
    title: Molecular mechanism of SSR128129E, an extracellularly acting, 
      small-molecule, allosteric inhibitor of FGF receptor signaling.
    findings: []
  - id: PMID:25241761
    title: Using an in situ proximity ligation assay to systematically profile 
      endogenous protein-protein interactions in a pathway network.
    findings: []
  - id: PMID:26267536
    title: Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer 
      Therapy.
    findings: []
  - id: PMID:33961781
    title: Dual proteome-scale networks reveal cell-specific remodeling of the 
      human interactome.
    findings: []
  - id: PMID:35384245
    title: Physical and functional interactome atlas of human receptor tyrosine 
      kinases.
    findings: []
  - id: PMID:35922511
    title: A physical wiring diagram for the human immune system.
    findings: []
  - id: PMID:7874170
    title: Jackson-Weiss and Crouzon syndromes are allelic with mutations in 
      fibroblast growth factor receptor 2.
    findings: []
  - id: PMID:7987400
    title: Mutations in the fibroblast growth factor receptor 2 gene cause 
      Crouzon syndrome.
    findings: []
  - id: PMID:8386828
    title: Activation of fibroblast growth factor (FGF) receptors by recombinant
      human FGF-5.
    findings: []
  - id: PMID:8663044
    title: Receptor specificity of the fibroblast growth factor family.
    findings: []
  - id: PMID:8676562
    title: '[Nucleotide sequences at intron 6 and exon 7 junction of fibroblast growth
      factor receptor 2 and rapid mutational analysis in Apert syndrome].'
    findings: []
  - id: Reactome:R-HSA-109699
    title: PI3K-containing complexes phosphorylate PIP2 to PIP3
    findings: []
  - id: Reactome:R-HSA-190258
    title: FGFR2c binds to FGF
    findings: []
  - id: Reactome:R-HSA-190260
    title: FGFR2b binds to FGF
    findings: []
  - id: Reactome:R-HSA-190408
    title: Autocatalytic phosphorylation of FGFR2b
    findings: []
  - id: Reactome:R-HSA-190413
    title: Autocatalytic phosphorylation of FGFR2c
    findings: []
  - id: Reactome:R-HSA-2029983
    title: Dimerization of FGFR2 ligand-independent mutants
    findings: []
  - id: Reactome:R-HSA-2029984
    title: Autocatalytic phosphorylation of FGFR2 ligand-independent  mutants
    findings: []
  - id: Reactome:R-HSA-2029988
    title: Dimerization of overexpressed FGFR2
    findings: []
  - id: Reactome:R-HSA-2029989
    title: Autocatalytic phosphorylation of overexpressed FGFR2 variants
    findings: []
  - id: Reactome:R-HSA-2029992
    title: Tyrosine kinase inhibitors bind to overexpressed FGFR2 variants
    findings: []
  - id: Reactome:R-HSA-2033472
    title: FGFR2c mutants bind an expanded range of ligands
    findings: []
  - id: Reactome:R-HSA-2033474
    title: FGFR2b mutants bind an expanded range of ligands
    findings: []
  - id: Reactome:R-HSA-2033479
    title: Dimerization of FGFR2 point mutants with enhanced kinase activity
    findings: []
  - id: Reactome:R-HSA-2033486
    title: Autocatalytic phosphorylation of FGFR2c mutants with enhanced ligand 
      binding
    findings: []
  - id: Reactome:R-HSA-2033488
    title: Autocatalytic phosphorylation of FGFR2b mutants with enhanced ligand 
      binding
    findings: []
  - id: Reactome:R-HSA-2033490
    title: Autocatalytic phosphorylation of FGFR2 point mutants with enhanced 
      kinase activity
    findings: []
  - id: Reactome:R-HSA-2067713
    title: GP369 inhibits activation of amplified FGFR2 signaling
    findings: []
  - id: Reactome:R-HSA-2077424
    title: Point mutants of FGFR2 bind and are inactivated by tyrosine kinase 
      inhibitors
    findings: []
  - id: Reactome:R-HSA-2316434
    title: PI3K phosphorylates PIP2 to PIP3
    findings: []
  - id: Reactome:R-HSA-2400009
    title: PI3K inhibitors block PI3K catalytic activity
    findings: []
  - id: Reactome:R-HSA-5654147
    title: Activated FGFR2 phosphorylates PLCG1
    findings: []
  - id: Reactome:R-HSA-5654157
    title: p-4Y-PLCG1 dissociates from activated FGFR2
    findings: []
  - id: Reactome:R-HSA-5654159
    title: Activated FGFR2 binds PLCG1
    findings: []
  - id: Reactome:R-HSA-5654397
    title: Activated FGFR2 phosphorylates FRS2
    findings: []
  - id: Reactome:R-HSA-5654399
    title: Activated FGFR2 binds FRS2
    findings: []
  - id: Reactome:R-HSA-5654402
    title: Activated FGFR2:p-SHC1:GRB2:SOS1 activates RAS nucleotide exchange
    findings: []
  - id: Reactome:R-HSA-5654404
    title: Activated FGFR2 binds SHC1
    findings: []
  - id: Reactome:R-HSA-5654406
    title: Activated FGFR2:p-SHC1 binds GRB2:SOS1
    findings: []
  - id: Reactome:R-HSA-5654407
    title: Activated FGFR2 phosphorylates SHC1
    findings: []
  - id: Reactome:R-HSA-5654562
    title: Activated ERK1/2 threonine-phosphorylates FGFR2-associated FRS2
    findings: []
  - id: Reactome:R-HSA-5654603
    title: Activated FGFR2 binds FRS3
    findings: []
  - id: Reactome:R-HSA-5654605
    title: Activated FGFR2 phosphorylates FRS3
    findings: []
  - id: Reactome:R-HSA-5654607
    title: Activated FGFR2 phosphorylates PPTN11
    findings: []
  - id: Reactome:R-HSA-5654608
    title: Activated FGFR2:p-FRS bind to PPTN11
    findings: []
  - id: Reactome:R-HSA-5654612
    title: Activated FGFR2:p-FRS2 binds GRB2:GAB1:PIK3R1
    findings: []
  - id: Reactome:R-HSA-5654614
    title: Activated FGFR2:p-FRS2:GRB2:GAB1:PI3KR1 binds PIK3CA
    findings: []
  - id: Reactome:R-HSA-5654615
    title: Activated FGFR2:pFRS binds GRB2:SOS1
    findings: []
  - id: Reactome:R-HSA-5654618
    title: Activated FGFR2:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange
    findings: []
  - id: Reactome:R-HSA-5654620
    title: Activated FGFR2:p-FRS2:p-PPTN11 binds GRB2:GAB1:PI3KR1
    findings: []
  - id: Reactome:R-HSA-5654622
    title: Activated FGFR2:p-FRS2:p-PPTN11:GRB2:GAB1:PIK3R1 binds PIK3CA
    findings: []
  - id: Reactome:R-HSA-5654677
    title: CBL ubiquitinates FRS2 and FGFR2
    findings: []
  - id: Reactome:R-HSA-5654697
    title: FGFR2- and PTPN11- associated PI3K phosphorylates PIP2 to PIP3
    findings: []
  - id: Reactome:R-HSA-5654701
    title: FGFR2-associated PI3K phosphorylates PIP2 to PIP3
    findings: []
  - id: Reactome:R-HSA-5654729
    title: p-CBL:GRB2 binds p-FRS2:activated FGFR2
    findings: []
  - id: Reactome:R-HSA-5654748
    title: p-4Y-PLCG1 dissociates from activated FGFR2 mutants
    findings: []
  - id: Reactome:R-HSA-5655233
    title: Activated FGFR2 mutants:p-FRS2 binds GRB2-SOS1
    findings: []
  - id: Reactome:R-HSA-5655241
    title: Activated FGFR2 mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide 
      exchange
    findings: []
  - id: Reactome:R-HSA-5655245
    title: Activated FGFR2 mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA
    findings: []
  - id: Reactome:R-HSA-5655268
    title: Activated FGFR2 mutants phosphorylate FRS2
    findings: []
  - id: Reactome:R-HSA-5655301
    title: Activated FGFR2 mutants phosphorylate PLCG1
    findings: []
  - id: Reactome:R-HSA-5655320
    title: Activated FGFR2 mutants:p-FRS2 binds GRB2:GAB1:PIK3R1
    findings: []
  - id: Reactome:R-HSA-5655323
    title: Activated FGFR2 mutant-associated PI3K phosphorylates PIP2 to PIP3
    findings: []
  - id: Reactome:R-HSA-5655339
    title: Activated FGFR2 mutants bind FRS2
    findings: []
  - id: Reactome:R-HSA-5655343
    title: Activated FGFR2 mutants bind PLCG1
    findings: []
  - id: Reactome:R-HSA-5672965
    title: RAS GEFs promote RAS nucleotide exchange
    findings: []
  - id: Reactome:R-HSA-8853313
    title: FGFR2 fusions autophosphorylate
    findings: []
  - id: Reactome:R-HSA-8853319
    title: FGFR2 fusions dimerize
    findings: []
  - id: Reactome:R-NUL-8853328
    title: Mouse FGFR2 IIIa TM binds FGF1,2 and full-length receptors
    findings: []